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Abstract 
 
Epidermal Langerhans cells (LCs) and multiple subsets of dermal dendritic cells 
(dDCs) make skin a valuable route for vaccination, offering the potential for antigen-
sparing immunisation. The interconnected immunological functions of dDC subsets and 
LCs are not fully understood however. This Thesis therefore aimed to explore the 
interactions of skin immune cells with viral pathogens and vaccines to inform the 
development of future therapeutics and intradermal vaccines. 
LCs and dDCs were isolated from ex vivo human skin tissue using a walkout 
protocol which allowed the enrichment of the migratory cells from the tissue. LCs and 
dDCs were infected with a lentiviral vector encoding GFP, allowing study of post-entry 
HIV viral restriction. The study uncovered the existence of a SAMHD-1-independent 
antiviral factor unique to LCs.  
LCs and dDCs from ex vivo skin were used to examine the cross-presentation of 
an inactivated influenza virus-derived matrix peptide to CD8+ T-cells. Two CD11c+ 
subsets of dDCs were found to potently cross present the antigen. Delivery of VLPs, 
which lack genetic material, markedly reduced cross-presentation, suggesting that viral 
genetic material is vital for dDCs to activate cross-presentation pathways. Future work 
is required to determine if this is true of other influenza peptides or pathogens. 
Vaccine delivery studies performed using murine and human models found that 
dDCs were responsible for the greatest uptake of ovalbumin peptide antigen and LCs did 
not migrate out of the epidermis in the first 4 hours after inactivated influenza virus 
vaccine delivery respectively. 
Collectively, this work highlighted the importance of dDCs in antigen uptake and 
cross-presentation to prime cytotoxic T-cell responses. Innovative delivery methods 
such as microneedles offer a means of accessing the dermal compartment in a pain-free 
manner, though further work is required to determine the optimal combination of 
vaccine formulation and delivery method to harness the immunostimulatory abilities of 
dDCs. 
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Chapter 1 - General Introduction 
1.1 The Human Immune System 
During normal interactions with its external environment, the human body is 
under constant threat from invading pathogens. These may be bacterial, viral or fungal, 
exploiting different pathways to lead to diseases (Murphy et al., 2012). For this reason, 
the human body has evolved multiple, often overlapping, systems which can allow it to 
resist invasion by pathogens. The subtleties of the immune system are important in 
allowing the body to differentiate between ‘self’ and ‘foreign’ cells and molecules in 
order to stop the growth of invading pathogens without adversely affecting host cells or 
systems (Dempsey et al., 2003). The components of the immune system are categorised 
into two structures- the innate immune system and the adaptive immune system. 
 
1.1.1 Innate Immunity 
The innate immune system is also known as the non-specific immune system as 
its components develop from birth and are not guided by exposure to specific pathogens 
as is the case for the adaptive immune system (Medzhitov and Janeway, 2000). Innate 
immunity can be considered a more primitive protective system than adaptive 
immunity, recognising and responding to a range of pathogens in a broadly similar 
manner (Kumar et al., 2011). The first line of innate immunity provides a physical barrier 
to pathogen entry, with the hydrophobic stratum corneum preventing ingress of 
pathogens into the skin (which represents the vast majority of the body’s surface which 
is exposed to the external environment) (Elias, 2007). There are also transit systems such 
as mucociliary clearance (Antunes and Cohen, 2007) and gastrointestinal peristalsis (Hao 
and Lee, 2004) that act to physically limit contact time of pathogens with bodily surfaces 
and thus reduce the chances of their entry into the body . 
Occasionally, a pathogen is able to overcome the external barriers and colonise 
the body, perhaps due to an injury which negates the barrier properties of the skin such 
as a burn or incision wound. The innate immune system possesses several mechanisms 
to neutralise such pathogens. Leukocytes such as neutrophils, macrophages and 
dendritic cells (DCs) are able to recognise pathogens based on shared structural 
2 
 
molecules known as pathogen-associated molecular patterns (PAMPs) via pattern 
recognition receptors (PRRs) on their surface (Kumar et al., 2011). These cells may then 
phagocytose the pathogen, degrading it via the lysosomal pathway or via a respiratory 
burst within the cell (Murphy et al., 2012). The triggering of PRRs on these cells also 
leads to the release of substances such as histamine, leukotrienes and prostaglandins 
which trigger inflammation in the local area (Medzhitov, 2008). Inflammation increases 
blood flow to the site of infection and increases the permeability of blood vessels, 
allowing entry of circulating immune cells such as granulocytes into the tissue (Takeuchi 
and Akira, 2010). If the pathogen entry is the result of local trauma, damaged cells will 
release substances that possess damage-associated molecular patterns (DAMPs) that 
are also recognised by leukocytes and trigger activation of inflammatory pathways 
(Bianchi, 2007). The innate immune system also includes the complement system, an 
array of small proteins that circulate in the blood and bind pathogens to indicate their 
presence to immune cells (known as opsonisation) or to initiate lysis of the pathogen by 
creating pores in the pathogen’s cell membrane (Murphy et al., 2012). 
Whilst many potentially harmful pathogens are recognised and stopped by the 
innate immune system, there are cases where the pathogen has evolved evasive 
strategies to allow it to circumvent the innate immune system. HIV-1 is a good example, 
circumventing early defences to propagate in the host (Piguet et al., 2014). In these 
cases, the adaptive immune system allows the body to recognise the pathogens and to 
mount an immune response against them and limit or prevent disease development 
depending on the pathogen. 
 
1.1.2 Adaptive Immunity 
The second arm of the immune system provides ‘acquired immunity’- creating 
an immunological memory to pathogens that it has encountered to allow more effective 
responses to be effected upon subsequent exposure to identical pathogens. It varies 
from the innate immune system in that the response which is raised against a pathogen 
is tailored to best combat that pathogen rather than the ‘one-size-fits-all’ approach of 
the innate immune system (Medzhitov and Janeway, 2000). The two main effector cell 
types of the adaptive immune system are T-cells and B-cells, collectively known as 
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lymphocytes (Rajewsky and von Boehmer, 2008). Unlike the cellular response that forms 
part of the innate immune response, each lymphocyte can only recognise a single PAMP 
in the form of an antigenic epitope (Dempsey et al., 2003). Antigen may be large 
structural components of pathogens such as polysaccharides (Weintraub, 2003) or small 
molecules such as the hapten urushiol (Kalish et al., 1994). This diversity of antigen 
detection allows the adaptive immune system to distinguish and counteract pathogens 
which have evolved means of evading innate immune system detection- for example 
bacteria with membranous envelopes which protect their bacterial cell wall from PRR 
recognition (Hornef et al., 2002). 
The initiation of an adaptive immune response that has not been encountered 
previously is dependent on antigen presenting cells (APCs) within the body. These fall 
into two categories: ‘professional’ APCs whose major function is the presentation of 
antigen and all other nucleated cells which may act in an APC capacity during 
intracellular infection (Murphy et al., 2012). Professional APCs include macrophages 
(Unanue, 1984) and DCs (Guermonprez et al., 2002) which are able to recognise 
pathogens via PRRs on their surface and uptake them. Following processing which lyses 
the pathogen into its antigenic components, the APCs present the antigen on their 
surface on major histocompatibility (MHC) molecules; the interaction with the 
antigen:MHC complex then activates lymphocytes (Heath and Carbone, 2001).  
B-cells are responsible for the humoral immune response, releasing antibodies 
which bind to specific epitopes on the pathogen. Antibodies, also known as 
immunoglobulin (Ig) molecules, are soluble proteins which possess antigen-binding 
regions which are specific to a single antigenic epitope (Schroeder and Cavacini, 2010). 
The simplest monomeric Ig molecule possesses two identical antigen binding sites, 
though they can form polymers of 2-5 monomers which can bind multiple copies of the 
epitope (Woof and Russell, 2011, Martin, 1969). Antibody binding may negate the threat 
of pathogens if they bind to cell surface proteins on the pathogen which allow it to 
mediate its effects such as cell entry (Forthal, 2014). The presence of more than one 
binding site on an Ig molecule means that they can also aggregate pathogens, rendering 
them ineffective and encouraging their phagocytosis (Thomas et al., 1986). Antibodies 
may also bind soluble bacterial toxins, forming insoluble precipitates and preventing 
their negative effects (Forthal, 2014). Antibody binding can also signal the initiation of 
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complement binding to the pathogen where it can mediate its chemoattractant and 
cytotoxic effects (Ochsenbein and Zinkernagel, 2000). Finally, antibodies can opsonise 
pathogens in a manner similar to complement, attracting cells which will engulf the 
pathogen (Dunkelberger and Song, 2010). Antibodies may also be linked to the surface 
of B-cells as part of the B-cell receptor (BCR), allowing the B-cell to recognise antigen 
and become activated (Murphy et al., 2012). 
T-cells possess T-cell receptors (TCRs) on their surface which, like Ig and the BCR, 
are specific to a single antigenic epitope. Unlike antibodies, the TCR requires antigen to 
be bound within a MHC molecule to be recognised (Davis et al., 1998). T-cells are able 
to perform one of a range of functions depending on which subtype of T-cell is activated 
(Broere et al., 2011). Cytotoxic T-cells are responsible for killing virally-infected or 
tumour cells to prevent the propagation of infection or the tumour respectively 
(Andersen et al., 2006). Helper T-cells direct other cells of the immune system- notably 
B-cells, cytotoxic T-cells and macrophages- to facilitate the humoral and cellular aspects 
of the adaptive immune response (Kaech et al., 2002). Regulatory T-cells have a 
tolerogenic role within the immune system, ensuring that immune responses do not go 
unchecked and cause damage to the host (Belkaid and Rouse, 2005). There are a further 
two minor subsets of human T-cells, γδ T-cells and natural killer T-cells, which are able 
to recognise antigen outside of MHC molecules and act in a manner that bridges both 
innate and adaptive immunity (Holtmeier and Kabelitz, 2005, Brennan et al., 2013). 
Whereas the cells of the innate immune system are able to recognise an array of 
PAMPs via a number of PRRs, the lymphocytes of the adaptive immune system are each 
only able to recognise a single antigenic epitope (Rajewsky and von Boehmer, 2008). 
Also, whereas PRRs and antibodies are able to bind epitopes on a range of antigen types, 
the TCR is only able to recognise peptide antigen (Ni and O'Neill, 1997).  
The raising of an adaptive immune response, particularly upon initial exposure 
to a pathogen, is a much lengthier process than an innate immune response. Whereas 
the cellular and complement innate responses are active within hours of exposure, a 
first adaptive immune response can take up to 5 days to be fully deployed (Murphy et 
al., 2012). Most of the lymphocytes that proliferate to implement the first adaptive 
immune response against a pathogen will die after the removal of the pathogen (Jiang 
5 
 
et al., 2012). A minority are instead differentiated into memory T- and B-cells (Kurosaki 
et al., 2015, Lalvani et al., 1997). These cells are able to respond upon subsequent 
exposure, producing a quicker and stronger immune response (Kaech et al., 2002). 
This ‘immunological memory’ is the goal of vaccination. Exposing a person to a 
weakened or dead form of a pathogen (which does not pose a threat of causing disease), 
can allow the adaptive immune response to produce an antigen-specific response 
mimicking that of initial exposure to the actual pathogen (Siegrist, 2013). After this, the 
quicker and more effective immune response can be launched against the pathogen and 
ideally prevent the pathogen from being able to replicate to a great enough level to 
produce the disease state in the patient (Murphy et al., 2012). 
 
1.2 Skin Structure 
Human skin is the interface between the external environment and the body’s 
internal microenvironment, which is prone to infection by an array of pathogens. For 
this reason, the complex structure of the skin is designed to act both as an impassive 
physical barrier and also as an active organ that can distinguish foreign antigen from 
innocuous substances and self-antigen (Elias, 2007, Pasparakis et al., 2014). The 
outermost skin layer is the epidermis and below it is the dermis (Figure 1.1), each of 
which is made up of multiple sub-layers. 
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1.2.1 Epidermis 
The outermost layers of the epidermis, the stratum corneum and stratum 
lucidum (Figure 1.2), are non-viable, lipophilic layers which act as a physical barrier to 
hydrophilic substances in the external environment (Elias, 2005). The stratum corneum 
is made up of layers of keratinocytes which have terminally differentiated into 
corneocytes- dead cells embedded in a matrix of keratin, fatty acids, cholesterol, and 
ceramides (Yamamoto et al., 1991, Norlén, 2006). The thickness of the stratum corneum 
varies by body site, with increased thickness on the palms of the hand and soles of the 
feet (Fore, 2006). Beneath this lies the viable stratum granulosum, stratum spinosum 
and stratum basale. The stratum basale contains basal keratinocyte stem cells which 
proliferate asymmetrically to maintain the population of stem cells and also to produce 
new keratinocytes (Lechler and Fuchs, 2005). These keratinocytes are pushed upwards 
by the proliferation of cells beneath them- moving them into the stratum spinosum 
(Fore, 2006). As keratinocytes move outwards, they begin to accumulate the lipid and 
protein deposits characteristic of the cells in the stratum corneum. After the stratum 
spinosum, they transition through the stratum granulosum where they lose their nuclei 
and begin to release lipids which will fill the intracellular space in the stratum corneum 
(Eckert and Rorke, 1989). The vast majority of cells in the viable layers are keratinocytes, 
Figure 1.1: The structure of human skin (adapted from: http://philschatz.com/anatomy-
book/resources/501_Structure_of_the_skin.jpg) 
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though the stratum spinosum and stratum basale also contain other cell types, including 
immunological Langerhans cells (LCs) (Berger et al., 2006), melanocytes (that confer skin 
pigmentation) (Fore, 2006), Merkel cells (touch receptors) (Maksimovic et al., 2014) and 
skin-resident T-cells (Clark, 2010). The basal lamina- or basement membrane- forms the 
junction between the epidermis and the dermis below it (Briggaman et al., 1971). 
The stratum corneum acts as both a passive and active barrier. The hydrophobic 
nature of the stratum corneum prevents water-soluble substances from entering the 
skin. The barrier function also limits the amount of trans-epidermal water loss, 
preventing dehydration over the large body surface area (Kalia et al., 2000). The ‘brick 
and mortar’ structure of the stratum corneum means it can only be penetrated by small 
molecules (ca. 500Da or less) and the diffusion path is tortuous, increasing diffusion time 
(Brown et al., 2006). Molecules can diffuse through the stratum corneum by one of two 
routes. The first is transcellular absorption, where the molecule crosses the plasma 
membrane of corneocytes into the cytoplasm and then out of the cell through the 
plasma membrane on the distal side. While this is the shortest route, it is less common 
as it requires the delivered molecule to possess lipophilic and hydrophilic characteristics 
to allow it to pass into the plasma membrane and corneocyte cytoplasm respectively 
(Barbero and Frasch, 2006). The most common route is the paracellular route, with the 
molecule passing between corneocytes without crossing the cells. This greatly increases 
the length of the diffusion path, increasing delivery time into the skin (Aungst, 2012). 
The properties of the stratum corneum mean that most pathogens are unable to 
permeate through intact skin. The constant turnover of skin cells and shedding of layers 
Figure 1.2: Structure of human epidermis (adapted from: http://www.molcare-
consulting.com/wp-content/uploads/Hautengl600dpib.jpg) 
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from the stratum corneum (known as desquamation) also reduces pathogen residence 
time on the skin and lowers the risk of entry into the skin (Milstone, 2004). As well as 
protection from physical insults, melanin which is produced by melanocytes and 
transferred into keratinocytes via melanosomes, also protects lower skin layers from the 
mutagenic effects of UV radiation in sunlight (Brenner and Hearing, 2008). The 
epidermis can respond to UV exposure, producing further melanin to allow greater 
protection. The epidermis also possesses resident immune cells, which are discussed in 
more detail later in this chapter. 
 
1.2.2 Dermis 
The dermis comprises two layers- the uppermost of which is the papillary dermis 
(stratum papillare) which possesses protuberances that project towards the epidermis 
housing blood capillaries and nerve endings (Figure 1.3). The protuberances allow a 
greater surface area of the blood capillaries to exchange oxygen and nutrients with the 
epidermis, which does not possess a blood supply of its own (Fore, 2006). Below this is 
the reticular dermis (stratum reticulare), a thicker layer containing large amounts of 
Figure 1.3: Structure of human dermis  (adapted from: 
http://www.austincc.edu/apreview/NursingPics/IntegumentPics/Picture2.jpg) 
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connective tissue, blood vessels and glands. The main components of the reticular 
dermis are fibroblasts, collagen and elastin fibrils and ground substance which acts to 
support the tissue (Holbrook et al., 1982). The various dermal components allow the 
skin to perform many of its regulatory functions. Sebaceous glands release a mixture of 
lipids at the surface of the skin, ensuring it remains hydrated and its barrier intact (Fluhr 
et al., 2003). Sweat glands and the arrector pilli muscles attached to hair follicles are 
important in thermoregulation during hot and cold conditions respectively 
(Romanovsky, 2014).  
The two dermal layers are home to a multitude of immunological cells- both 
resident and transiently-present cells. Under homeostatic conditions, resident DCs and 
macrophages patrol the dermis in search of pathogenic antigen (Haniffa et al., 2009, 
Malissen et al., 2014). Tissue-resident dermal T-cells are also present and able to elicit 
an adaptive immune response (Clark, 2010). The dermis also contains lymph vessels 
which are utilised to transport antigen and immune cells from the skin to lymph nodes 
where they can initiate adaptive immune responses (Lukas et al., 1996). Under 
inflammatory conditions, blood flow to the capillaries of the dermis is increased and the 
vessel wall permeability increases, allowing the migration of leukocytes and 
immunological proteins into the tissue to assist in removing pathogens (Pasparakis et 
al., 2014). 
 
1.3 Skin Immune cells 
To allow it to perform its complex role as an active barrier against pathogenic 
ingress into the body, the skin possesses an assortment of immune cells that combine 
to effect innate and adaptive immune functions. 
 
1.3.1 Dermal Dendritic Cells (dDCs) 
DCs are broadly divided into myeloid and plasmacytoid DCs- the former is of 
interest to this project due to their residence in tissues (e.g. skin), whereas plasmacytoid 
DCs are found in the blood and lymphoid organs of humans (Banchereau and Steinman, 
1998, Dudziak et al., 2007). Myeloid dDCs express human leukocyte antigen type DR 
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(HLA-DR; part of the MHC-II complex), allowing them to present antigen to CD4+ T-cells 
(Janeway, 1991). They also express cluster of differentiation 45 (CD45)- also known as 
the common leukocyte antigen- on their surface, due to their leukocyte lineage (Merad 
et al., 2013). The DCs of the dermis are a heterogeneous population with several subsets 
existing. Early work utilising dDCs in homeostatic human skin classified them into CD1a+ 
and CD14+ subsets (Haniffa et al., 2009, Nestle et al., 1993), though gating strategies 
varied between groups. One method involves gating human skin dDCs on CD14 
expression, then subdivide the CD14- dDCs (which are referred to collectively as CD1a+ 
dDCs) into CD141+ and CD141- dDC subsets (Artyomov et al., 2015, Klechevsky et al., 
2008b). Another method gates human skin dDCs on CD14 initially but subsequently 
divides the CD14- dDCs into CD11c+ and CD141+ subsets (Carpentier et al., 2016, Haniffa 
et al., 2012). The CD14+ dDCs have been classified as monocyte-derived cells (thus not 
from the same precursors as myeloid DCs) (Carpentier et al., 2016, Haniffa et al., 2012), 
though CD14 has also been found to be co-expressed by human CD141+ dDCs (Chu et 
al., 2012). Recent work has classified dDCs into CD141+ and CD1c+ subsets (Chu et al., 
2012, Haniffa et al., 2012), though overlap of markers (such as CD14 and CD11c) 
between the two subsets means classification is still not straightforward (Carpentier et 
al., 2016). The divisions in function between the dDC subsets are not currently fully 
understood (Carpentier et al., 2016). 
Immature human dDCs develop from CD34+ hematopoietic bone marrow 
progenitor cells and enter the dermis via its capillary beds (Nguyen et al., 2002). At 
steady state, dDCs are motile and patrol the dermis in search of antigen. Their dendritic 
morphology increases their surface area and allows them to interact with a greater area 
of their external environment (Steinman, 1991). They uptake antigen by endocytosis 
following binding of antigen to cell-surface receptors (Engering et al., 1997), 
macropinocytosis of the external liquid phase containing soluble antigen (Sallusto et al., 
1995) or phagocytosis of large particulate antigen or whole pathogens (Inaba et al., 
1998, Guermonprez et al., 2002). Encounters with foreign antigen signals maturation in 
human dDCs which leads to a reduction in antigen uptake ability (Sallusto and 
Lanzavecchia, 1994) alongside upregulation of MHC-I and MHC-II molecules to improve 
antigen presentation (Hackstein and Thomson, 2004). Mature human dDCs express the 
maturation markers CD80, CD83 and CD86 (Hackstein and Thomson, 2004, Aerts-
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Toegaert et al., 2007).  CD80 and CD86 are important co-stimulatory molecules that 
determine the T-cell response that will be raised in the lymph node (Hubo et al., 2013). 
Mature dDCs upregulate CCR7 which facilitates their migration to the lymph node in 
both mice (Forster et al., 2008) and humans (Bruckner et al., 2012). Upon entering the 
lymph node, dDCs present the antigen to T-cells to initiate an adaptive immune response 
if the antigen is deemed to be pathogenic. 
 
1.3.2 Langerhans Cells (LCs) 
Found exclusively in the epidermis, LCs are immature myeloid-derived cells with 
multiple dendritic processes that extend between keratinocytes (Berger et al., 2006). 
LCs precursors are found in the epidermis prior to the development of haematopoiesis 
in human embryos, suggesting that they are formed from yolk sac and foetal liver 
precursors as is the case in mice (Hoeffel et al., 2012). Under steady state, human LCs 
can divide by mitosis to maintain cell numbers (Czernielewski and Demarchez, 1987, 
Kanitakis et al., 1993). LC precursors are also produced in the bone marrow and migrate 
towards the skin in blood vessels. Upon exiting the blood vessels, they migrate towards 
the epidermis where they take up residence. LC migration into and continued residence 
in the epidermis in mice has been shown to be controlled by transforming growth factor 
beta (TGF-β) which is activated from its precursor by keratinocytes (Mohammed et al., 
2016).  
LC dendrites allow them to uptake antigen from a relatively large area of the 
epidermis without the constant movement employed by dDCs (Merad et al., 2008). They 
are spatially arranged within the epidermis to create a close-knit network which reduces 
the chances of pathogens evading their detection (Romani et al., 2010). When LCs 
uptake antigen in human skin, they become mature (expressing maturation markers and 
co-stimulatory molecules on their surface) and withdraw their dendrites, taking on a 
more rounded morphology (Pearton et al., 2010b). They then extend towards the 
basement membrane and enter the dermis where they enter lymph vessels. Following 
migration to lymph nodes, LCs present antigen to T-cells, initiating an adaptive immune 
response (Stoitzner et al., 2006, Hunger et al., 2004). At rest, there is a constant turnover 
of LCs with cells spontaneously migrating towards the lymph node (Merad et al., 2002). 
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At steady state, mitosis is sufficient to maintain adequate LC numbers (Czernielewski 
and Demarchez, 1987, Kanitakis et al., 1993). In cases of mouse model inflammation or 
tissue insult where LC numbers are greatly reduced they are replaced by precursors 
recruited from the blood (Merad et al., 2002).  
Unlike dDCs, LCs are a homogeneous population with no subsets. Human LCs 
express CD45 and HLA-DR owing to their leukocyte lineage and role as professional APCs 
respectively (Merad et al., 2008) along with high levels of CD1a which is involved in 
presentation of lipid and glycolipid antigen to T-cells (Hunger et al., 2004). They are 
however distinguishable from other skin DCs by their expression of Langerin (CD207) 
within Birbeck granules and on the cell surface in mice and humans (Romani et al., 2010, 
Merad et al., 2008). CD207 is a C-type lectin receptor with specificity for mannose, 
allowing LCs to efficiently bind and uptake glycosylated antigen (Ng et al., 2016, Engering 
et al., 1997). CD207 is also implicated in viral uptake by LCs in viruses such as influenza 
A (Ng et al., 2016) and HIV (Ahmed et al., 2015). 
 
1.3.3 Dendritic Cells in Human and Mouse Skin 
Immunological studies are often carried out using murine models due to the 
similarities between murine and human immune systems. It is important, therefore, that 
correct alignment of immune cell subsets across the two species is made if results in the 
animal model can inform human immunology. Table 1 contains LC and dDC populations 
which have been aligned based on recent reviews of the literature. 
 
1.3.4 Skin-Resident T-cells 
As discussed in Section 1.1.2, cytotoxic and helper T-cells are integral in the 
implementation of adaptive immune responses against a pathogen. The skin is home to 
roughly 20 billion T-cells, the largest reservoir of any organ and twice the number in the 
systemic circulation (Clark, 2010). Only about 5% of these T-cells are naïve, indicating a 
limited scope for raising an initial immune response purely within the skin (Bos et al., 
1989). The vast majority of T-cells present (95%) are memory T-cells, which allows the  
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Table 1.1: Alignment of dendritic cell subsets in mouse and human skin 
 
 
  
DC Subset 
Human 
Phenotype 
Mouse 
Phenotype 
Major 
Function(s) 
References 
Langerhans 
cells 
CD1a+ 
CD207+ 
HLA-DR+ 
CD205+ 
CD11c+ 
CD1a+ 
CD207+ 
HLA-DR+ 
CD205+ 
CD11c+ 
CD11b+ 
Conflicting 
evidence 
suggesting 
antigen 
presentation/ 
cross-
presentation or 
tolerising/self-
recognition 
roles 
(Artyomov et al., 2015, 
Carpentier et al., 2016, Ginhoux 
and Merad, 2010, Hunger et al., 
2004, Klechevsky et al., 2008b, 
Malissen et al., 2014, Merad et 
al., 2008, Mutyambizi et al., 2009, 
Romani et al., 1989, Romani et 
al., 2012, Shklovskaya et al., 
2011, Stoitzner et al., 2006, 
Stoitzner, 2010, van der Aar et 
al., 2013, van der Vlist et al., 
2011) 
‘Cross-
presenting’ 
dermal 
dendritic cells 
XCR1+ 
CD11c+ 
HLA-DR+ 
CLEC9A+ 
CD141+ 
CD103+ 
 
CD11b- 
CD207+ 
XCR1+ 
CD11c+ 
HLA-DR+ 
CLEC9A+ 
CD103+ 
Cross-
presentation of 
pathogen and 
dead tumour 
cell-associated 
antigens to 
CD8+ naïve T-
cells 
(Artyomov et al., 2015, Bachem 
et al., 2010, Bigley et al., 2015, 
Chu et al., 2012, Haniffa et al., 
2012, Jongbloed et al., 2010, 
Poulin et al., 2010, Lauterbach et 
al., 2010) 
Conventional 
dermal 
dendritic cells 
CD1c+ 
CD11b+ 
CD11c+ 
HLA-DR+ 
CD16+ 
CLEC7A+ 
CLEC6A+ 
 
CD11b+ 
CD207- 
CD172a+ 
HLA-DR+ 
CX3CR1+ 
 
Antigen 
presentation to 
naïve CD4+ T-
cells. Produce 
IL-12 and TNF-α 
upon activation 
(Dutertre et al., 2014, 
Wollenberg et al., 2002, 
Carpentier et al., 2016, Harman 
et al., 2013, Lundberg et al., 
2013, Malissen et al., 2014, 
Merad et al., 2013, Satpathy et 
al., 2012, Ganguly et al., 2013) 
XCR1-/CD11c- 
double-
negative 
dermal 
dendritic cells 
Not yet 
reliably 
characterised 
in human skin 
XCR1- 
CD207- 
CD11b-
/low 
Function 
unknown 
(Mollah et al., Tamoutounour et 
al., 2013, Henri et al., 2010, 
Malissen et al., 2014) 
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rapid initiation of a response to a previously-encountered pathogen (Nomura et al., 
2014). The initiation of an immune response against a previously unencountered 
pathogen leads to the seeding of distal sites with memory T-cells, thus creating 
widespread systemic immunity (Clark, 2010). The distribution of T-cells is not even, with 
CD8+ cytotoxic T-cells preferentially locating in the epidermis- mostly in the acrosyringial 
epithelium of eccrine sweat ducts (Challier et al., 2013). Conversely, dermal-resident T-
cells are mostly CD4+ helper cells and located in the area immediately surrounding the 
dermal vasculature (Nomura et al., 2014). 
 
1.3.5 Macrophages 
As one of the cellular mediators of innate and adaptive immunity, macrophages 
patrol the tissues of the body in search of pathogens. Within the skin, macrophages are 
found in the dermis but not the epidermis (Malissen et al., 2014). If they encounter 
pathogens they are able to uptake them and process their antigen for presentation to 
T-cells (Unanue, 1984). They are also able to release a number of cytokines which can 
activate the other skin immune cells and lead to recruitment of further immune cells 
from the blood (Murphy et al., 2012). Macrophages are derived from circulating CD14+ 
monocytes within the blood and become tissue-resident macrophages upon exit from 
the vasculature into the dermal environment (McGovern et al., 2014). 
 
1.3.6 Inflammatory Response Cells 
Under homeostatic conditions, the immune cells of the skin exist in a state of 
preparedness for the ingress of pathogens into the body. If a pathogen or some other 
immunogenic stimuli is encountered, the skin undergoes a number of changes to assist 
in combating the threat. Mast cells in the dermis are able to detect pathogens via Fc 
receptors, PAMPs or DAMPs on their surface and this triggers degranulation of the cells, 
releasing histamine and other inflammatory mediators into the local environment 
(Sangiuliano et al., 2014, Theoharides et al., 2012). This leads to an increase in local 
blood flow and increased permeability of the vasculature walls, causing the redness and 
swelling associated with inflammation (Medzhitov, 2008). The leakage of plasma into 
the tissue carries with it complement proteins and antibodies which can help to 
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counteract the pathogen (Murphy et al., 2012). The permeability of the vasculature 
walls allows entry of leukocytes into the tissue (Pasparakis et al., 2014). Monocytes are 
in particular recruited and can become macrophages (Malissen et al., 2014) or a further 
type of DC- the monocyte-derived dendritic cell (moDC) (Leon et al., 2005). Following 
antigen presentation in the lymph node and T-cell proliferation, the effector T-cells that 
will implement the adaptive immune response will also enter the tissue via the 
permeable vasculature (Clark, 2010).  
 
1.4 Vaccination 
Since its invention by Edward Jenner in 1796, vaccination has been established 
as one of the most effective tools in the battle against human disease (Morgan and 
Parker, 2007). It involves administering dose(s) of antigen representative of a pathogen, 
allowing the body’s adaptive immune system to be primed in the way it would do if the 
actual pathogen was encountered (Murphy et al., 2012). The antigen used in place of 
the pathogen may be a component of the pathogen, one of its products or a whole killed 
or inactivated pathogen (Siegrist, 2013). This eschews the need for exposure to the 
pathogen to create an initial adaptive response. In many cases the long lag time for an 
initial adaptive response to be mounted after exposure to a pathogen will provide the 
pathogen with enough time to cause serious morbidity or mortality in the patient 
(Duclos and Bentsi-Enchill, 1993). If the immunised person should subsequently 
encounter the actual pathogen, an effective adaptive immune response can be raised 
thereby preventing potential harmful infection (Siegrist, 2013). The benefits of 
vaccination also extend beyond the vaccinated individual via a phenomenon termed 
‘herd immunity’, whereby if enough people are immunised then it is impossible for a 
pathogen to create a ‘chain of infection’, thus passively protecting unimmunised 
individuals (Fox et al., 1971). 
Given that the antigen must be encountered by the systemic immune system 
and the oral route would lead to degradation of the vast majority of antigen (Russell-
Jones, 2000), vaccine delivery is normally via the parenteral route. Although the very 
first ‘vaccine’ involved variolation of a patient’s skin, historically nearly all subsequent 
vaccines have been delivered by the intramuscular (IM) route (Hickling et al., 2011). This 
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involves the delivery of a small volume of liquid formulation through a hypodermic 
needle inserted through the skin to the muscle tissue below. The muscle tissue receives 
relatively high blood supply, allowing blood-resident APCs (including DCs) to access the 
antigen which they can then present in the lymph nodes or spleen to initiate adaptive 
immunity (Zuckerman, 2000). Some common IM vaccines include vaccines against 
diphtheria, tetanus, pertussis, haemophilus influenzae type b, hepatitis A/B, human 
papillomavirus and influenza (IAC, 2015). Although IM injection has proved to be an 
effective delivery route- drastically reducing the number of cases of diseases that used 
to be common (e.g. polio (Bhaumik, 2012) or measles (Levin et al., 2011)) - it also 
possesses a number of disadvantages. The injection is painful, as the muscle tissue is 
well innervated and not suited to receiving volumes of liquid (Jin et al., 2015). The 
variable blood flow in muscle tissue can affect antigen kinetics (Parthasarathi et al., 
2004). It is also does not have scope to provide site-specific immunisation at the site of 
infection for most vaccines (Leenaars and Hendriksen, 1998). IM vaccines also create 
disposal issues relating to the production of contaminated sharps associated with the 
use of hypodermic needles (Beltrami et al., 2000). Finally, although it is well supplied 
with blood, the muscle is not a particularly potent immune target- meaning that large 
or repeated doses of antigen are often required to elicit immunity (Hickling et al., 2011). 
For this reason, there has been a large amount of research in recent years into vaccine 
delivery into skin which may prove advantageous for a number of reasons. 
 
1.5 Intradermal Delivery of Vaccines 
The accessibility of skin and its large population of immune cells make it a 
suitable route for immunisation. Classically, intradermal (ID) injection has been utilised 
to take advantage of the skin’s immunological properties. This is normally achieved by 
the Mantoux technique- a short, small bore needle is inserted into the dermis at an angle 
almost parallel to the skin surface then withdrawn slightly before the liquid formulation 
is injected into the dermal tissue (Norman et al., 2014). The elastic nature of the dermis 
allows it to expand slightly to accommodate the liquid, forming the characteristic ‘bleb’ 
associated with ID injection (Figure 1.4). The injection technique demands a higher level 
of skill than IM injection and high variability in delivery depth can occur between 
healthcare professionals (Kim and Prausnitz, 2011, Suh et al., 2014a). Where it is used 
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correctly, it allows the delivery of liquid formulation into the dermis where it can be 
accessed by dDCs. The fibrous nature of the dermis means that the formulation will also 
be able to permeate towards the basement membrane, where it will be encountered by 
LCs (Liard et al., 2012). Finally, the high level of hydrostatic pressure associated with ID 
injection forces some of the formulation into the lymph vessels of the dermis (Tozuka et 
al., 2016). In the case of vaccines, this will allow the transport of antigen to the lymph 
nodes where it can be processed by resident APCs resulting in adaptive immune 
response (Murphy et al., 2012). 
At present only the Bacille Calmette-Guérin (BCG) vaccine against tuberculosis 
and rabies vaccine are preferentially delivered into skin (Hickling et al., 2011). The BCG 
vaccine is delivered intradermally to reduce the risk of neurovascular injury if the live 
bacillus within the vaccine is delivered to deeper tissues (WHO, 2012b). The rabies 
vaccine is delivered intradermally mostly in developing countries due to the reduced 
cost (a 60-80% reduction) and increased coverage with a limited supply of vaccine that 
is achieved by the antigen-sparing achieved by this delivery route (WHO, 2010). 
Research into a number of other intradermal vaccines is ongoing (Kenney et al., 2004, 
Soonawala et al., 2013, van den Berg et al., 2009, Caucheteux et al., 2016). An ID 
influenza vaccine was first made available during the 2011-12 influenza season and 
possesses advantages over the established intramuscular (IM) injection in antigen 
sparing (using only 60% of the antigen of an IM dose) and patient acceptability (due to 
a smaller hypodermic needle being used) (Reygrobellet et al., 2010). As discussed in 
Section 1.3.3, the induction of an immune response via skin-draining lymph nodes leads 
Figure 1.4: Intradermal injection by the Mantoux technique  
(adapted from: http://www.novosanis.com/sites/default/files/application/ 
field_image/Mantoux_tuberculin_skin_test.jpg) 
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to the population of other tissues with pathogen-specific CD8+ T-cells. In the case of 
influenza, an intradermal injection of antigen leads to the population of lung mucosa 
with influenza-specific CD8+ T-cells which have been shown to be vital in viral clearance 
from the lung (Helft et al., 2012). 
Though there is currently no HIV vaccine available for delivery by any route, the 
intradermal route is a logical choice for testing new vaccine candidates. When HIV is 
transmitted via mucous membranes (e.g. during sexual activity) (de Witte et al., 2007), 
the DCs present within the membranes have been shown to uptake the virus and 
transport it to lymph nodes, where it is transmitted to T-cells (which it remains able to 
infect) (Ahmed et al., 2015). Therefore, the DCs of the skin may be a useful target for 
vaccination if they can be conditioned to recognise and destroy HIV rather than 
transmitting it to T-cells. Thus effective systemic immunity may be best created using 
vaccine antigen delivered intradermally (Johnston and Fauci, 2008, Caucheteux et al., 
2016). 
 
1.6 Intradermal Delivery Technologies 
There are established methods for delivering low molecular weight drugs 
(typically only up to a few hundred Daltons such as opioid analgesics, local anaesthetics 
and hormonal contraceptives) into the skin (Prausnitz and Langer, 2008). Transdermal 
patches (Isaac and Holvey, 2012) and topical semisolid formulations (Touitou, 2002) can 
facilitate the delivery of small molecules of appropriate molecular properties into the 
skin without the need for compromising the stratum corneum. Vaccine antigens are 
macromolecular in nature however, therefore these delivery technologies are not viable 
for vaccination- the size and hydrophilicity of the antigen prevents entry into the skin 
through an intact stratum corneum (Kim and Prausnitz, 2011). Instead, some physical 
disruption of the hydrophobic stratum corneum must occur to allow delivery of vaccines 
into the skin.  
The variable nature of intradermal injections via Mantoux technique and the 
high level of skill required have led to research into a number of alternative delivery 
methods into the skin that look to take advantage of its immunological properties. As 
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well as delivery of liquid vaccine formulation via a smaller hypodermic needle (as in the 
Fluzone™ vaccine), a number of technologies have been explored to deliver vaccine to 
skin immune cells. All of them aim to overcome the hydrophobic physical barrier of the 
stratum corneum to deliver to the cellular epidermal and dermal compartments below.  
 
1.6.1 Negation of the Stratum Corneum Barrier 
In order for large and/or hydrophilic vaccine antigen to be delivered to skin-
resident immune cells, the stratum corneum must somehow be bypassed. One strategy 
to achieve this goal is temporary chemical permeabilisation of the barrier by application 
of formulation applied to the surface of the skin (Andrews et al., 2013, Benson and 
Namjoshi, 2008). A study utilising combinations of permeation enhancers used 
commonly in topical formulations increased the delivery of macromolecules such as 
luteinising hormone-releasing hormone and heparin into porcine skin by 50- to 100- fold 
without skin irritation (Karande et al., 2004). The study was not able to deliver either 
substance at therapeutic concentrations however. Vaccination, which requires much 
lower levels of macromolecule delivery was shown to be effective using penetration 
enhancers to both deliver and increase the antigenicity of ovalbumin in murine skin 
(Karande et al., 2009). This strategy will preferentially deliver to the epidermal 
compartment given the application to the skin’s surface. 
It is also possible to physically negate the stratum corneum barrier using tape-
stripping, where multiple applications of adhesive tape pull off successive layers of the 
hydrophobic barrier (Bashir et al., 2001). Tape-stripping prior to application of whole 
inactivated influenza virus has been shown to induce both cellular and humoral immune 
responses especially when delivered to mice along with cholera toxin or the penetration 
enhancers oleic acid and retinoic acid (Skountzou et al., 2006). Another study found that 
tape-stripping murine skin enhanced T-helper cell responses against both protein and 
DNA vaccines (Vandermeulen et al., 2009).  
Alternative methods of ablating the stratum corneum include the use of laser 
(Jacques et al., 1987, Nelson et al., 1991) or electrical energy (Chen et al., 1998, 
Fukushima et al., 2001). As well as helping to breach the stratum corneum, laser 
treatment of murine skin has been shown to improve cellular and humoral responses 
20 
 
against intradermally-delivered ovalbumin or influenza vaccine (Chen et al., 2010). It has 
been noted that laser enhancement of delivery into the skin provides only a moderate 
benefit and skin healing after treatment is slow (Lee et al., 2010). Electroporation has 
been shown to induce a peptide-specific cytotoxic T-cell immune response against the 
ovalbumin peptide SIINFEKL equivalent to an intradermal injection control in mice (Zhao 
et al., 2006). Electroporation is often used in combination with DNA vaccines, showing 
promising results for vaccination against influenza in rhesus macaque (Laddy et al., 
2009) as well as therapeutic vaccination against hepatitis C in human patients (Weiland 
et al., 2013). 
 
1.6.2 Jet Injectors 
Alternatively, transient physical disruption of the stratum corneum barrier can 
be achieved using a jet injector device (Williams et al., 2000, Soonawala et al., 2013) 
which uses high pressure air to mechanically breach the stratum corneum and deliver a 
liquid formulation into the skin (Zehrung, 2009). The stream characteristics (such as 
shape and width) along with the velocity of liquid delivered can be tailored in order to 
deliver to a specific depth within the skin (Schramm-Baxter et al., 2004). Jet injectors 
have shown promising results in non-inferiority human clinical trials versus 
intramuscular injection of trivalent influenza vaccine (McAllister et al., 2014). As a result, 
the FDA approved the use of the PharmaJet Stratis 0.5ml Needle-free Jet Injector for 
delivery of AFLURIA® by bioCSL Inc. for patients 18-64 years old in 2014 (Hogan et al., 
2015). Jet injectors have also been used clinically to immunise against tuberculosis 
(Parker, 1984), measles (Kok et al., 1983) and hepatitis A (Williams et al., 2000). 
 
1.6.3 Gene Gun Technology 
Particle bombardment can also be used for the delivery of solid particles into the 
skin, though the technology is associated with higher frequencies of local skin reaction 
(Levine, 2003) and delivery depth varies with differing skin sites (Schramm and 
Mitragotri, 2002). Studies utilising DNA vaccines formulated onto particles for delivery 
via gene gun have shown consistent immunisation in mice against ovalbumin compared 
to an intramuscular control (Yoshida et al., 2000) and promising results in a small cohort 
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of patients immunised against Plasmodium, the causative agent of malaria (Bergmann-
Leitner and Leitner, 2015). 
 
1.6.4 Microneedle (MN) Technology 
MN arrays are a promising technology based on their ability to deliver antigen 
efficiently to the immune cell-rich uppermost skin layers for potent immunisation (Van 
Damme et al., 2009). Their reduction of post-injection pain and bleeding (Gill et al., 
2008) and the avoidance of hypodermic needles maximise patient acceptability. Some 
MN approaches may offer avoidance of cold-chain requirements for vaccine transport, 
which can help to improve vaccine coverage in developing countries (Zehrung, 2009). 
The broad definition of a MN is a needle less than 1mm in length and the devices are 
generally classified as solid MNs, hollow MNs and dissolvable MNs.  
 
1.6.4.1 Solid Microneedles 
Solid MNs can be manufactured from a variety of inert materials- most 
commonly silicon (Kim et al., 2006, McGrath et al., 2011) or stainless steel (Torrisi et al., 
2013, Gill and Prausnitz, 2007a). MNs are often manufactured in arrays containing tens 
or hundreds of needles in an evenly-spaced array (Zehrung, 2009). Care must be taken 
to ensure appropriate sharpness and spacing of needles to ensure effective skin 
penetration and avoid the ‘bed of nails’ effect (Cheung et al., 2014). These arrays can 
then be used in a number of ways. The arrays may be pre-applied into the skin, creating 
a number of small channels in the stratum corneum. After the array is removed, a topical 
liquid or semi-solid formulation (Pearton et al., 2008) or transdermal patch (Prausnitz, 
2004) can be applied to the treated area where drug will be able to permeate into the 
skin more freely through the breaches in the stratum corneum. This is a straightforward, 
albeit two-step, approach, allowing conventional liquid and topical formulations to be 
used in combination with the new technology. The arrays might have a relatively 
straightforward route to regulatory approval as a single array type could be used in 
combination with many formulations. It does not, however, offer any potential for cold 
chain avoidance as existing formulations will be used. Also, in the absence of topical 
vaccine formulations, new formulations would have to be developed. Finally, it would 
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likely be an inefficient delivery method and difficult to guarantee that a 
therapeutic/protective dose had been delivered. 
It is also possible to coat liquid formulation onto the surface of the needles, 
allowing it to dry and solidify (Gill and Prausnitz, 2007a). The coating ideally does not 
negate the needle array’s ability to penetrate the stratum corneum (Pearton et al., 
2010c). Following insertion, the interstitial fluid of the skin rehydrates the formulation 
and dissolves it from the array- leaving it deposited in the skin when the array is removed 
(Bariya et al., 2012). Microneedles coated with a reduced dose of influenza vaccine have 
been shown to provide protective immunity comparable to the intramuscular injection 
in mice (Kim et al., 2010). Another study in mice showed priming of CD8+ T-cells 
following administration of a DNA vaccine against hepatitis C coated onto microneedles 
(Gill et al., 2010). 
This represents an efficient method of delivery as theoretically all of the 
formulation can be delivered into skin, though this may vary with both skin insertion 
success and formulation release. It may also be possible to colour the formulation so 
that its deposition in skin can be assessed visually by the health care professional or 
patient. Importantly for improving vaccine coverage in developing countries, a dry 
formulation would be the most likely to eschew the need for cold chain storage 
(Zehrung, 2009). The straightforward application process (provided device design is 
robust) could allow for self-application of vaccines, also reducing the burden on 
healthcare professionals (Donnelly et al., 2014). Regulatory approval of coated MNs 
represents a major barrier to these products though, given that they will likely involve 
novel formulation components and manufacturing processes (Ita, 2015). 
 
1.6.4.2 Hollow Microneedles 
Similar in concept to a smaller hypodermic needle, hollow MNs can allow the 
delivery of liquid formulation into the upper layers of the skin (Norman et al., 2013, Kim 
et al., 2012b). The hydrostatic pressure generated by passing liquid through a small-bore 
channel and the limited liquid capacity of a given area of dermis means that hollow MN 
are also often used in arrays (Wang et al., 2006) to distribute the hydrostatic pressure 
across multiple channels. The use of arrays also acts as a failsafe if one needle channel 
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becomes blocked during injection. The number of hollow needles in arrays are often 
lower than their solid counterparts. It is possible to design arrays that can be attached 
to a syringe for ease of use (Levin et al., 2015). The close analogy to conventional 
hypodermic needle injections means that liquid formulations may not need to be 
redesigned to be used with these MNs, and regulatory approval may be more 
straightforward. Studies in rats using the commercial poliovirus vaccine showed 
equivalency at a reduced dose compared to intramuscular vaccination (Kouiavskaia et 
al., 2015). Studies in human patients have shown superiority to intradermal vaccination 
against influenza by the Mantoux technique (Levin et al., 2014). Care must be taken in 
MN design as incomplete insertion of an array will lead to formulation following the path 
of least resistance and being lost outside of the skin. Their use does generate 
contaminated sharps with the associated health risks and cost of disposal, though 
shallow insertion depths should lower the risk of blood-borne pathogens contaminating 
the arrays.  
 
1.6.4.3 Dissolvable Microneedles 
A third MN approach is to design arrays where the therapeutic cargo is 
incorporated into dissolvable hydrophilic polymers or sugars (Lee et al., 2008). The MNs 
remain solid at room temperature, allowing them to be inserted into the skin (Hirobe et 
al., 2015). They are then able to uptake interstitial fluid in a manner similar to coated 
MN formulations leading to their dissolution in the skin (Moga et al., 2013). This will 
allow for quick visual confirmation of delivery success and will also avoid the generation 
of contaminated sharps. For vaccines, it is possible to disperse the antigen in the needle 
polymer so it can be delivered into skin. A study delivering influenza vaccine dispersed 
in polymer microneedles showed improved viral clearance from the lungs compared to 
intramuscular vaccination (Sullivan et al., 2010). Again, a non-liquid formulation may be 
able to reduce or avoid the need for cold chain transport. It will be important to design 
packaging that avoids atmospheric humidity from being absorbed by the needles which 
could soften them and prevent proper skin penetration (Chu et al., 2016). As this 
approach uses novel formulations and manufacturing processes there will be a need to 
overcome a raft of regulatory obstacles for clinical translation of the technology. 
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1.6.5 Intrafollicular Delivery 
Hair follicles present on skin represent a potential delivery route into the skin. 
They are well-populated with immune cells, making them ideal targets for vaccination 
(Fan et al., 1999). Antigen-conjugated nanoparticle vaccines have shown particular 
suitability for this route where they can penetrate deeper into the follicles of porcine 
skin than a solution of peptide (Mittal et al., 2013). Another study using ovalbumin-
conjugated nanoparticles in mice found that adjuvant is necessary within the 
formulation to ensure cellular and humoral immune responses are generated (Mittal et 
al., 2015). Intrafollicular application to murine skin of a DNA vaccine encoding hepatitis 
B surface antigen has been shown to provide an equivalent immune response to the 
commercially available intramuscular polypeptide vaccine (Fan et al., 1999). 
 
1.6.6 Cellular Targeting of Skin Immune Cells 
As well as the methods mentioned above, many of which can be tailored to 
target a particular region or depth within the skin, it is also possible to design vaccines 
to have an affinity for a specific immune cell population. For example, conjugating 
ovalbumin to monovalent monoclonal antibodies against the C-type lectin receptor 
CD205 has been shown to improve CD8+ T-cell responses in mice (Bonifaz et al., 2002, 
Bonifaz et al., 2004). One caveat of these promising results is that if DC-targeted vaccines 
are delivered in the absence of DC activating substances (such as adjuvant), then DCs 
will induce a state of tolerance against the antigen rather than immunity (Hawiger et al., 
2001). The ability to target specific subsets of DCs can allow for the desired immune 
response to be tailored- for example delivery of identical antigen conjugated to 
antibodies either specific for CD205 or the dendritic cell inhibitory receptor-2 (DCIR2) to 
murine skin showed preferential CD8+ or CD4+ T-cell responses respectively (Dudziak et 
al., 2007). It is important that the full phenotype and functions of the various DC subsets 
are well understood before this method of vaccination can be implemented successfully.  
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1.7 Project Rationale 
The intradermal delivery of vaccines represents a potentially beneficial 
healthcare approach. Intradermal delivery has been described in a PATH report as 
having the potential to reduce the cost of vaccination whilst improving compliance, 
immunisation success rates and geographical coverage (Zehrung, 2009). The high cost 
and regulatory obstacles associated with developing novel intradermal vaccines suggest 
that it may not be commercially attractive to replace vaccines which are currently 
delivered effectively via the IM route. Perhaps the best candidates would be novel 
vaccines against pathogens where no vaccine currently exist and will benefit from early 
stage research to optimise intradermal delivery. Influenza vaccines, where new vaccines 
must be delivered annually to immunise against the currently prevalent strains may also 
be a candidate for a new delivery approach (Kenney et al., 2004). The commercial 
success of FluMist® quadrivalent intranasal and Fluzone™ Fluzone quadrivalent 
intradermal vaccines show that new delivery approaches are marketable and it may be 
possible that technological development can further improve vaccine efficiency. This 
may become important in pandemic situations, where a limited supply of antigen is 
available at short notice and as many people need to be vaccinated as possible.  
Given that intradermal vaccination may become an important route for 
emerging vaccines, it is vital that the characteristics of the skin tissue and the behaviours 
of the immune cells that reside there are fully understood. Whilst LCs were first 
described in 1868, it was over 100 years until they were recognised for their role in the 
immune system (Jolles, 2002). Dermal DCs were described later, with Ralph Steinman 
being recognised for his work in the field during the latter half of the 20th century with 
the 2011 Nobel Prize in Physiology or Medicine (Moberg, 2011). Subsequent work has 
uncovered the complexities that exist within the subsets of dDCs and the heterogeneity 
of function between these cells and LCs. Our understanding of the adaptive immune 
system and virology are concurrently expanding, allowing us to better comprehend and 
thereby treat or prevent pathogenic disease. 
This project has the aim of improving the knowledge of human skin immune cells 
in the context of host interactions and intradermal vaccination. Specifically, their 
interactions with viral pathogens and vaccines against viral pathogens will be explored. 
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This will be combined with research into novel delivery technologies with the hope of 
informing intradermal vaccine research in the future. 
 
1.8 Thesis Aim and Objectives 
The aim of this Thesis is to further the understanding of human skin immune cells 
in order to inform how best to deliver vaccines into the skin for effective immunisation. 
The objectives are: 
 Characterise the coating of peptide, protein and particulate vaccines 
onto solid MN arrays 
 Assess the delivery of peptide, protein and particulate vaccines into the 
skin by MNs and to assess the response of skin cells 
 Optimise a protocol to obtain migratory immune cells from skin for use 
in downstream cellular experiments 
 Use the skin cell model to measure the immunostimulatory properties of 
vaccine candidates 
 Utilise the skin cell model to study the infection pathways of the HIV virus 
 Attempt to differentiate the vaccine antigen presentation properties of 
LCs and the subsets of dDCs in skin 
 Assess whether novel formulation technologies can assist in the delivery 
of vaccines into the skin  
 
 
 
 
 
 
27 
 
1.9 Bibliography 
AHMED, Z., KAWAMURA, T., SHIMADA, S. & PIGUET, V. 2015. The role of human 
dendritic cells in HIV-1 infection. J Invest Dermatol, 135, 1225-33. 
ANDERSEN, M. H., SCHRAMA, D., THOR STRATEN, P. & BECKER, J. C. 2006. 
Cytotoxic T cells. J Invest Dermatol, 126, 32-41. 
ANDREWS, S. N., JEONG, E. & PRAUSNITZ, M. R. 2013. Transdermal delivery of 
molecules is limited by full epidermis, not just stratum corneum. Pharm 
Res, 30, 1099-109. 
ANTUNES, M. B. & COHEN, N. A. 2007. Mucociliary clearance--a critical upper 
airway host defense mechanism and methods of assessment. Curr Opin 
Allergy Clin Immunol, 7, 5-10. 
ARTYOMOV, M. N., MUNK, A., GORVEL, L., KORENFELD, D., CELLA, M., TUNG, T. & 
KLECHEVSKY, E. 2015. Modular expression analysis reveals functional 
conservation between human Langerhans cells and mouse cross-priming 
dendritic cells. J Exp Med, 212, 743-57. 
AUNGST, B. J. 2012. Absorption Enhancers: Applications and Advances. The AAPS 
Journal, 14, 10-18. 
BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic cells and the control of 
immunity. Nature, 392, 245-252. 
BARBERO, A. M. & FRASCH, H. F. 2006. Transcellular route of diffusion through 
stratum corneum: results from finite element models. J Pharm Sci, 95, 
2186-94. 
BARIYA, S. H., GOHEL, M. C., MEHTA, T. A. & SHARMA, O. P. 2012. Microneedles: 
an emerging transdermal drug delivery system. J Pharm Pharmacol, 64, 11-
29. 
BELKAID, Y. & ROUSE, B. T. 2005. Natural regulatory T cells in infectious disease. 
Nat Immunol, 6, 353-60. 
BELTRAMI, E. M., WILLIAMS, I. T., SHAPIRO, C. N. & CHAMBERLAND, M. E. 2000. 
Risk and Management of Blood-Borne Infections in Health Care Workers. 
Clinical Microbiology Reviews, 13, 385-407. 
BENSON, H. A. E. & NAMJOSHI, S. 2008. Proteins and Peptides: Strategies for 
Delivery to and Across the Skin. Journal of Pharmaceutical Sciences, 97, 
3591-3610. 
28 
 
BERGER, C. L., VASQUEZ, J. G., SHOFNER, J., MARIWALLA, K. & EDELSON, R. L. 2006. 
Langerhans cells: Mediators of immunity and tolerance. The International 
Journal of Biochemistry & Cell Biology, 38, 1632-1636. 
BHAUMIK, S. 2012. Polio eradication: Current status and challenges. Journal of 
Family Medicine and Primary Care, 1, 84-85. 
BIANCHI, M. E. 2007. DAMPs, PAMPs and alarmins: all we need to know about 
danger. J Leukoc Biol, 81, 1-5. 
BOS, J. D., HAGENAARS, C., DAS, P. K., KRIEG, S. R., VOORN, W. J. & KAPSENBERG, 
M. L. 1989. Predominance of "memory" T cells (CD4+, CDw29+) over 
"naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. 
Arch Dermatol Res, 281, 24-30. 
BRENNAN, P. J., BRIGL, M. & BRENNER, M. B. 2013. Invariant natural killer T cells: 
an innate activation scheme linked to diverse effector functions. Nat Rev 
Immunol, 13, 101-117. 
BRENNER, M. & HEARING, V. J. 2008. The Protective Role of Melanin Against UV 
Damage in Human Skin. Photochemistry and photobiology, 84, 539-549. 
BRIGGAMAN, R. A., DALLDORF, F. G. & WHEELER, C. E., JR. 1971. Formation and 
origin of basal lamina and anchoring fibrils in adult human skin. J Cell Biol, 
51, 384-95. 
BROERE, F., APASOV, S. G., SITKOVSKY, M. V. & VAN EDEN, W. 2011. A2 T cell 
subsets and T cell-mediated immunity. In: NIJKAMP, F. P. & PARNHAM, J. 
M. (eds.) Principles of Immunopharmacology: 3rd revised and extended 
edition. Basel: Birkhäuser Basel. 
BROWN, M. B., MARTIN, G. P., JONES, S. A. & AKOMEAH, F. K. 2006. Dermal and 
transdermal drug delivery systems: current and future prospects. Drug 
Deliv, 13, 175-87. 
CARPENTIER, S., VU MANH, T.-P., CHELBI, R., HENRI, S., MALISSEN, B., HANIFFA, 
M., GINHOUX, F. & DALOD, M. 2016a. Comparative genomics analysis of 
mononuclear phagocyte subsets confirms homology between lymphoid 
tissue-resident and dermal XCR1+ DCs in mouse and human and 
distinguishes them from Langerhans cells. J Immunol Methods, 432, 35-49. 
CARPENTIER, S., VU MANH, T.-P., CHELBI, R., HENRI, S., MALISSEN, B., HANIFFA, 
M., GINHOUX, F. & DALOD, M. 2016b. Comparative genomics analysis of 
mononuclear phagocyte subsets confirms homology between lymphoid 
tissue-resident and dermal XCR1+ DCs in mouse and human and 
distinguishes them from Langerhans cells. Journal of Immunological 
Methods, 432, 35-49. 
29 
 
CAUCHETEUX, S. M., MITCHELL, J. P., IVORY, M. O., HIROSUE, S., HAKOBYAN, S., 
DOLTON, G., LADELL, K., MINERS, K., PRICE, D. A., KAN-MITCHELL, J., 
SEWELL, A. K., NESTLE, F., MORIS, A., KAROO, R. O., BIRCHALL, J. C., 
SWARTZ, M. A., HUBBEL, J. A., BLANCHET, F. P. & PIGUET, V. 2016. 
Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-
Mediated Specific Immune Responses against HIV-1. J Invest Dermatol, 136, 
1172-81. 
CHALLIER, J., BRUNIQUEL, D., SEWELL, A. K. & LAUGEL, B. 2013. Adenosine and 
cAMP signalling skew human dendritic cell differentiation towards a 
tolerogenic phenotype with defective CD8(+) T-cell priming capacity. 
Immunology, 138, 402-10. 
CHEUNG, K., HAN, T. & DAS, D. B. 2014. Effect of Force of Microneedle Insertion 
on the Permeability of Insulin in Skin. Journal of Diabetes Science and 
Technology, 8, 444-452. 
CHU, C. C., ALI, N., KARAGIANNIS, P., DI MEGLIO, P., SKOWERA, A., NAPOLITANO, 
L., BARINAGA, G., GRYS, K., SHARIF-PAGHALEH, E., KARAGIANNIS, S. N., 
PEAKMAN, M., LOMBARDI, G. & NESTLE, F. O. 2012. Resident CD141 
(BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory 
T cells that suppress skin inflammation. J Exp Med, 209, 935-45. 
CHU, L. Y., YE, L., DONG, K., COMPANS, R. W., YANG, C. & PRAUSNITZ, M. R. 2016. 
Enhanced Stability of Inactivated Influenza Vaccine Encapsulated in 
Dissolving Microneedle Patches. Pharm Res, 33, 868-78. 
CLARK, R. A. 2010. Skin resident T cells: the ups and downs of on site immunity. 
The Journal of investigative dermatology, 130, 362-370. 
CZERNIELEWSKI, J. M. & DEMARCHEZ, M. 1987. Further evidence for the self-
reproducing capacity of Langerhans cells in human skin. J Invest Dermatol, 
88, 17-20. 
DAVIS, M. M., BONIFACE, J. J., REICH, Z., LYONS, D., HAMPL, J., ARDEN, B. & CHIEN, 
Y. 1998. Ligand recognition by alpha beta T cell receptors. Annu Rev 
Immunol, 16, 523-44. 
DE WITTE, L., NABATOV, A., PION, M., FLUITSMA, D., DE JONG, M. A., DE GRUIJL, 
T., PIGUET, V., VAN KOOYK, Y. & GEIJTENBEEK, T. B. 2007. Langerin is a 
natural barrier to HIV-1 transmission by Langerhans cells. Nat Med, 13, 367-
71. 
DEMPSEY, P. W., VAIDYA, S. A. & CHENG, G. 2003. The art of war: Innate and 
adaptive immune responses. Cell Mol Life Sci, 60, 2604-21. 
DONNELLY, R. F., MOFFATT, K., ALKILANI, A. Z., VICENTE-PEREZ, E. M., BARRY, J., 
MCCRUDDEN, M. T. & WOOLFSON, A. D. 2014. Hydrogel-forming 
30 
 
microneedle arrays can be effectively inserted in skin by self-application: a 
pilot study centred on pharmacist intervention and a patient information 
leaflet. Pharm Res, 31, 1989-99. 
DUCLOS, P. & BENTSI-ENCHILL, A. 1993. Current thoughts on the risks and benefits 
of immunisation. Drug Saf, 8, 404-13. 
DUDZIAK, D., KAMPHORST, A. O., HEIDKAMP, G. F., BUCHHOLZ, V. R., 
TRUMPFHELLER, C., YAMAZAKI, S., CHEONG, C., LIU, K., LEE, H.-W. & PARK, 
C. G. 2007. Differential antigen processing by dendritic cell subsets in vivo. 
Science, 315, 107-111. 
DUNKELBERGER, J. R. & SONG, W. C. 2010. Complement and its role in innate and 
adaptive immune responses. Cell Res, 20, 34-50. 
ECKERT, R. L. & RORKE, E. A. 1989. Molecular biology of keratinocyte 
differentiation. Environmental Health Perspectives, 80, 109-116. 
ELIAS, P. M. 2005. Stratum corneum defensive functions: an integrated view. J 
Invest Dermatol, 125, 183-200. 
ELIAS, P. M. 2007. The skin barrier as an innate immune element. Seminars in 
Immunopathology, 29, 3-14. 
ENGERING, A. J., CELLA, M., FLUITSMA, D. M., HOEFSMIT, E. C., LANZAVECCHIA, A. 
& PIETERS, J. 1997. Mannose receptor mediated antigen uptake and 
presentation in human dendritic cells. Adv Exp Med Biol, 417, 183-7. 
FLUHR, J. W., MAO-QIANG, M., BROWN, B. E., WERTZ, P. W., CRUMRINE, D., 
SUNDBERG, J. P., FEINGOLD, K. R. & ELIAS, P. M. 2003. Glycerol regulates 
stratum corneum hydration in sebaceous gland deficient (asebia) mice. J 
Invest Dermatol, 120, 728-37. 
FORE, J. 2006. A review of skin and the effects of aging on skin structure and 
function. Ostomy Wound Manage, 52, 24-35; quiz 36-7. 
FORSTER, R., DAVALOS-MISSLITZ, A. C. & ROT, A. 2008. CCR7 and its ligands: 
balancing immunity and tolerance. Nat Rev Immunol, 8, 362-71. 
FORTHAL, D. N. 2014. Functions of Antibodies. Microbiology spectrum, 2, 1-17. 
FOX, J. P., ELVEBACK, L., SCOTT, W., GATEWOOD, L. & ACKERMAN, E. 1971. Herd 
Immunity: Basic Concept and Relevance to Public Health and Immunization 
Practices. American Journal of Epidemiology, 94, 179-189. 
GILL, H. S., DENSON, D. D., BURRIS, B. A. & PRAUSNITZ, M. R. 2008. Effect of 
microneedle design on pain in human volunteers. Clin J Pain, 24, 585-94. 
31 
 
GILL, H. S. & PRAUSNITZ, M. R. 2007. Coated microneedles for transdermal 
delivery. J Control Release, 117, 227-37. 
GRANUCCI, F., FERRERO, E., FOTI, M., AGGUJARO, D., VETTORETTO, K. & 
RICCIARDI-CASTAGNOLI, P. 1999. Early events in dendritic cell maturation 
induced by LPS. Microbes and Infection, 1, 1079-1084. 
GUERMONPREZ, P., VALLADEAU, J., ZITVOGEL, L., THERY, C. & AMIGORENA, S. 
2002. Antigen presentation and T cell stimulation by dendritic cells. Annu 
Rev Immunol, 20, 621-67. 
HACKSTEIN, H. & THOMSON, A. W. 2004. Dendritic cells: emerging 
pharmacological targets of immunosuppressive drugs. Nat Rev Immunol, 4, 
24-34. 
HANIFFA, M., GINHOUX, F., WANG, X. N., BIGLEY, V., ABEL, M., DIMMICK, I., 
BULLOCK, S., GRISOTTO, M., BOOTH, T., TAUB, P., HILKENS, C., MERAD, M. 
& COLLIN, M. 2009. Differential rates of replacement of human dermal 
dendritic cells and macrophages during hematopoietic stem cell 
transplantation. J Exp Med, 206, 371-85. 
HANIFFA, M., SHIN, A., BIGLEY, V., MCGOVERN, N., TEO, P., SEE, P., WASAN, P. S., 
WANG, X. N., MALINARICH, F., MALLERET, B., LARBI, A., TAN, P., ZHAO, H., 
POIDINGER, M., PAGAN, S., COOKSON, S., DICKINSON, R., DIMMICK, I., 
JARRETT, R. F., RENIA, L., TAM, J., SONG, C., CONNOLLY, J., CHAN, J. K., 
GEHRING, A., BERTOLETTI, A., COLLIN, M. & GINHOUX, F. 2012. Human 
tissues contain CD141hi cross-presenting dendritic cells with functional 
homology to mouse CD103+ nonlymphoid dendritic cells. Immunity, 37, 60-
73. 
HAO, W. L. & LEE, Y. K. 2004. Microflora of the gastrointestinal tract: a review. 
Methods Mol Biol, 268, 491-502. 
HEATH, W. R. & CARBONE, F. R. 2001. Cross-presentation, dendritic cells, tolerance 
and immunity. Annu Rev Immunol, 19, 47-64. 
HELFT, J., MANICASSAMY, B., GUERMONPREZ, P., HASHIMOTO, D., SILVIN, A., 
AGUDO, J., BROWN, B. D., SCHMOLKE, M., MILLER, J. C., LEBOEUF, M., 
MURPHY, K. M., GARCIA-SASTRE, A. & MERAD, M. 2012. Cross-presenting 
CD103+ dendritic cells are protected from influenza virus infection. J Clin 
Invest, 122, 4037-47. 
HICKLING, J. K., JONES, K. R., FRIEDE, M., ZEHRUNG, D., CHEN, D. & KRISTENSEN, 
D. 2011. Intradermal delivery of vaccines: potential benefits and current 
challenges. Bulletin of the World Health Organization, 89, 221-226. 
HIROBE, S., AZUKIZAWA, H., HANAFUSA, T., MATSUO, K., QUAN, Y.-S., KAMIYAMA, 
F., KATAYAMA, I., OKADA, N. & NAKAGAWA, S. 2015. Clinical study and 
32 
 
stability assessment of a novel transcutaneous influenza vaccination using 
a dissolving microneedle patch. Biomaterials, 57, 50-58. 
HOEFFEL, G., WANG, Y., GRETER, M., SEE, P., TEO, P., MALLERET, B., LEBOEUF, M., 
LOW, D., OLLER, G., ALMEIDA, F., CHOY, S. H. Y., GRISOTTO, M., RENIA, L., 
CONWAY, S. J., STANLEY, E. R., CHAN, J. K. Y., NG, L. G., SAMOKHVALOV, I. 
M., MERAD, M. & GINHOUX, F. 2012. Adult Langerhans cells derive 
predominantly from embryonic fetal liver monocytes with a minor 
contribution of yolk sac–derived macrophages. J Exp Med, 209, 1167-1181. 
HOLBROOK, K. A., BYERS, P. H. & PINNELL, S. R. 1982. The structure and function 
of dermal connective tissue in normal individuals and patients with 
inherited connective tissue disorders. Scan Electron Microsc, 1731-44. 
HOLTMEIER, W. & KABELITZ, D. 2005. gammadelta T cells link innate and adaptive 
immune responses. Chem Immunol Allergy, 86, 151-83. 
HORNEF, M. W., WICK, M. J., RHEN, M. & NORMARK, S. 2002. Bacterial strategies 
for overcoming host innate and adaptive immune responses. Nat Immunol, 
3, 1033-40. 
HUBO, M., TRINSCHEK, B., KRYCZANOWSKY, F., TÜTTENBERG, A., STEINBRINK, K. 
& JONULEIT, H. 2013. Costimulatory molecules on immunogenic versus 
tolerogenic human dendritic cells. Frontiers in Immunology, 4. 
HUNGER, R. E., SIELING, P. A., OCHOA, M. T., SUGAYA, M., BURDICK, A. E., REA, T. 
H., BRENNAN, P. J., BELISLE, J. T., BLAUVELT, A., PORCELLI, S. A. & MODLIN, 
R. L. 2004. Langerhans cells utilize CD1a and langerin to efficiently present 
nonpeptide antigens to T cells. Journal of Clinical Investigation, 113, 701-
708. 
IAC. 2015. How to Administer Intramuscular and Subcutaneous Vaccine Injections 
[Online]. Minnesota: Centers for Disease Control and Prevention. Available: 
http://www.immunize.org/catg.d/p2020.pdf [Accessed 30 June 2016]. 
INABA, K., TURLEY, S., YAMAIDE, F., IYODA, T., MAHNKE, K., INABA, M., PACK, M., 
SUBKLEWE, M., SAUTER, B., SHEFF, D., ALBERT, M., BHARDWAJ, N., 
MELLMAN, I. & STEINMAN, R. M. 1998. Efficient presentation of 
phagocytosed cellular fragments on the major histocompatibility complex 
class II products of dendritic cells. J Exp Med, 188, 2163-73. 
ISAAC, M. & HOLVEY, C. 2012. Transdermal patches: the emerging mode of drug 
delivery system in psychiatry. Therapeutic Advances in 
Psychopharmacology, 2, 255-263. 
ITA, K. 2015. Transdermal Delivery of Drugs with Microneedles-Potential and 
Challenges. Pharmaceutics, 7, 90-105. 
33 
 
JANEWAY, C. A., JR. 1991. The co-receptor function of CD4. Semin Immunol, 3, 153-
60. 
JIANG, X., CLARK, R. A., LIU, L., WAGERS, A. J., FUHLBRIGGE, R. C. & KUPPER, T. S. 
2012. Skin infection generates non-migratory memory CD8+ TRM cells 
providing global skin immunity. Nature, 483, 227-231. 
JIN, J.-F., ZHU, L.-L., CHEN, M., XU, H.-M., WANG, H.-F., FENG, X.-Q., ZHU, X.-P. & 
ZHOU, Q. 2015. The optimal choice of medication administration route 
regarding intravenous, intramuscular, and subcutaneous injection. Patient 
preference and adherence, 9, 923-942. 
JOHNSTON, M. I. & FAUCI, A. S. 2008. An HIV vaccine--challenges and prospects. N 
Engl J Med, 359, 888-90. 
JOLLES, S. 2002. Paul Langerhans. Journal of Clinical Pathology, 55, 243-243. 
KAECH, S. M., WHERRY, E. J. & AHMED, R. 2002. Effector and memory T-cell 
differentiation: implications for vaccine development. Nat Rev Immunol, 2, 
251-262. 
KALIA, Y. N., ALBERTI, I., SEKKAT, N., CURDY, C., NAIK, A. & GUY, R. H. 2000. 
Normalization of Stratum Corneum Barrier Function and Transepidermal 
Water Loss In Vivo. Pharmaceutical Research, 17, 1148-1150. 
KALISH, R. S., WOOD, J. A. & LAPORTE, A. 1994. Processing of urushiol (poison ivy) 
hapten by both endogenous and exogenous pathways for presentation to 
T cells in vitro. Journal of Clinical Investigation, 93, 2039-2047. 
KANITAKIS, J., HOYO, E., PERRIN, C. & SCHMITT, D. 1993. Electron-microscopic 
observation of a human epidermal Langerhans cell in mitosis. J Dermatol, 
20, 35-9. 
KENNEY, R. T., FRECH, S. A., MUENZ, L. R., VILLAR, C. P. & GLENN, G. M. 2004. Dose 
sparing with intradermal injection of influenza vaccine. N Engl J Med, 351, 
2295-301. 
KIM, S., SHETTY, S., PRICE, D. & BHANSALI, S. 2006. Skin penetration of silicon 
dioxide microneedle arrays. Conf Proc IEEE Eng Med Biol Soc, 1, 4088-91. 
KIM, Y.-C., PARK, J.-H. & PRAUSNITZ, M. R. 2012. Microneedles for drug and 
vaccine delivery. Advanced drug delivery reviews, 64, 1547-1568. 
KIM, Y.-C. & PRAUSNITZ, M. R. 2011. Enabling skin vaccination using new delivery 
technologies. Drug Delivery and Translational Research, 1, 7-12. 
KLECHEVSKY, E., MORITA, R., LIU, M., CAO, Y., COQUERY, S., THOMPSON-SNIPES, 
L. A., BRIERE, F., CHAUSSABEL, D., ZURAWSKI, G., PALUCKA, A. K., REITER, 
Y., BANCHEREAU, J. & UENO, H. 2008. Functional Specializations of Human 
34 
 
Epidermal Langerhans Cells and CD14(+) Dermal Dendritic Cells. Immunity, 
29, 497-510. 
KUMAR, H., KAWAI, T. & AKIRA, S. 2011. Pathogen recognition by the innate 
immune system. Int Rev Immunol, 30, 16-34. 
KUROSAKI, T., KOMETANI, K. & ISE, W. 2015. Memory B cells. Nat Rev Immunol, 
15, 149-159. 
LALVANI, A., BROOKES, R., HAMBLETON, S., BRITTON, W. J., HILL, A. V. & 
MCMICHAEL, A. J. 1997. Rapid effector function in CD8+ memory T cells. J 
Exp Med, 186, 859-65. 
LECHLER, T. & FUCHS, E. 2005. Asymmetric cell divisions promote stratification and 
differentiation of mammalian skin. Nature, 437, 275-280. 
LEE, J. W., PARK, J.-H. & PRAUSNITZ, M. R. 2008. Dissolving microneedles for 
transdermal drug delivery. Biomaterials, 29, 2113-2124. 
LEENAARS, M. & HENDRIKSEN, C. F. 1998. Influence of Route of Injection on 
Efficacy and Side Effects of Immunisation. Altex, 15, 87. 
LEON, B., LOPEZ-BRAVO, M. & ARDAVIN, C. 2005. Monocyte-derived dendritic 
cells. Semin Immunol, 17, 313-8. 
LEVIN, A., BURGESS, C., GARRISON, L. P., JR., BAUCH, C., BABIGUMIRA, J., SIMONS, 
E. & DABBAGH, A. 2011. Global eradication of measles: an epidemiologic 
and economic evaluation. J Infect Dis, 204 Suppl 1, S98-106. 
LEVIN, Y., KOCHBA, E., HUNG, I. & KENNEY, R. 2015. Intradermal vaccination using 
the novel microneedle device MicronJet600: Past, present, and future. 
Hum Vaccin Immunother, 11, 991-7. 
LEVINE, M. M. 2003. Can needle-free administration of vaccines become the norm 
in global immunization? Nat Med, 9, 99-103. 
LIARD, C., MUNIER, S., JOULIN-GIET, A., BONDUELLE, O., HADAM, S., DUFFY, D., 
VOGT, A., VERRIER, B. & COMBADIERE, B. 2012. Intradermal immunization 
triggers epidermal Langerhans cell mobilization required for CD8 T-cell 
immune responses. J Invest Dermatol, 132, 615-25. 
LUKAS, M., STOSSEL, H., HEFEL, L., IMAMURA, S., FRITSCH, P., SEPP, N. T., 
SCHULER, G. & ROMANI, N. 1996. Human cutaneous dendritic cells migrate 
through dermal lymphatic vessels in a skin organ culture model. J Invest 
Dermatol, 106, 1293-9. 
MAKSIMOVIC, S., NAKATANI, M., BABA, Y., NELSON, A. M., MARSHALL, K. L., 
WELLNITZ, S. A., FIROZI, P., WOO, S.-H., RANADE, S., PATAPOUTIAN, A. & 
35 
 
LUMPKIN, E. A. 2014. Epidermal Merkel cells are mechanosensory cells that 
tune mammalian touch receptors. Nature, 509, 617-621. 
MALISSEN, B., TAMOUTOUNOUR, S. & HENRI, S. 2014. The origins and functions 
of dendritic cells and macrophages in the skin. Nat Rev Immunol, 14, 417-
28. 
MARTIN, N. H. 1969. The immunoglobulins: a review. Journal of Clinical Pathology, 
22, 117-131. 
MCGOVERN, N., SCHLITZER, A., GUNAWAN, M., JARDINE, L., SHIN, A., POYNER, E., 
GREEN, K., DICKINSON, R., WANG, X.-N., LOW, D., BEST, K., COVINS, S., 
MILNE, P., PAGAN, S., ALJEFRI, K., WINDEBANK, M., SAAVEDRA, DIEGO M., 
LARBI, A., WASAN, PAVANDIP S., DUAN, K., POIDINGER, M., BIGLEY, V., 
GINHOUX, F., COLLIN, M. & HANIFFA, M. 2014. Human Dermal CD14(+) 
Cells Are a Transient Population of Monocyte-Derived Macrophages. 
Immunity, 41, 465-477. 
MCGRATH, M. G., VRDOLJAK, A., O’MAHONY, C., OLIVEIRA, J. C., MOORE, A. C. & 
CREAN, A. M. 2011. Determination of parameters for successful spray 
coating of silicon microneedle arrays. International Journal of 
Pharmaceutics, 415, 140-149. 
MEDZHITOV, R. 2008. Origin and physiological roles of inflammation. Nature, 454, 
428-435. 
MEDZHITOV, R. & JANEWAY, C. 2000. Innate Immunity. N Engl J Med, 343, 338-
344. 
MERAD, M., GINHOUX, F. & COLLIN, M. 2008. Origin, homeostasis and function of 
Langerhans cells and other langerin-expressing dendritic cells. Nat Rev 
Immunol, 8, 935-947. 
MERAD, M., MANZ, M. G., KARSUNKY, H., WAGERS, A., PETERS, W., CHARO, I., 
WEISSMAN, I. L., CYSTER, J. G. & ENGLEMAN, E. G. 2002. Langerhans cells 
renew in the skin throughout life under steady-state conditions. Nat 
Immunol, 3, 1135-41. 
MERAD, M., SATHE, P., HELFT, J., MILLER, J. & MORTHA, A. 2013. The Dendritic Cell 
Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the 
Steady State and the Inflamed Setting. Annual review of immunology, 31, 
10.1146/annurev-immunol-020711-074950. 
MILSTONE, L. M. 2004. Epidermal desquamation. J Dermatol Sci, 36, 131-40. 
MOBERG, C. L. 2011. An appreciation of Ralph Marvin Steinman (1943–2011). The 
Journal of Experimental Medicine, 208, 2337-2342. 
36 
 
MOGA, K. A., BICKFORD, L. R., GEIL, R. D., DUNN, S. S., PANDYA, A. A., WANG, Y., 
FAIN, J. H., ARCHULETA, C. F., O'NEILL, A. T. & DESIMONE, J. M. 2013. 
Rapidly-dissolvable microneedle patches via a highly scalable and 
reproducible soft lithography approach. Adv Mater, 25, 5060-6. 
MOHAMMED, J., BEURA, L. K., BOBR, A., ASTRY, B., CHICOINE, B., KASHEM, S. W., 
WELTY, N. E., IGYARTO, B. Z., WIJEYESINGHE, S., THOMPSON, E. A., MATTE, 
C., BARTHOLIN, L., KAPLAN, A., SHEPPARD, D., BRIDGES, A. G., SHLOMCHIK, 
W. D., MASOPUST, D. & KAPLAN, D. H. 2016. Stromal cells control the 
epithelial residence of DCs and memory T cells by regulated activation of 
TGF-beta. Nat Immunol, 17, 414-21. 
MORGAN, A. J. & PARKER, S. 2007. Translational Mini-Review Series on Vaccines: 
The Edward Jenner Museum and the history of vaccination. Clinical and 
Experimental Immunology, 147, 389-394. 
MURPHY, K., TRAVERS, P., WALPORT, M. & JANEWAY, C. 2012. Janeway's 
Immunobiology (8th ed.), New York, Garland Science. 
NESTLE, F. O., ZHENG, X. G., THOMPSON, C. B., TURKA, L. A. & NICKOLOFF, B. J. 
1993. Characterization of dermal dendritic cells obtained from normal 
human skin reveals phenotypic and functionally distinctive subsets. J 
Immunol, 151, 6535-45. 
NG, W. C., LONDRIGAN, S. L., NASR, N., CUNNINGHAM, A. L., TURVILLE, S., BROOKS, 
A. G. & READING, P. C. 2016. The C-type Lectin Langerin Functions as a 
Receptor for Attachment and Infectious Entry of Influenza A Virus. J Virol, 
90, 206-21. 
NI, K. & O'NEILL, H. C. 1997. The role of dendritic cells in T cell activation. Immunol 
Cell Biol, 75, 223-30. 
NOMURA, T., KABASHIMA, K. & MIYACHI, Y. 2014. The panoply of αβT cells in the 
skin. Journal of Dermatological Science, 76, 3-9. 
NORLÉN, L. 2006. Stratum corneum keratin structure, function and formation – a 
comprehensive review. International Journal of Cosmetic Science, 28, 397-
425. 
NORMAN, J. J., CHOI, S. O., TONG, N. T., AIYAR, A. R., PATEL, S. R., PRAUSNITZ, M. 
R. & ALLEN, M. G. 2013. Hollow microneedles for intradermal injection 
fabricated by sacrificial micromolding and selective electrodeposition. 
Biomed Microdevices, 15, 203-10. 
NORMAN, J. J., GUPTA, J., PATEL, S. R., PARK, S., JARRAHIAN, C., ZEHRUNG, D. & 
PRAUSNITZ, M. R. 2014. Reliability and accuracy of intradermal injection by 
Mantoux technique, hypodermic needle adapter, and hollow microneedle 
in pigs. Drug Deliv Transl Res, 4, 126-30. 
37 
 
OCHSENBEIN, A. F. & ZINKERNAGEL, R. M. 2000. Natural antibodies and 
complement link innate and acquired immunity. Immunol Today, 21, 624-
30. 
PARTHASARATHI, G., NYFORT-HANSEN, K. & NAHATA, M. C. 2004. A text book of 
clinical pharmacy practice : essential concepts and skills, Hyderabad ; Great 
Britain, Orient Longman Ltd. 
PASPARAKIS, M., HAASE, I. & NESTLE, F. O. 2014. Mechanisms regulating skin 
immunity and inflammation. Nature Reviews Immunology, 14, 289-301. 
PEARTON, M., ALLENDER, C., BRAIN, K., ANSTEY, A., GATELEY, C., WILKE, N., 
MORRISSEY, A. & BIRCHALL, J. 2008. Gene Delivery to the Epidermal Cells 
of Human Skin Explants Using Microfabricated Microneedles and Hydrogel 
Formulations. Pharmaceutical Research, 25, 407-416. 
PEARTON, M., KANG, S.-M., SONG, J.-M., ANSTEY, A. V., IVORY, M., COMPANS, R. 
W. & BIRCHALL, J. C. 2010a. Changes in Human Langerhans Cells Following 
Intradermal Injection of Influenza Virus-Like Particle Vaccines. PLoS ONE, 5, 
e12410. 
PEARTON, M., KANG, S.-M., SONG, J.-M., KIM, Y.-C., QUAN, F.-S., ANSTEY, A., 
IVORY, M., PRAUSNITZ, M. R., COMPANS, R. W. & BIRCHALL, J. C. 2010b. 
Influenza Virus-Like Particles coated onto microneedles can elicit 
stimulatory effects on Langerhans cells in human skin. Vaccine, 28, 6104-
6113. 
PIGUET, V., CAUCHETEUX, S. M., IANNETTA, M. & HOSMALIN, A. 2014. Altered 
antigen-presenting cells during HIV-1 infection. Curr Opin HIV AIDS, 9, 478-
84. 
PRAUSNITZ, M. R. 2004. Microneedles for transdermal drug delivery. Advanced 
Drug Delivery Reviews, 56, 581-587. 
PRAUSNITZ, M. R. & LANGER, R. 2008. Transdermal drug delivery. Nature 
biotechnology, 26, 1261-1268. 
PRAZMA, C. M. & TEDDER, T. F. 2008. Dendritic cell CD83: A therapeutic target or 
innocent bystander? Immunology Letters, 115, 1-8. 
RAJEWSKY, K. & VON BOEHMER, H. 2008. Lymphocyte development. Overview. 
Curr Opin Immunol, 20, 127-130. 
REYGROBELLET, C., VIALA-DANTEN, M., MEUNIER, J., WEBER, F. & NGUYEN, V. H. 
2010. Perception and acceptance of intradermal influenza vaccination: 
Patient reported outcomes from phase 3 clinical trials. Hum Vaccin, 6, 336-
45. 
38 
 
ROMANI, N., CLAUSEN, B. E. & STOITZNER, P. 2010. Langerhans cells and more: 
langerin-expressing dendritic cell subsets in the skin. Immunological 
reviews, 234, 120-141. 
ROMANOVSKY, A. A. 2014. Skin temperature: its role in thermoregulation. Acta 
physiologica (Oxford, England), 210, 498-507. 
RUSSELL-JONES, G. J. 2000. Oral vaccine delivery. Journal of Controlled Release, 65, 
49-54. 
SALLUSTO, F., CELLA, M., DANIELI, C. & LANZAVECCHIA, A. 1995. Dendritic cells use 
macropinocytosis and the mannose receptor to concentrate 
macromolecules in the major histocompatibility complex class II 
compartment: downregulation by cytokines and bacterial products. J Exp 
Med, 182, 389-400. 
SANGIULIANO, B., PEREZ, N. M., MOREIRA, D. F. & BELIZARIO, J. E. 2014. Cell death-
associated molecular-pattern molecules: inflammatory signaling and 
control. Mediators Inflamm, 2014, 821043. 
SCHRAMM, J. & MITRAGOTRI, S. 2002. Transdermal drug delivery by jet injectors: 
energetics of jet formation and penetration. Pharm Res, 19, 1673-9. 
SCHROEDER, H. W. & CAVACINI, L. 2010. Structure and Function of 
Immunoglobulins. The Journal of allergy and clinical immunology, 125, S41-
S52. 
SIEGRIST, C.-A. 2013. 2 - Vaccine immunology. In: OFFIT, S. A. P. A. O. A. (ed.) 
Vaccines (Sixth Edition). London: W.B. Saunders. 
SOONAWALA, D., VERDIJK, P., WIJMENGA-MONSUUR, A. J., BOOG, C. J., KOEDAM, 
P., VISSER, L. G. & ROTS, N. Y. 2013. Intradermal fractional booster dose of 
inactivated poliomyelitis vaccine with a jet injector in healthy adults. 
Vaccine, 31, 3688-3694. 
STEINMAN, R. M. 1991. The dendritic cell system and its role in immunogenicity. 
Annu Rev Immunol, 9, 271-96. 
STOITZNER, P., TRIPP, C. H., EBERHART, A., PRICE, K. M., JUNG, J. Y., BURSCH, L., 
RONCHESE, F. & ROMANI, N. 2006. Langerhans cells cross-present antigen 
derived from skin. Proc Natl Acad Sci U S A, 103, 7783-8. 
SUH, H., SHIN, J. & KIM, Y.-C. 2014. Microneedle patches for vaccine delivery. 
Clinical and Experimental Vaccine Research, 3, 42-49. 
SULLIVAN, S. P., KOUTSONANOS, D. G., DEL PILAR MARTIN, M., LEE, J. W., 
ZARNITSYN, V., CHOI, S.-O., MURTHY, N., COMPANS, R. W., SKOUNTZOU, I. 
39 
 
& PRAUSNITZ, M. R. 2010. Dissolving polymer microneedle patches for 
influenza vaccination. Nat Med, 16, 915-920. 
TAKEUCHI, O. & AKIRA, S. 2010. Pattern recognition receptors and inflammation. 
Cell, 140, 805-20. 
THEOHARIDES, T. C., ALYSANDRATOS, K.-D., ANGELIDOU, A., DELIVANIS, D.-A., 
SISMANOPOULOS, N., ZHANG, B., ASADI, S., VASIADI, M., WENG, Z., 
MINIATI, A. & KALOGEROMITROS, D. 2012. Mast cells and inflammation. 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1822, 21-
33. 
THOMAS, A. A., VRIJSEN, R. & BOEYE, A. 1986. Relationship between poliovirus 
neutralization and aggregation. J Virol, 59, 479-85. 
TORRISI, B. M., ZARNITSYN, V., PRAUSNITZ, M. R., ANSTEY, A., GATELEY, C., 
BIRCHALL, J. C. & COULMAN, S. A. 2013. Pocketed microneedles for rapid 
delivery of a liquid-state botulinum toxin A formulation into human skin. J 
Control Release, 165, 146-52. 
TOUITOU, E. 2002. Drug delivery across the skin. Expert Opin Biol Ther, 2, 723-33. 
TOZUKA, M., OKA, T., JOUNAI, N., EGAWA, G., ISHII, K. J., KABASHIMA, K. & 
TAKESHITA, F. 2016. Efficient antigen delivery to the draining lymph nodes 
is a key component in the immunogenic pathway of the intradermal 
vaccine. Journal of Dermatological Science, 82, 38-45. 
UNANUE, E. R. 1984. Antigen-presenting function of the macrophage. Annu Rev 
Immunol, 2, 395-428. 
VAN DAMME, P., OOSTERHUIS-KAFEJA, F., VAN DER WIELEN, M., ALMAGOR, Y., 
SHARON, O. & LEVIN, Y. 2009. Safety and efficacy of a novel microneedle 
device for dose sparing intradermal influenza vaccination in healthy adults. 
Vaccine, 27, 454-9. 
VAN DEN BERG, J. H., NUJIEN, B., BEIJNEN, J. H., VINCENT, A., VAN TINTEREN, H., 
KLUGE, J., WOERDEMAN, L. A., HENNINK, W. E., STORM, G., SCHUMACHER, 
T. N. & HAANEN, J. B. 2009. Optimization of intradermal vaccination by DNA 
tattooing in human skin. Hum Gene Ther, 20, 181-9. 
WANG, P. M., CORNWELL, M., HILL, J. & PRAUSNITZ, M. R. 2006. Precise 
Microinjection into Skin Using Hollow Microneedles. Journal of Investigative 
Dermatology, 126, 1080-1087. 
WEINTRAUB, A. 2003. Immunology of bacterial polysaccharide antigens. 
Carbohydr Res, 338, 2539-47. 
40 
 
WHO 2010. Rabies vaccines: WHO position paper. Weekly Epidemiological Record, 
32, 309-320. 
WHO. 2012. Module 2- Types of Vaccine and Adverse Reactions [Online]. Available: 
http://vaccine-safety-training.org/route-of-administration.html [Accessed 
July 11th 2016]. 
WILLIAMS, J., FOX-LEYVA, L., CHRISTENSEN, C., FISHER, D., SCHLICTING, E., 
SNOWBALL, M., NEGUS, S., MAYERS, J., KOLLER, R. & STOUT, R. 2000. 
Hepatitis A vaccine administration: comparison between jet-injector and 
needle injection. Vaccine, 18, 1939-1943. 
WOOF, J. M. & RUSSELL, M. W. 2011. Structure and function relationships in IgA. 
Mucosal Immunol, 4, 590-7. 
YAMAMOTO, A., SERIZAWA, S., ITO, M. & SATO, Y. 1991. Stratum corneum lipid 
abnormalities in atopic dermatitis. Archives of Dermatological Research, 
283, 219-223. 
ZEHRUNG, D. 2009. Intradermal Delivery of Vaccines: A review of the literature 
and the potential for development for use in low- and middle income 
countries. In: KRISTENSEN, D. (ed.). Program for Appropriate Technology in 
Health (PATH). 
ZUCKERMAN, J. N. 2000. The importance of injecting vaccines into muscle : 
Different patients need different needle sizes. BMJ : British Medical Journal, 
321, 1237-1238. 
41 
 
Chapter 2: The Ex Vivo Human Skin Model 
2.1 Introduction 
This chapter will explore an ex vivo human skin model as a useful tool for 
assessing intradermal vaccine delivery. It will assess the delivery of two different vaccine 
types into skin. It will also examine the response of skin immune cells to intradermally 
delivered vaccine. 
 
2.1.1 Vaccine Technologies 
Vaccine technologies have developed markedly since their inception. Early 
vaccines were often inactivated forms of the pathogen, with heat or formaldehyde being 
used to neutralise the virulence of the pathogen whilst maintaining its antigenicity 
(Stern and Markel, 2005). Inactivated vaccines possess advantages in that antigen is 
presented in its natural state and so will be processed, and immunity raised, via similar 
pathways to those that will counteract infection on subsequent exposure (Sanders et 
al., 2015). It is also possible to deliver live pathogen which has been attenuated to 
reduce its pathogenicity, termed an attenuated vaccine. Attenuated vaccines do not 
undergo heat or chemical treatment to facilitate inactivation and therefore damage to 
antigenic structures is minimised (Galinski et al., 2015). Both inactivated and attenuated 
vaccines possess an associated risk of infection following vaccination if pathogens 
escape complete inactivation or revert to the wild unattenuated state (Hanley, 2011, 
Sanders et al., 2015). 
One strategy to avoid the risk of infection from vaccine reversion to the wild type 
pathogen is to only deliver part of the target pathogen, referred to as a subunit vaccine. 
For example, delivering envelope proteins from a virus can condition the immune 
system against the virion, whose particles contain that particular envelope protein (Khan 
et al., 2012). The antigen may be isolated from the wild type pathogen or produced in 
recombinant vectors, such as yeast (Bill, 2015). It is also possible, in diseases where a 
toxic substance released from a bacterium is the main cause of morbidity, to deliver 
inactivated toxin as a vaccine. These are termed toxoid vaccines, such as the diphtheria 
vaccine (Tiwari and Wharton, 2013). These vaccines are often less potently antigenic 
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than killed or attenuated vaccines so must be delivered with one or more 
immunostimulatory adjuvants to ensure an immune response is actualised (Coffman et 
al., 2010). The reduced potency is due to a subset of the total antigen from the pathogen 
being represented and that in isolation, the antigen may not exist in the same 
conformation as it does within the pathogen (Steimer and Haigwood, 1991)- both of 
which reduce the likelihood of a full immune response being raised against the 
pathogen. An adjuvant may be a separate chemical substance (e.g. alum) (Coffman et 
al., 2010) that is co-delivered with the antigen or, in the case of conjugate vaccines, 
covalently linked to the poorly antigenic molecule e.g. tetanus toxoid conjugated to 
haemophilus influenzae type B (HiB) polysaccharide to increase the latter’s antigenicity 
in the HiB vaccine (Ravenscroft et al., 2015).  
Nanoparticle technology may also be utilised in vaccines. Peptide conjugated to 
nanoparticles (solid particles under 1µm in diameter) offers improved stability and 
immunogenicity, versus free peptide (Wang et al., 2008, Caucheteux et al., 2016). 
Another vaccine technology that avoids the use of an attenuated or inactivated form of 
the wild-type virus is the virus-like particle (VLP) vaccine. VLP vaccines involve the 
manufacture of viral nucleocapsid and envelope structures without the inclusion of the 
pathogen’s genetic material (Sitrin et al., 2015). This way the antigenic structures are 
maintained without the risk of viral replication and reversion to wild type. Finally, it is 
possible to use genetic vaccines, where DNA or RNA that encode antigenic peptides are 
delivered to cells. The successful delivery and expression of these vaccines leads to in 
situ production of antigenic peptides in a manner similar to the viral replication cycle 
following infection. This allows for the possibility of presenting antigen on MHC-I 
molecules and generating cellular immunity to a pathogen mediated by cytotoxic CD8+ 
T-cells (Srivastava and Liu, 2003).  
2.1.2 Vaccine Research 
When designing a novel vaccine, it is vital that the antigenic epitopes and their 
native conformations involved in an adaptive immune response are understood. An 
appropriate vaccine technology (inactivated virus, subunit, nanoparticle, etc.) can then 
selected and a vaccine formulation designed. The risk of an ineffective vaccine leaving a 
patient vulnerable to infection by a pathogen mean that thorough pre-clinical testing of 
vaccines is required. There is also a risk of local reactions (Cody et al., 1981) at the 
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delivery site or triggering autoimmune disease if the vaccine should elicit a cross-
reactive response against self-antigen (Wraith et al., 2003). The intricacies of 
immunisation mean that complex models must be used- normally these are in vivo 
animal models. However, there are marked differences, both physical and 
immunological, between the commonly used animal models and human skin (Mestas 
and Hughes, 2004, Bronaugh et al., 1982, van der Worp et al., 2010, Netzlaff et al., 2006) 
which has led to the development of human skin models.  
 
2.1.3 The Ex Vivo Human Skin Model 
The ex vivo human skin model provides a useful laboratory tool to bridge the gap 
between animal models and the clinical scenario (Ng et al., 2009, van den Berg et al., 
2009, Wu et al., 2000). This model utilises excised skin typically obtained from routine 
surgical procedures such as mastectomy/breast reduction (Pearton et al., 2010c), infant 
circumcision (Berton et al., 2000) or abdominoplasty (Chu et al., 2012). Skin is collected 
from patients and, with proper handling and culture conditions, can be maintained 
viable for at least 72 hours (Ng et al., 2009). The model has been used for a number of 
study types including wound repair (Danso et al., 2015, Xu et al., 2012), transdermal 
drug delivery (Swarbrick et al., 1982, Schmalfuß et al., 1997) and immunological studies 
(Wu et al., 2000, Chu et al., 2012). 
Within Cardiff University, ex vivo human skin has been utilised to study 
intradermal delivery deposition and localised kinetics (Coulman et al., 2009, Torrisi et 
al., 2013), the delivery of genetic material (Chong et al., 2013) and transfection within 
the tissue (Ng et al., 2009, Pearton et al., 2012). The ex vivo skin model has also been 
used for immunological studies, showing changes in gene expression to vaccine delivery 
via microarray analysis (Pearton et al., 2013) as well as changes in LCs following the 
delivery of vaccine into the skin, showing their morphological changes and migration out 
of the epidermis (Pearton et al., 2010b, Pearton et al., 2010c).  
Ex vivo human skin holds advantages over animal models in that it is human 
tissue and so represents the in vivo situation more closely. The use of tissue also allows 
for the complex interactions between the diverse skin cell populations to be studied. 
The model is, however, limited by a short window of viability following removal from 
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the patient which limits the range of experiments which it can be used for. It also 
possesses limitations in that it exists in isolation of the full human immune system. This 
means that cellular and chemical signalling which is delivered to skin via the circulatory 
system in vivo is not present in ex vivo human skin. The isolated nature of the tissue also 
means that cells which migrate through tissue are liable to migrate out into culture 
media from which they are unlikely to return into the skin tissue. The lack of a full 
immune system means that immune cell precursors cannot be recruited from the blood 
and so the overall immune cell population within the ex vivo skin tissue will decrease 
with increased culture time. Finally, the irregularity of surgical procedures means that 
tissue is not frequently available and sample size can vary greatly between patients 
depending on the nature of the surgery. 
 
2.1.4 Histological Analysis of Human Skin 
Given that changes in the ex vivo human skin model following treatment with a 
vaccine will largely occur at the cellular level, histological processes are commonly 
employed to allow their visualisation. The nature of full-thickness skin samples means 
that conventional microscopy cannot be used to analyse the sample, as light will not 
pass through the sample to the objective lens for visualisation (Murphy and Davidson, 
2012). To allow the use of light or fluorescence microscopy, tissue is normally cut into 
thin sections which allow the transmission of light through the sample. 
 
2.1.4.1 Sectioning of Tissue 
There are two commonly used processes for sectioning of tissues- microtome 
sectioning or cryosectioning. Both are similar in concept- the sample is passed over a 
blade, removing a thin slice from the outside of the sample. The section is attached to a 
microscope slide, where it can undergo staining and imaging. The equipment then 
moves the sample forward by the desired section thickness and the process repeated, 
generating further sections. The two methods vary in how the sample is preserved and 
supported for sectioning. In both cases, tissue is fixed to halt cellular processes and 
maintain the integrity of the tissue structure (Zeller, 2001). Microtome sectioning 
involves the dehydration of tissue before embedding it in paraffin to allow it to be 
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sectioned. Cryosectioning of tissue involved the embedding of tissue in specially-
designed media before freezing. The frozen tissue can then be sectioned in a cryotome, 
a microtome contained within a cooled housing that ensures the tissue remains frozen.   
While both techniques for tissue sectioning have similar capabilities in terms of 
the tissue types that can be sectioned and the thickness of sections that can be 
produced, there are marked differences in the processing times of the tissue for the two 
processes (Winsor, 1994). The paraffin-embedding of tissue can be quite time-
consuming, with tissue being moved through a water-ethanol gradient of increasing 
ethanol concentrations to remove water from the sample before infiltration with 
chloroform and finally molten paraffin. Following sectioning, paraffin must be removed 
from the sections which requires the use of organic solvent such as xylene. The tissue 
must then be rehydrated through an ethanol-gradient before it can be stained and 
imaged. In the case of cryosectioning, tissue can be snap frozen immediately after 
treatment and can be sectioned once it is completely frozen. As the embedding media 
protects the tissue from dehydration during freezing (Jones et al., 1986), sections can be 
stained following a PBS wash.  
Tissue sections may be imaged without further treatment but in many cases, the 
subtleties of tissue structure and cellular behaviours cannot be seen without staining 
the tissue in some way (Kanitakis, 2002). For gross tissue structure, haematoxylin and 
eosin (H&E) staining is often used. Haematoxylin is used to stain the nuclei within the 
tissue blue. Eosin is then added which stains cytoplasm orange, collagen in pink and 
erythrocytes red. Other cellular structures are stained in shades of orange, red and pink. 
Specific cells will show characteristic H&E staining, allowing their identification in tissue 
(Fischer et al., 2008). For some investigations however, H&E staining does not provide 
adequate distinction between cell types and so more complex staining techniques must 
be used. 
 
2.1.4.2 Immunohistochemistry and Immunofluorescence 
Both immunohistochemistry (IHC) and immunofluorescence (IF) involve the use 
of antibodies to identify areas of interest within a tissue sample. The specificity of 
antibodies (as discussed in Section 1.1.2) means that they will bind to a single epitope. 
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Antibodies raised in animals to human epitopes can allow cells to be identified within 
tissue (Vandesande, 1979). For example, an antibody raised to an epitope within the 
CD207 receptor can be added to tissue where it will bind to LCs (Stoitzner et al., 2003). 
Where IHC and IF differ is how the antibody-stained areas within the tissue are 
visualised. IHC utilises enzyme-conjugated antibodies whereas IF uses fluorescently-
conjugated antibodies. The conjugated antibody may be the primary antibody (specific 
to the target epitope) or a secondary antibody which binds to the primary antibody. The 
use of conjugated secondary antibodies can increase signal strength if multiple 
secondary antibodies can bind a single primary antibody (Buchwalow et al., 2011).  
Following IHC antibody staining, a chemical substrate is added to the tissue 
which undergoes a colour change in the presence of the enzyme-linked antibody and 
stains the tissue. An example substrate is 3,3'-diaminobenzidine (DAB) which reacts in 
the presence of horseradish peroxidase-conjugated antibody to produce a dark brown 
colour which can be distinguished amongst H&E-stained tissue (Hobot and Newman, 
1996). It is possible to stain a tissue with more than one enzyme-linked antibody, 
provided the coloured products of the substrates of the two enzymes are distinct from 
one another (Vandesande, 1979). 
The antibodies used in IF are conjugated to a fluorophore that emits light at a 
given wavelength following excitation with a laser (Rani and Hussain, 2003). This allows 
IF-stained tissue to be visualised on a fluorescence microscope. It is possible to combine 
multiple fluorescent antibodies or stains (such as the nuclear stain Hoechst 33342) to 
distinguish between multiple cell types in a tissue section. It is important that the 
excitation/emission wavelengths of the fluorophores used do not overlap as this can 
provide false positive staining which will affect the reliability of data (Vandesande, 
1979).  
 
2.1.5 Influenza  
Seasonal influenza is responsible for 3-5 million cases of serious illness and 250-
500,000 deaths worldwide per year (WHO, 2014). Influenza represents a group of three 
genera: Influenzavirus A, Influenzavirus B and Influenzavirus C. Influenza A and B are 
most commonly associated with the seasonal epidemics in humans. Genetically, the 
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influenza virus is a negative-sense single-stranded RNA (ssRNA) virus- it contains single-
stranded RNA which must be translated by RNA polymerase to produce the 
corresponding positive-sense mRNA to elicit viral production in the host cell (Samji, 
2009). The ssRNA is contained within a protein ‘core’ which is in turn enveloped by a 
lipid bilayer (from the host cell in which it was produced) which contains two 
glycoproteins (Figure 2.1): haemagglutinin and neuraminidase- the subtypes of which 
are used to classify viral strains (e.g. H5N1, H1N1, etc.) (Samji, 2009). Infection by the 
virus causes respiratory symptoms (rhinorrhoea, cough and sore throat) as well as fever, 
myalgia, headache, malaise and (normally only in high-risk patients such as the elderly) 
death (Taubenberger and Morens, 2008). The virus undergoes constant antigenic shift, 
producing the various subtypes. Each emerging strain is able to evade immune 
responses against previous strains, rendering adaptive immune responses ineffective 
season to season (Taubenberger and Kash, 2010). 
2.1.6 Influenza Vaccines 
Multivalent (i.e. containing antigen representative of multiple strains) 
inactivated virus vaccines for influenza have been available since 1942 (Hannoun, 2013). 
These have proven to be useful for protection against the strains of virus which they 
contain. However, influenza’s constant antigenic shift amongst strains means that new 
vaccines must be under constant development. The ongoing development of vaccines 
has led to research into methods of improving vaccination. The potential for antigen 
sparing by intradermal immunisation has been recognised as potentially useful, 
Figure 2.1: Structure of the influenza virus (adapted from: 
http://www.virology.ws/2009/04/30/structure-of-influenza-virus/) 
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especially in pandemic situations where a limited amount of vaccine antigen will be 
available at short notice to immunise as many people as possible (Kenney et al., 2004, 
Van Damme et al., 2009).  
 
2.1.7 Changes in Human Skin Following Intradermal Influenza Vaccination 
Intradermal delivery of influenza vaccines has been studied previously, both in 
exploring the development of novel vaccines (Kang et al., 2009) and in studying the 
alternative delivery of existing intramuscular vaccines (Kenney et al., 2004). Work in 
animal models or human subjects provide useful systemic immune response data but 
possess disadvantages in terms of cost and ethical considerations. Clinical studies are 
also limited in their use of novel vaccines due to the need for extensive preclinical data 
to show suitability for delivery into human subjects. Some work has been done using ex 
vivo skin to provide this necessary preclinical data but this tended to be in suction 
blisters (Dearman et al., 2004). In previous work utilising the ex vivo human skin model, 
we have shown the response of Langerhans cells to both inactivated virus and novel 
virus-like particle vaccines (Pearton et al., 2010a, Pearton et al., 2010c). At 24 and 48 
hours’ post-vaccination there was a marked reduction in the number of Langerhans cells 
in the epidermis (Figure 2.2). There was also a change in the morphology of Langerhans 
cells, withdrawing their lateral dendrites before extending towards the basement 
membrane, suggesting migration towards the lymph vessels of the dermis. The data 
provided evidence for the use of virus-like particles as well as helping to characterise the 
early response seen in skin following intradermal vaccination. 
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2.2 Aims and Objectives 
This chapter aims to use ex vivo human skin to visualise the intradermal delivery 
of protein or nanoparticle vaccines. It also aims to investigate the effects of influenza 
vaccine on Langerhans cells at early time points after delivery. The specific practical 
objectives are: 
1. Formulate a model protein and a nanoparticle vaccine to enable coating onto 
solid stainless steel microneedles. Utilise fluorescence microscopy to visualise 
the coating of formulation on the needles’ surface. 
2. Insert formulation-coated microneedles into ex vivo human skin then, following 
their removal from skin, re-image the arrays to determine if formulation release 
was successful. 
3. Utilise cryosectioning and histological staining of coated microneedle-treated 
skin to image deposition of formulation into the skin 
4. Formulate inactivated influenza virus vaccine for coating onto solid stainless 
steel microneedles.  
5. Utilise the previously described ex vivo human skin culture protocol and 
immunohistochemistry to characterise the migration of LCs out of the epidermis 
at 2 and 4 hours after vaccine delivery. 
Figure 2.2: LC numbers in epidermal sheets following PBS ID 
injection (grey bars) or H1 virus-like particles (white bars) 
[***p<0.001] taken from (Pearton et al., 2010c) 
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2.3 Materials and Methods 
[All reagents were obtained from Fisher Scientific, UK unless otherwise stated] 
2.3.1 Microneedle Arrays 
Microneedle arrays, consisting of 10 needles in plane, were fabricated from 
stainless steel sheets using wire electrical discharge machining (EDM) by colleagues 
within Cardiff University. The arrays were subsequently electropolished in a solution of 
60% glycerine, 30% ortho-phosphoric acid (85% solution) and 10% distilled-deionised 
water (ddH2O) under a current of 1.8 mA/mm2 at 70˚C for 15 minutes. A copper rod 
acted as the cathode and the microneedles as the anode. A magnetic stirrer was used 
to agitate the electropolishing solution and the anode was vibrated using a custom 
sonication device to prevent build-up of gas bubbles at the anode’s surface. Following 
electropolishing, needle arrays were washed thoroughly in alternating ddH2O and nitric 
acid (25% solution) for three repeats before a final wash in ddH2O. Needles were allowed 
to air dry for 1 hour, wrapped in lens tissue and stored in airtight containers prior to use. 
The length and width of individual microneedles was reduced as a result of the polishing 
process. This was consistent between arrays, giving a final length of 640µm with 1mm 
spacing between microneedle tips (Figure 2.3). 
 
2.3.2 Fluorescent Protein Formulation 
To assess the capability of coating solid microneedle arrays with a protein-
containing formulation, ovalbumin protein with Alexa Fluor™ 555 Conjugate (Fl-OVA; 
Invitrogen, UK) was utilised. A coating solution containing 1.25% w/v Fl-OVA plus 15% 
Figure 2.3: Solid stainless steel microneedle arrays after electropolishing. Arrays consist of 10 
needles of 640µm length with 1mm spacing at the needle tips. BD Microlance 26G 10mm 
hypodermic needle (BD Biosciences, UK) included for scale. 
1mm 
640µm 
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w/v trehalose, 1% w/v carboxymethylcellulose sodium salt (average molecular weight: 
90,000 Daltons) and 0.5% w/v Lutrol F-68 NF (all Sigma-Aldrich, UK) in ddH2O was 
prepared and stored at 4˚C prior to use.  
Two methods were used to coat microneedle arrays. In the first (method A), 
0.6µl of coating solution was drawn up into a fine-tipped gel-loading pipettor tip. The 
tip was then removed from the pipettor body and pressure applied to the top of the 
pipettor tip by a gloved finger, forcing the coating solution out of the fine end of the tip 
a small volume at a time- forming a small droplet due to surface tension of the viscous 
coating solution. This droplet was applied to the surface of the needle to coat a layer of 
solution onto it over approximately 75% of the needle length. All needles were coated, 
the coating was allowed to air dry for 2 minutes and then coating repeated until all of 
the solution had been used. The volume used (0.6µl) was divided between 3 
microneedles arrays- i.e. approximately 0.2µl was applied to each array of 10 needles.  
The second coating method (method B), involved drawing 10µl of coating 
solution into a standard 200µl pipettor tip, which has had the end cut off to increase the 
bore diameter. Rather than expelling the liquid from the pipettor tip (as in method A), 
each needle on the array was individually inserted into the formulation in situ in the 
pipettor tip then removed to apply formulation to the needle surface. The coated 
needles were allowed to air dry for two minutes before repeating. The 10µl volume was 
used to coat three arrays (i.e. approximately 3.33µl was applied to each array). 
Coated arrays were stored in a sealed container with silica gel desiccant at 4˚C 
prior to use. Coating success was determined by imaging needles using a DM IRB 
epifluorescence microscope (Leica, Germany) with Retiga Exi Fast digital camera 
(QImaging, Canada). Image post-processing was performed using ImageJ software 
(National Institutes of Health, USA). 
 
2.3.3 Fluorescent Nanoparticle Formulation 
A fluorescent model for influenza virions was assessed for its ability to be 
incorporated into a formulation, coated onto microneedles and then delivered into skin. 
Fluorescent red sulphate-modified polystyrene nanoparticles (Fl-NPs) (Sigma-Aldrich, 
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UK) with a mean diameter of 100nm were selected based on their similarity in size to 
influenza virions, which have a diameter of 80-120nm (Kang et al., 2009). A coating 
solution containing 1.25% w/v Fl-NPs, 15% w/v trehalose, 1% w/v 
carboxymethylcellulose sodium salt and 0.5% w/v Lutrol F-68 NF in ddH2O was produced 
and stored at 4˚C prior to use. Coating was performed using Method B as described in 
Section 2.3.2. 
 
2.3.4 Insertion of Microneedles into Ex Vivo Human Skin 
Human skin samples were obtained from female patients undergoing 
mastectomy or breast reduction surgery under informed written patient consent and 
local ethical committee approval (South East Wales Research Ethics Committees Panel 
C, Reference: 08/WSE03/55). Skin was collected immediately following surgery and 
transported to the laboratory in Dulbecco's Modified Eagle's medium (DMEM) 
supplemented with 1% penicillin and streptomycin (100 IU/ml each) at 4˚C. Samples 
used in this study were frozen upon arrival and defrosted prior to use. Skin tissue was 
prepared for use by removal of subcutaneous fat tissue by blunt dissection. Skin was 
then pinned, epidermis uppermost, to cork board ready for microneedle treatment. 
Microneedle arrays, coated with either Fl-NP or Fl-OVA coating formulations, 
were inserted into human skin explants by manual application using downward pressure 
perpendicular to the skin surface and held in place for 60s to allow dissolution of the 
formulation from the microneedle surface and deposition into the skin. Arrays were 
then removed from the skin and imaged as described in Section 2.3.2 to visualise the 
amount of formulation remaining on the microneedle arrays. 
 
2.3.5 Microneedle Skin Penetration and Formulation Release in Skin 
Microneedle-treated skin areas were excised, embedded in Optimal Cutting 
Temperature (OCT) embedding media and snap frozen in hexane cooled by an outer dry 
ice-methanol bath. Samples were stored at -80˚C prior to sectioning. Sections of 10µm 
thickness were generated using a Cryotome FSE (ThermoFisher Scientific, UK) onto 
SuperFrost™ Plus microscope slides (ThermoFisher Scientific, UK). Following fixing in 
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acetone at -20˚C for 20 minutes, skin sections treated with Fl-OVA-coated microneedles 
were mounted using PBS under glass cover slips and imaged using the DM IRB 
epifluorescent microscope (Leica, Germany) with Retiga Exi Fast digital camera 
(QImaging, Canada) in both fluorescent and brightfield imaging modes to visualise 
delivery within the skin. The cover slips were removed and the slides washed before 
staining using H&E. For H&E staining, slides were held in haematoxylin for 5 minutes 
then rinsed in tap water for 2 minutes. Sections were then differentiated by immersing 
the slides in 1% v/v acid alcohol (1% v/v HCl in 70% v/v ethanol in water) for 1 second. 
Finally, slides were held in eosin stain aqueous solution for 10 seconds before rinsing in 
running water. Slides were then re-mounted in PBS under glass cover slips and imaged 
using light microscopy with digital image capture as above. The resulting images were 
processed using ImageJ software (National Institutes of Health, USA). 
Skin sections treated with Fl-NP-coated microneedles were fixed in acetone at     
-20˚C for 20 minutes before being stained with phycoerythrin-conjugated anti-CD207 
mouse IgG1 antibody (Beckman Coulter, UK) and Hoechst stain solution (Sigma-Aldrich, 
UK) to visualise the epidermal LCs and cell nuclei respectively. Sections were then 
mounted on slides using ProLong® Diamond Antifade Mountant (Invitrogen, UK) 
according to the manufacturer’s protocol. Image capture and processing was performed 
as above. 
 
2.3.6 Changes in Langerhans Cell Numbers After Intradermal Vaccination 
Previous studies (Pearton et al., 2010b, Pearton et al., 2010c) identified changes 
in Langerhans cell numbers in the epidermis at 24 and 48 hours after inactivated and 
VLP influenza vaccine delivery into ex vivo human skin. In this study, inactivated 
influenza virus (A/California/7/2009 (H1N1) pdm09-like virus), as used in the 
commercially-available trivalent influenza vaccine each season since the 2010-11 
influenza season, was used to assess the response of ex vivo human skin to influenza 
vaccine delivery at earlier time points (pre-24 hours). The inactivated virus vaccine was 
formulated in a coating solution containing trehalose, carboxymethylcellulose sodium 
salt and Lutrol F-68 NF as described in Section 2.3.2 to produce a final concentration of 
1 mg/ml inactivated virus and was coated onto microneedle arrays using Method B as 
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described in Section 2.3.2. Coated arrays were stored in a sealed container with silica 
gel desiccant at 4˚C prior to use. The arrays used were obtained from collaborators at 
Georgia Institute of Technology, Atlanta GA, USA and were identical to those used in the 
previously published work (Pearton et al., 2010b, Pearton et al., 2010c). These arrays 
were produced from stainless steel sheets, possessed a needle length of 700µm and a 
spacing of 1.5mm between needle tips. Skin was obtained and prepared for treatment 
as described in Section 2.3.4.  
Inactivated influenza virus was then delivered either by application of the coated 
microneedles as described in Section 2.3.4 or by a traditional Mantoux-style ID injection 
into the upper dermis (Norman et al., 2014). Control samples received either an 
equivalent volume of sterile phosphate-buffered saline (PBS) by ID injection or MN array 
coated in coating formulation without virus. Six-millimetre punch biopsies were isolated 
from the treated areas and these were cultured at the media-air interface using a 
previously described method (Ng et al., 2009) for 2 or 4 hours. Following culture, the 
epidermis was removed from the skin biopsies using heat separation by submersing the 
tissue in ddH2O at 60°C for 55 seconds.  This allowed manual removal of the epidermis 
from the dermis as a single, intact sheet. Sheets were briefly rinsed in PBS before being 
fixed in -20°C acetone for 20 minutes. Following a further PBS rinse, the sheets were 
incubated in 1/200 anti-CD207 mouse monoclonal antibody (mAb; Abcam, UK) at 4°C 
overnight. An EnVision+ system-HRP (DAB) kit (Dako UK Ltd, UK) was used to detect the 
presence of the primary mAb according to the kit’s included protocol. Stained epidermal 
sheets were dehydrated and mounted using xylene-based mounting media before being 
imaged by a digital microscope camera (VWR, UK). The field of view for images was 
850µm x 640µm. Three skin samples (aged 53, 73 and 81) were used, with two full visual 
fields analysed per sample.  
LC counts were performed using ImageJ software. In line with previously 
published protocols (Pearton et al., 2010a), the total number of LCs were counted and 
then this number divided by the area analysed to determine the LC density (as number 
of LCs per 1000µm2). The data were compared between treated and untreated skin 
biopsies at both 2 and 4 hours to determine whether LC density changes were 
significantly different between the two. Statistical tests comprised one-way analysis of 
55 
 
variance (ANOVA) followed by Tukey's post hoc analysis performed using IBM SPSS 
Statistics (IBM, USA). 
 
2.4 Results and Discussion 
2.4.1 Formulation Coating onto Solid Microneedles 
Characterisation of the microneedles coated with Fl-OVA coating solution by the 
two methods (Figure 2.4) revealed that both were able to produce visibly uniform 
coating of the formulation which did not change the overall shape of the needle tips 
(important to maintain sharpness so as to allow skin penetration). There was, however, 
a marked difference in the formulation coverage area of the two coating processes- 
method A coated formulation at the terminal end of the needles as shown in Figure 2.4 
(A & B). Method B covered a much larger area of the array with formulation- coating the 
entire needle from tip to base. It was also evident that a large amount of the coating 
Figure 2.4: Solid stainless steel microneedles coated with Fl-OVA-containing coating solution using either 
method A (A, B) which deposited formulation specifically on the needle tips or method B (C, D) which 
distributed formulation across the entirety of the needle and also the base of the array. Each image is 
representative of the coating of a separate array of 10 needles each. Scale bars = 200µm 
A 
C 
B 
D 
in
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solution had been applied to the base of the array (Figure 2.4 C & D). This represents 
lost formulation as the base will not be inserted into the skin and so the formulation will 
not dissolve off of the array. 
 
2.4.2 Insertion of Microneedles into Ex Vivo Human Skin 
Re-imaging the microneedle arrays following insertion into ex vivo human skin 
explants allowed visual assessment of formulation which had failed to dissolve from the 
needle surface. Figure 2.5 indicates that the Fl-OVA-containing formulation was 
dissolved preferentially from the tip of the needles, the portion of the needle being 
inserted deepest into the skin. The natural water gradient of the skin, from its dry 
exterior to aqueous internal environment (Bjorklund et al., 2010) means that the needle 
tips are most likely to encounter sufficient fluid to dissolve the needle coating. The 
insertion depth of needles was therefore important. It appeared that the natural elastic 
property of skin acted to resist needle insertion as the arrays were applied firmly to the 
skin’s surface. The needles at the edge of arrays (such as the leftmost needle in Figure 
Figure 2.5: Microneedle arrays that had been coated with Fl-OVA-containing coating solution using 
either method A (A, B) or method B (C,D) following 60-second insertion into ex vivo human skin. Each 
image is representative of the removal of formulation from the needles’ surface of a separate array 
of 10 needles each. Scale bars = 200µm 
A 
C 
B 
D 
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2.5 B) appeared to be able to penetrate the skin most fully and as a result showed the 
most complete dissolution of formulation. The inner needles on the array showed 
greater formulation retention on the needles. The fact that the ex vivo skin samples used 
had been previously frozen without cryoprotective media may have also reduced 
dissolution. The freezing process can dehydrate tissue (Pegg, 1987), particularly at the 
outermost surfaces. This will affect the water gradient by reducing the amount of 
interstitial fluid in outer layers of the skin which can rehydrate the microneedle coating 
and allow its deposition in skin. Finally, as a thin layer of formulation on the needles will 
still show fluorescence, it is not possible to determine whether some, rather than all, of 
the formulation had been deposited into the skin from the lower part of the needles. 
 
2.4.3 Microneedle Skin Penetration and Formulation Deposition in Skin 
 Having determined that formulation had been removed from the microneedles’ 
surface following insertion into skin, it was important to characterise the location of 
deposition in the skin. Fluorescence microscopy revealed that formulation was 
deposited in the area immediately surrounding the microneedle channel (Figure 2.6 A & 
B) i.e. mostly into the epidermis and papillary dermis. Haematoxylin and eosin staining 
of microneedle-treated skin confirmed this penetration profile. Some residual 
formulation (pink) could also be seen in the H&E stained sections (Figure 2.6 C & D). The 
formulation was retained within skin sections following the vigorous washing during 
H&E staining, suggesting association with the tissue if not internalisation into the skin 
cells.  
Samples treated with fluorescent nanoparticles were stained with fluorescently-
conjugated anti-CD207 antibody prior to imaging. This allowed the visualisation of 
Langerhans cells within the epidermis and confirmed that formulation released from 
microneedles was deposited adjacent to them (Figure 2.6 E & F). The depth and angle 
of microneedle channels, which are perpendicular to the skin’s surface, meant that the 
majority of formulation was deposited in the upper dermis. The loose connective tissue 
of the dermis also allowed some permeation of protein or nanoparticle formulations 
away from the channel itself (visible in Figure 2.6 B & E). 
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Figure 2.6: Representative images of deposition of fluorescent formulation from coated microneedle 
arrays into ex vivo human skin samples. A-B: Fl-OVA-containing formulation (red) overlaid with brightfield 
image of skin section. C-D: H&E stained skin sections showing the densely nucleated epidermal layer and 
microneedle channel with deposited pink Fl-OVA formulation (red arrows). E-F: Fl-NP deposition in skin 
(yellow) with nuclei (blue), LCs (red) and skin auto-fluorescence (green) also visible.  
A 
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2.4.4 Changes in Langerhans Cell Numbers After Intradermal Vaccination 
Submerging the ex vivo skin samples in water at 60°C for 55 seconds allowed for 
the mechanical separation of the epidermis from the dermis as a single sheet. Utilising 
the DAKO kit following staining with anti-CD207 antibody allowed for the Langerhans 
cells to be imaged in situ within the epidermis (Figure 2.7). The Langerhans cells appear 
as a central rounded cell body with a number of dendritic processes extending from it, 
creating a network across the skin’s surface. 
Following treatment by inactivated influenza virus vaccine delivered either by 
standard intradermal injection or coated onto microneedle arrays, the density of LCs 
within epidermal sheets was assessed. The difference in density of LCs present in the 
sheets at 2 and 4 hours was not statistically significant between the control samples and 
those to which influenza vaccine was delivered by MN array or hypodermic needle 
(Figure 2.8). There was also no significant difference in LC density in any sample between 
the 2- and 4-hour time points. There was also a high level of variance between images 
from samples receiving identical treatments. This compared to the previously published 
Figure 2.7: Epidermal sheet stained for CD207 showing the dendritic nature of LCs within 
epidermal sheets (left) and example of LC morphology (right). 
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data at 24 hours (Pearton et al., 2010b) where LC density in vaccine-treated skin was 
70% less than untreated controls.  
 
2.5 General Discussion 
The results of this investigation provide further evidence that microneedles are 
a potentially viable delivery method for intradermal vaccines. Stainless steel arrays can 
be reproducibly produced to specifications of microneedle shape and length (Gill and 
Prausnitz, 2007a). The reproducible coating of solid microneedles, however, is a 
challenging area both in process development and regulatory approval (Zehrung, 2009). 
This chapter utilised a model protein and nanoparticle which were fluorescently 
conjugated to allow for straightforward visualisations of formulation coated on 
microneedles and delivered to skin.  
The first of the two coating processes used in this chapter (method A) required 
a high level of operator skill to ensure that needles were coated consistently on the 
needle tips only. It is also a time-consuming process, with a set of three arrays taking 
approximately 30 minutes to coat. The second method tested (method B) reduces both 
the coating time and the level of operator skill required. Method B also involved much 
less efficient coating onto needle tips with a large proportion of the formulation ending 
up on the base of the array where it will not be delivered to skin. With vaccine antigen, 
Figure 2.8: LC densities in treated samples and controls at 2 and 4 hours. Error bars at 2hrs are 
±SD (2hrs: n = 3; 4hrs: n=2) 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Untreated Blank-coated
MN array
PBS ID injection Vaccine-coated
MN array
Vaccine
delivered by ID
injection
LC
 D
e
n
is
ty
 (
LC
s/
1
0
0
0
μ
m
²)
Treatment
2hr
Samples
4hr
Samples
61 
 
which can be costly to produce, this would represent an unacceptable cost to a 
pharmaceutical manufacturer. Method B was similar to previously described methods 
which use a reservoir for coating solution (Gill and Prausnitz, 2007a), which is also 
associated with a large amount of formulation loss remaining within the reservoir. The 
reproducibility of the coating process is also important, to ensure that equivalent 
amounts of vaccine are coated onto each needle. The nature of coated microneedles 
means that they require reformulation of vaccines into coating formulation which must 
then be approved along with the coating process by regulatory authorities (Ita, 2015). 
Compared to hollow microneedles, which after approval as a medical device may be 
used in combination with previously approved injectables, this represents a significant 
hurdle to getting coated microneedles into clinical use (Kim et al., 2012a).  
The coating processes were able to leave a visually uniform layer of formulation 
on the needles regardless of whether the coating solution was loaded with nanoparticles 
or protein, suggesting neither significantly affected the physical properties of the 
formulation at the concentrations used. The even appearance of nanoparticle-
containing formulation coating suggests that the viscosity of the formulation and the 
small size of the nanoparticles prevented them from undergoing sedimentation out of 
suspension over the time period required for coating. This is important as novel vaccines 
might be virion- or protein-based. These studies utilised simple formulations without 
adjuvants present. The addition of adjuvants may be necessary for immunisation, 
particularly in the case of a protein vaccine which will likely be non-immunogenic 
without them. Therapeutic proteins (for example botulinum toxin) do not require 
adjuvants and so the formulation used within this chapter may be a suitable vehicle for 
their intradermal delivery. Conjugation of peptide to nanoparticles may increase their 
immunogenicity, potentially avoiding the need for adjuvants.  
One limitation of the microneedle technology is the low volumes that can be 
delivered. Method A requires the desired vaccine dose for an array to be contained in 
0.2µl of formulation. Whilst a suspension can be used (for example the model 
nanoparticle vaccine) if the vaccine is poorly soluble, there will be a limit of vaccine 
concentration over which it will affect the physical properties and coating might be 
adversely affected.  The volume limits can be overcome somewhat by the use of multiple 
arrays concurrently within an applicator device (Suh et al., 2014b), though this will also 
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possess an upper size limit over which the applicator will be too cumbersome to ensure 
consistent microneedle insertion. Though the limits may be feasible for vaccines, they 
have been a major obstacle to drug delivery via microneedles, where doses are normally 
in the mg rather than µg range (Bariya et al., 2012). 
Following insertion into the skin, the amount of formulation left on microneedle 
arrays varied between needles on an array. The assessment of coating in this 
investigation was qualitative rather than quantitative which limits the conclusions that 
can be drawn. The differences in formulation deposition may have been due to the 
penetration depth of needles not being consistent, though it is difficult to assess the 
depth to which needles have been inserted or to match a channel in a skin section to 
the corresponding needle. The varying insertion depths of needles may be due to 
multiple factors. Firstly, the natural elasticity of the skin acts to resist penetration by the 
microneedles (Groves et al., 2012). The skin will deform with the force of array 
application until the microneedles breach the stratum corneum, after which applied 
pressure will force the needles deeper into the skin (Groves et al., 2012). The setup using 
ex vivo skin attempts to replicate natural skin elasticity by pinning it out taut on a cork 
board backing. Though this is more representative of skin in situ than an explant which 
is not pinned out, it is not able to fully recreate the natural tautness of skin. The flexibility 
of the cork board backing can allow the skin to deform rather than allowing full 
penetration. Thus, the performance of microneedles in ex vivo skin may not correspond 
accurately with in vivo tissue behaviour. Work is currently underway within the research 
group to produce support apparatus for ex vivo skin which better mimics the tautness 
of skin and the firm underlying tissue in vivo. 
Studies also investigated the deposition of a model protein and model 
nanoparticle following application of coated microneedles. As could be predicted from 
the passive nature of microneedle formulation depositing in the skin following 
rehydration, the formulation was deposited in the vicinity of the microneedle channel 
only. The use of previously frozen skin meant that any active transport processes which 
might occur in vivo did not happen in this model. Thus, the results can be interpreted as 
a snapshot of initial deposition patterns rather than the true spatial kinetics of 
intradermal vaccine delivery into skin.  The deposition patterns were similar between 
protein and nanoparticle formulations in the previously frozen skin. The soluble nature 
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of the protein means that it may distribute away from the delivery site more rapidly in 
tissue fluid than insoluble nanoparticles in fully hydrated live skin. 
Whilst some formulation could be seen in the epidermis, a large proportion was 
deposited in the papillary dermis.  Though this limits the amount of vaccine delivered to 
LCs, vaccine in the dermis may be internalised by dDCs. Delivery specifically to the 
epidermis is challenging due to the thinness of the skin layer and the densely packed 
cells contained within it which hinder the movement of formulation delivered there. It 
is possible that some formulation which had dissolved in the interstitial fluid could 
permeate up to the basement membrane where Langerhans cells might encounter it. 
Also, while this chapter focusses heavily on LCs’ interaction with vaccine antigen, it is 
important to note that dDCs are also potent antigen-presenting cells that will also be 
involved in bringing about an immune response to vaccine antigen. 
Assessing the density of Langerhans cells in epidermal sheets failed to show a 
response in the skin tissue cultured after 2 or 4 hours. It can be concluded that the early 
time points selected did not represent long enough for the LCs to uptake antigen, 
become activated and migrate out of the epidermis, hence the lack of significant 
difference between the numbers present in a given area of treated or untreated 
epidermis. It is likely that the differences between treated and control samples would 
become apparent after 24 hours based on previously published results using an identical 
protocol for vaccine delivery (Pearton et al., 2010a, Pearton et al., 2010c). Further work 
is required to determine when between 4 hours and 24 hours the LCs begin to migrate 
in significant numbers from the epidermis in response to vaccine delivery. This delay in 
migration out of the skin will increase the time taken for LCs to reach lymph nodes where 
they can present vaccine antigen and therefore increase the time it will take a person to 
develop immunity. This may partly explain the presence of resident memory CD8+ T-
cells in the epidermis who can mount a response against previously encountered 
pathogens in a more rapid manner (Nomura et al., 2014). It is also possible that dDCs 
are able to transport vaccine antigen to the lymph nodes more quickly given their motile 
nature. Vaccines delivered to LCs may benefit from reformulation to increase residence 
time in the epidermis and improve exposure of LCs to the vaccine. As frozen skin was 
used in the delivery studies in this chapter, it was not possible to quantify co-localisation 
of fluorescent vaccine models with LCs or dDCs. The ability of both LCs and dDCs to raise 
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an immune response will need to be properly assessed before the relative importance 
of each immune cell type in vaccination can be concluded. 
 
2.6 Potential for Publication 
The work focussing on coating of microneedles with a model antigen formulation 
was performed to validate that formulation could be applied to the surface of a new 
design of microneedle array and then delivered into ex vivo human skin. This type of 
investigation has been performed (and published) many times previously and, as such, 
does not represent publishable work. The changes in numbers of LCs in ex vivo human 
epidermis to intradermally delivered inactivated influenza vaccine was not found to be 
significant. For this data to be publishable, further work is required to quantify the LC 
response at time points between 4 hours (studied in this chapter) and 24 hours 
(previously published (Pearton et al., 2010c)) to provide a more detailed timescale of LC 
activation and migration out of the skin following intradermal vaccination. 
 
2.7 Conclusion 
This chapter provided qualitative data on two coating methods for solid stainless 
steel microneedles. Both were shown to coat protein or nanoparticle onto needles 
which could then be delivered into skin. The quantities of formulation on the needles 
before and after skin were not quantified, limiting the conclusions that can be made on 
delivery efficiency. Whilst the dose of influenza vaccine that can be delivered into ex 
vivo human skin by microneedles had been previously shown to induce a response in 
LCs indicative of activation 24 hours after delivery, this chapter found the response did 
not develop after 2 or 4 hours. The implications of the timescale of LC responses within 
ex vivo human skin will be considered in later chapters as they may affect the optimal 
delivery kinetics for targeting these cells in intradermal vaccination.  
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Chapter 3 - The Ex Vivo Human Skin Immune Cell Model 
3.1 Introduction 
The previous chapter explored the ex vivo human skin model as a useful tool for 
assessing intradermal vaccine delivery. This chapter will consider the limitations of the 
model and explore the possibility of a cellular model derived from ex vivo skin as a 
complementary means of preclinical vaccine testing. 
 
3.1.1 Limitations of the Human Ex Vivo Skin Model 
Whilst full thickness ex vivo human skin allows the behaviour of skin immune 
cells to be studied in situ, there are limitations to the analysis techniques that can be 
used with the model. The thickness of skin prevents visible or laser light penetration, so 
it must be sectioned (Wu et al., 2000) or the epidermis isolated (Larsen et al., 1990) in 
order to allow imaging via microscopy. Immunofluorescence can allow for clear 
distinction of markers within a tissue but has limitations with photobleaching, tissue 
autofluorescence (Jensen, 2012)and spectral overlap if multiple fluorophores are used 
(Lichtman and Conchello, 2005). Spectral overlap is inconsequential if imaging a single 
marker e.g. Langerhans cells (LCs), which can be visualised by staining for CD207 
(Pearton et al., 2010b). However, it is a significant issue for visualising subsets of dermal 
dendritic cells (dDCs) that possess more complex phenotypes (Nestle et al., 1993).  
There are also practical issues related to the spatial distribution of immune cells 
within the ex vivo human skin samples. To deliver vaccine to a high number of cells, 
delivery must occur across a large area of skin. Many intradermal delivery methods only 
deliver formulation to a limited area proximal to the site of injection however (Witting 
et al., 2000). Delivery to large areas of skin also requires large amounts of reagents, 
which in the case of vaccines can represent significant cost (Kenney et al., 2004). The 
amount of excised skin obtained from each surgical procedure is also variable and 
therefore is not always large enough to complete such studies. Thus, to enable more 
intricate experiments, which allow for the observation of numerous cellular factors 
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concurrently, isolation of viable immune cells from the skin for downstream 
experimentation was explored.  
 
3.1.2 Methods of Obtaining Cells from Skin 
There have been three main methods previously reported for obtaining cells 
from skin. The first is a direct walkout from skin, where skin is floated on media directly 
after collection and the migratory cells collected from media 48 hours later (Goddard et 
al., 2004, Segura et al., 2012). This utilises split-thickness skin i.e. full thickness skin that 
has had a proportion of the dermis mechanically removed, to reduce the migratory 
distance for cells to exit the tissue and ensures the skin floats on the media. Because 
only migratory cells will actively move into the media, this technique represents an 
enrichment of these cells compared to their purity in the skin. Whilst this involves a 
minimal amount of skin processing, it does not allow for separation of epidermal and 
dermal migratory cells and also does not produce high yields of cells. The lengthy 
walkout process may also reduce the viability of migratory cells which are terminally 
differentiated and will not proliferate in culture. A longer walkout period was reported 
to increase yield but at a cost of lower viability (Nestle et al., 1993), so a balance must 
be struck between the two factors.  
The second reported method uses enzyme treatment of skin to allow mechanical 
separation of the epidermis from the dermis. The two can then be cultured separately 
and the migratory cells collected from each. The enzymes used vary but normally involve 
dispase (Pena-Cruz et al., 2001) or collagenase (Hentzer and Kobayasi, 1978). Enzyme 
incubation time also varies from 30 mins at 37°C (McCully et al., 2012) to overnight at 
4°C (Klechevsky et al., 2008a). The shortest incubation time reported used a 
combination of Dispase II, collagenase D and DNase (McCully et al., 2012). The walkout 
times reported tend to be similar, with 48-72 hours being commonly used. This 
possesses an advantage over the split thickness skin walkout as it allows dermal and 
epidermal migratory cells to be studied separately. The separated skin layers also 
possess a greater surface area from which cells can migrate and reduces the migration 
distance of LCs, which no longer have to migrate through the dermis into media. The 
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increased handling time and exposure to enzymes compared to the direct walkout 
method may affect cell viability or phenotype negatively though. 
The final method involves enzymatic and/or mechanical dissociation of the skin 
to produce a complete cell suspension (Bigley et al., 2015, Haniffa et al., 2012). This may 
be done after enzymatic separation of the epidermis and dermis to produce separate 
epidermal and dermal cell suspensions. The method allows for the collection of immune 
cells within a few hours of collecting the tissue and thus is a relatively rapid method for 
cell isolation. As the entire tissue is processed it is possible to collect the complete 
immune cell populations present in the skin. The purity of cells will be reduced 
compared to the walkout method though, as non-migratory cells will also be included in 
the suspension. Again, the exposure to enzymes and/or mechanical stress may affect 
the viability/phenotype of the cells collected, which must be considered in any results 
obtained. 
 
3.1.3 The Skin Cell Walkout Method 
It was identified that allowing migratory cells to migrate from the skin was the 
favoured method of isolation due to the resulting increase in purity which will reduce 
reagent usage over a smaller cell population. Enzymatic pre-treatment would be 
performed to allow dermal and epidermal cells to be studied separately but in parallel 
from a given donor and to increase the yield of cells. Due to its short incubation time (30 
mins at 37°C), the enzyme cocktail used by McCully et al (2012) was selected to separate 
the dermis and epidermis. This utilises a combination of Dispase II and collagenase to 
catalyse the breakdown of the basement membrane (Stenn et al., 1989) alongside 
DNase I which reduces clumping caused by DNA released from lysed cells (Stenn et al., 
1989). 
  
3.1.4 Assessing Dendritic Cell Responsiveness 
The ability to recognise and be activated by foreign antigen is central to LCs and 
dDCs’ ability to initiate an immune response (Banchereau and Steinman, 1998). They do 
so with a range of cell membrane and cytoplasmic receptors which bind to specific 
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antigens in the extra- and intra-cellular environments respectively (Dudziak et al., 2007). 
These receptors recognise certain structural sequences specific to pathogens, pathogen-
associated molecular patterns (PAMPs), and are termed pattern recognition receptors 
(Reis e Sousa, 2004). One subset of pattern recognition receptors are toll-like receptors 
(TLRs) (Aderem and Ulevitch, 2000). This family of receptors can bind a variety of PAMPs, 
after which the TLR initiates a signal transduction pathway which can mediate a range 
of effects including gene expression, production of cytokines or cell maturation 
(Medzhitov, 2001). The antigen-induced signal transduction pathway varies with the 
PAMP and the TLR that binds it (Reis e Sousa, 2004). This investigation will focus on two 
TLRs that recognise bacterial cell wall components and viral double-stranded RNA. 
Lipopolysaccharide (LPS) is a component of Gram-negative bacterial cell walls 
made up of fatty acids bound to a polysaccharide structure (Gangloff et al., 1999). It is 
one of the most potently immunostimulatory substances in nature (Beutler, 2000). DCs 
are able to detect LPS via Toll-like receptor 4 (TLR4) on their surface membranes (Lu et 
al., 2008). Signalling via TLR4 in the presence of LPS leads to maturation and the release 
of cytokines such as tumour necrosis factor-α (TNF-α) and interleukin 12 (IL-12) (Duraes 
et al., 2009). Polyinosinic:polycytidylic acid (poly(I:C)) comprises two repeating 
sequences of nucleotides, a chain of inosinic acid and a chain of cytidylic acid bound to 
one another, and is used as a synthetic analogue of viral double-stranded RNA (Ichinohe 
et al., 2005). On immune cells, this is recognised by TLR3 (Lee et al., 2006) which also 
signals the expression of cytokines such as TNF-α (Reimer et al., 2008). This investigation 
aims to vindicate the responsiveness of skin-derived DCs to stimulation by LPS and 
poly(I:C) to assess the usefulness of these cells as a model for immune system 
stimulation in vivo. 
 
3.1.5 Human Immunodeficiency Virus (HIV) 
HIV is part of the Lentivirus genus and is classified into two species: Human 
immunodeficiency virus 1 (HIV-1) and Human immunodeficiency virus 2 (HIV-2). Both 
species are further subdivided into multiple groups and subtypes based on genetic 
differences, with prevalence of the various subtypes varying across geographical regions 
(Perrin et al., 2003). HIV-1, and more specifically its subtype ‘M’, is responsible for the 
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vast majority of HIV infections in humans (Murphy et al., 2012). There are currently over 
34 million people worldwide who are HIV-positive and the virus has been responsible 
for over 25 million deaths in the last 30 years (WHO, 2012a). It is transmitted via infected 
bodily fluids during sexual activity, from mother to child in childbirth/breastfeeding or 
in intravenous drug users sharing needles (Gouws et al., 2006). HIV possesses RNA as its 
genetic material which must be transcribed to DNA by reverse transcriptase before 
mRNA coding for viral replication can be produced (hence it is referred to as a retrovirus) 
(Murphy et al., 2012). Infection by the virus leads to depletion of CD4+ T-cells over a 
number of years. This leads to acquired immunodeficiency syndrome (AIDS), which 
occurs when the CD4+ cell count falls below 200/µl blood (Lindback et al., 1994). The 
inability of an AIDS patient’s body to mount an effective immune response leads to 
opportunistic infections and cancers, which are the primary cause of mortality in the 
infected population (WHO, 2012a). Whilst there are effective anti-retroviral treatments 
available that can suppress a patient’s viral load, they are not able to completely 
eliminate the infection. A vaccine would represent an extremely useful tool, allowing 
people to avoid initial infection altogether. Though some candidate vaccines have 
shown promise in clinical trials, no vaccine has made it to market yet. The extremely 
high mutation rate of HIV and the broad range of subtypes represent significant 
challenges to the creation of an effective vaccine (Johnston and Fauci, 2008). 
One of the major challenges within laboratory HIV research is poor entry of the 
virus into cultured cells. It requires binding of two cell surface receptors, CD4 and a co-
receptor such as CCR5 or CXCR4, to be internalised (Wilen et al., 2012). A low entry and 
therefore low infection rate in experiments can affect the robustness of readouts when 
assessing treatments. This has led to models of HIV infection being developed utilising 
pseudotyped virus models that increase the infectivity of the virions themselves by 
improving cell entry. 
Another hurdle to the study of HIV infection in the laboratory is the lack of 
infectivity in species commonly used as animal models. Outside of humans, HIV only 
infects certain primate species that are associated with high research costs 
(Hatziioannou and Evans, 2012). These are therefore controversial models (Goodman 
and Check, 2002). It is also possible to produce humanised mouse models that can be 
infected with HIV (Rizza et al., 1996, Aldrovandi et al., 1993), though these models do 
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not possess multi-lineage human haematopoiesis or a functional human immune system 
(Berges et al., 2006). Human ex vivo skin presents a potentially useful tool in the study 
of HIV, particularly due to its populations of LCs. LCs are present on genital mucosa, the 
most common route of HIV infection, and have been implicated in the transmission of 
the virus to T-cells (Miller and Shattock, 2003). CD207 has also been shown to bind HIV 
and internalise it, though it has been shown to be involved in the degradation of the 
virus within LCs (de Witte et al., 2007). As human ex vivo genital mucosa is not readily 
available, skin provides an alternative source for these cells for use in HIV infection 
studies. 
 
3.1.6 Pseudotyped Virus Models 
Pseudotyped viruses are those where the envelope of one virus is combined with 
the viral core of another, usually to tailor the cell entry properties of the virus and deliver 
the viral core to the cells of interest (Sanders, 2002). For the purpose of this 
investigation, the HIV-1 virus will be pseudotyped to broaden its tropism and therefore 
provide a greater population of infected cells that can be studied. Using pseudotyped 
virus to negate the limited capacity of HIV to enter cells allows post-entry HIV restriction 
to be studied. 
 
3.1.6.1 Vesicular Stomatitis Virus (VSV) 
The Vesicular stomatitis Indiana virus (VSV) is a member of the viral family 
Rhabdoviridae. In the wild, it mainly affects animals such as horses and cattle but has 
the potential to zoonotically infect humans (Quiroz et al., 1988). It enters cells via the 
binding of glycoprotein G molecules on its viral envelope to low-density lipoprotein (LDL) 
receptors on target cells (Finkelshtein et al., 2013). It passes through the endocytic 
machinery in a clathrin-dependent pathway before delivering its nucleocapsid into the 
cytosol where it can infect the host cell (Albertini Aé et al., 2012). The LDL receptor is 
highly retained across cell types, allowing the virus to enter a wide range of unrelated 
cells (Superti et al., 1987). For this reason, viral envelopes containing VSV glycoprotein 
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G (VSV-G) are often used in pseudotyped retroviruses to broaden the range of cells 
which they can infect (Zufferey et al., 1997).  
 
3.1.6.2 GFP-Encoding VSV-G-Pseudotyped HIV 
This investigation will utilise a HIV-1 lentiviral vector pseudotyped with VSV-G 
envelope to remove the receptor binding requirements that normally limits HIV entry 
into DCs (Aiken, 1997).  This will allow post-entry behaviour of the virus to be studied 
more robustly by improving delivery of the HIV nucleocapsid into cells. The vector is 
replication-deficient so only a single round of infection will occur (infected cells will not 
produce further virus) (Da Costa et al., 1999). This means viral titre remains directly 
proportional to the starting dose throughout the experiment, whereas wild type virus 
would replicate and titre would vary with culture time. The insertion of a green 
fluorescent protein (GFP) gene into the vector means that cells that are infected will 
fluoresce with laser excitation, allowing for a straightforward means of quantifying 
infection without the need for staining viral antigen in cells (Auewarakul et al., 2001). 
 
3.1.7 SAM and HD Domain-Containing Protein 1 (SAMHD1) 
The sterile alpha motif and histidine-aspartate domain-containing protein 1 
(SAMHD1) is an antiviral factor within dDCs and LCs that allows them to resist infection 
by retroviruses (Laguette et al., 2011). Its expression is induced by interferon-γ (IFN-γ), 
a cytokine released in response to viral infection (Li et al., 2000). SAMHD1 catalyses 
hydrolysis of deoxynucleoside triphosphates (dNTPs) in the cytosol into their constituent 
nucleoside and phosphate components (Ji et al., 2014). This decreases dNTP availability 
to viral reverse transcriptase (which utilises dNTPs for transcribing viral RNA to DNA), 
thereby reducing viral replication (Pauls et al., 2013).  
 
3.1.7.1 Simian Immunodeficiency Virus and Vpx Protein 
Simian immunodeficiency virus (SIV) is a retrovirus from the genus Lentivirus 
along with HIV-1 and HIV-2. As the name suggests, it infects non-human primates. In 
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many host species, it does not present with clinical symptoms but in a small number it 
can cause a depletion in the immune system similar to AIDS in humans (Melby and 
Altman, 1974). Structurally, SIV and HIV possess a number of similarities. Of interest to 
this investigation is the accessory proteins Vif, Vpx, Vpr, Vpu, and Nef, which are 
expressed by lentiviruses that allow them to counteract intrinsic antiviral factors in cells 
and allow reverse transcription to proceed (Goujon et al., 2007). Vpx will be utilised in 
particular due to its ubiquitin-proteasome-dependent degradation of SAMHD1. Vpx is 
present on a number of strains of SIV and HIV-2 but not HIV-1 (Hrecka et al., 2011). 
Exposing cells to SIV before infection with a HIV-1 lentiviral vector will allow the effect 
of SAMHD1 protection on HIV-1 infection to be quantified. 
 
3.1.8 Flow Cytometry 
Chapter 2 utilised immunofluorescence to visualise cell markers within the skin. 
Flow cytometry also uses fluorescently-conjugated antigen-specific antibodies or other 
fluorescent substrates to bind to the target cells and thus enable their detection and/or 
quantification. However, instead of the sample being a tissue section it is a cell 
suspension. This allows labelling of individual cells extracellularly or, if the cell 
membrane is permeabilised before the addition of antibodies, intracellularly (Foster et 
al., 2007). Analysis is also different from immunofluorescence. In flow cytometry, the 
labelled cell suspension is passed in a single-file stream past a number of lasers which 
interrogate each cell individually. The use of dichromatic mirrors and filters means 
multiple wavelengths of excitation and emission can be analysed on each cell (Wang et 
al., 2010). Thus, multiple antibodies and/or substrates can be used concurrently and 
multiple marker expression analysed on each cell. Common flow cytometers have the 
ability to distinguish between 8 different fluorophores though systems exist that can 
analyse a greater number (Chattopadhyay et al., 2006).  
Flow cytometry also has the ability to quantify the fluorescence signal present 
from different fluorophores. It does so by measuring the intensity of output light after 
excitation with a defined laser intensity. The intensity of light output is proportional to 
the number of fluorophores i.e. if staining is performed with an excess of antibody, it 
can be used to quantify cell marker or cytokine expression (Chen et al., 1999). This is 
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useful both in terms of distinguishing between positive and negative populations but 
can also show the up- or down-regulation of a particular marker/cytokine in a cell 
population. Flow cytometers also have the ability to measure the size and complexity of 
cells. Size is measured by the forward scatter (FSC), which is determined by the amount 
of refraction that occurs along the same axis as the original laser path (Shapiro, 2005). 
The larger a cell is, the greater the level of refraction and the higher the FSC signal will 
be. Complexity, mainly granularity and membrane roughness, is measured by the side 
scatter (SSC) that occurs in a cell i.e. the amount of light that is reflected at a right angle 
to the direction of the original laser (Shapiro, 2005). The more complex a cell, the greater 
the amount of light will be scatted at 90° angle and the greater the SSC signal will be. 
 
3.1.8.1 Compensation Controls 
Though the fluorophores used in flow cytometry analysis panels have 
fluorescence emission peaks at different wavelengths, some possess slight spectral 
overlap. Figure 3.1 shows a common example of the overlap between fluorescein 
isothiocyanate (FITC) and phycoerythrin (PE) spectra. Both fluorophores are excited by 
the 488nm laser and excitation of FITC produces a weak signal in the PE 575nm bandpass 
filter (Baumgarth and Roederer, 2000). To compensate for this, samples are analysed 
which are stained for each fluorophore individually and the ‘spillover’ signal detected in 
Figure 3.1: Fluorescence emission spectra overlap between fluorescein isothiocyanate 
(FITC) and phycoerythrin (PE) [Taken from: http://flowbook.denovosoftware.com/chapter-
5-immunofluorescence-and-colour-compensation] 
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other channels is quantified. This can then be subtracted from the signals in the 
experimental samples, ensuring only fluorophore-specific signal is measured in each 
channel (Shapiro, 2005). The cells that will be used in the investigation may be used for 
compensation controls or, if this is not possible, polymer beads with antibody binding 
sites can be used (Roederer, 2002). 
 
3.1.8.2 Isotype Control Antibodies 
In flow cytometry it is important to negate the effects within results of non-
specific binding of antibodies to cells, this can either be due to binding to Fc receptors 
on the cell surface or entrapment of the antibody on/in the cell. To control for this it is 
common to use isotype antibodies to create staining controls. These are antibodies 
conjugated with the fluorophores being used but not possessing antigen specificity to 
any marker that is present on the cells (Maecker and Trotter, 2006). Thus, the only 
antibody staining that will occur will be due to non-specific binding. The flow cytometric 
data can then be gated based on the isotype controls to determine the fluorescence 
levels (a combination of autofluorescence and non-specific antibody staining) of marker-
negative populations. 
 
3.1.8.3 Live/Dead Cell Staining 
As well as antibody staining of cells, it is possible to chemically label cells with 
fluorescence. One particularly useful staining technique is the use of live/dead cell 
stains. These substances will not pass through intact cell membranes on viable cells but 
can easily pass into the permissive membranes of dead cells (King, 2000). This creates 
two populations: the non-fluorescent live cells where no dye has entered and the 
fluorescent dead cells which contain the stain, the proportions of which represent the 
viability of the cells at the time of staining. Some dyes are also fixable, meaning the cells 
can be fixed with paraformaldehyde or a similar fixative after live/dead staining and then 
stained with fluorophore-conjugated antibodies subsequently without degrading the 
viability dye staining.  
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3.1.8.4 Fluorescence-Activated Cell Sorting 
Fluorescence-activated cell sorting (FACS) is a variation on flow cytometry that 
allows for the pooling of cell populations based on their fluorescence after staining. The 
staining protocol used is similar to flow cytometry apart from cells are not fixed and 
sterile conditions maintained. Gating is then applied to the sample in real time and cells 
possessing the characteristics of choice selected. The stream of cells passes out of the 
machine, forming droplets, each of which contains a single cell. The cytometer applies 
an electrical charge to the liquid at the moment it forms a droplet, creating a charged 
droplet which can be directed by a charge gate into the receptacle of choice (Herzenberg 
et al., 2002). The use of different charge polarity and deflection charge allow cells to be 
sorted into multiple directions. Highly pure viable cell populations can then be collected 
and used in downstream experimentation. 
 
3.2 Aims and Objectives 
This chapter aims to extend use of human ex vivo human skin beyond the full 
thickness skin model by extracting immune cells from it. The phenotype, viability and 
functionality of these cells will then be assessed. The specific practical objectives are: 
1. Optimise a protocol for obtaining dDCs and epidermal LCs from skin 
which maximises yield, viability and purity of the cells. 
2. Characterise the cell populations using flow cytometry to identify 
phenotypic markers. 
3. Utilise live/dead cell staining to assess the viability of cells in combination 
with antibody staining to determine viability within immune cell 
populations specifically. 
4. Utilise TLR agonists to assess the capacity of skin immune cells to respond 
to immune challenge representative of bacterial and viral pathogens. 
5. Utilise SIV virus to knockdown SAMHD1 in dDCs and LCs obtained from 
skin. 
6. Apply the skin cell model to validate results of a study on the effect of 
SAMHD1 on post-entry HIV-1 viral infection.  Initial results were obtained 
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by a colleague using monocyte-derived DCs and so the skin cell model 
should provide data that is more representative of the in vivo situation. 
 
3.3 Materials and Methods 
[All reagents were obtained from Fisher Scientific, UK unless otherwise stated] 
3.3.1 Isolation of Dermal and Epidermal Walkout Cells from Skin  
Human skin samples were collected following mastectomy or breast reduction 
surgery at the Royal Gwent Hospital, Newport and transported to the laboratory for use 
as described in Section 2.3.2. Subcutaneous fat was removed using surgical scissors and 
the skin pinned, epidermis uppermost, onto a corkboard. The uppermost 300µm of the 
skin was isolated using a dermatome (Nouvag AG, Switzerland), a surgical instrument 
used to harvest skin from patients during skin graft surgery. The remaining skin (lower 
dermis) was discarded. The 300µm-thickness skin was then cut into pieces, roughly 1cm2 
in size, using a scalpel and placed in Roswell Park Memorial Institute medium (RPMI; 
Sigma-Aldrich, UK) plus 10 mg/ml collagenase (Invitrogen, UK), 20 U/ml DNase I (Sigma-
Aldrich, UK) and 10 mg/ml Dispase II (Invitrogen, UK) and incubated with agitation in a 
shaking water bath (at 175 strokes/min) for 30 mins at 37°C. Following removal from the 
enzyme solution, mechanical separation of the epidermal and dermal regions at the 
basement membrane using forceps was possible. Dermal and epidermal tissue were 
then washed briefly in PBS and divided between wells of a 6-well plate containing RPMI 
supplemented with 10% human AB serum (Sigma-Aldrich, UK) and 1% 
Pen/Strep/Fungizone solution (Sigma-Aldrich, UK) (DC-RPMI). The plate was then 
incubated at 37°C for 48 hours to allow the migration of cells out of the tissue and into 
the media. Following incubation, media was collected, passed through a 100µm cell 
strainer and spun down to collect cells. Cells were counted using a haemocytometer 
prior to use. 
 
3.3.2 Characterisation of LCs and dDCs 
Dermal and epidermal walkout cells were fixed in 1% paraformaldehyde (PFA) in 
PBS at room temperature for 10 mins then washed in PBS. Fixed cells were aliquoted at 
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1 x 105 cells per well of a round-bottomed 96-well plate, spun down and then 
resuspended in 50µl FACS buffer (1% bovine serum albumin (Sigma-Aldrich, UK) and 
0.025% sodium azide in PBS) containing manufacturer’s recommended concentration of 
the antibodies shown in Table 3.1. 
 
Table 3.1: Antibodies used to assess phenotype of skin walkout cells via flow cytometry 
 Antibody Conjugated Fluorophore Manufacturer 
Dermal 
Dendritic 
Cell Panel 
Anti-CD3 Fluorescein isothiocyanate (FITC) BD Biosciences, UK 
Anti-CD19 FITC Dako, Denmark 
Anti-CD20 FITC BioLegend, UK 
Anti-CD56 FITC BioLegend, UK 
Anti-CD45 Phycoerythrin (PE) Miltenyi Biotec, UK 
Anti-HLA-
DR 
Allophycocyanin (APC) BD Biosciences, UK 
Anti-CD14 Peridinin chlorophyll (PerCP) Miltenyi Biotec, UK 
Anti-CD141 VioBlue® Miltenyi Biotec, UK 
Anti-CD11c 
Allophycocyanin-cyanine 7 (APC-
Cy7) 
BD Biosciences, UK 
Epidermal 
Langerhans 
Cell Panel 
Anti-CD1a FITC BD Biosciences, UK 
Anti-CD207 PE 
Beckman Coulter, 
UK 
Anti-HLA-
DR 
APC BD Biosciences, UK 
Isotype 
Control 
Panel 
IgG1 κ FITC BD Biosciences, UK 
IgG1 κ PE BD Biosciences, UK 
IgG1 κ APC BD Biosciences, UK 
IgG1 κ PerCP BD Biosciences, UK 
IgG1 κ VioBlue® Miltenyi Biotec, UK 
IgG1 κ APC-Cy7 BD Biosciences, UK 
 
Cells were incubated in antibody solutions and protected from light for 60 mins 
at 4°C. After staining, cells were washed and resuspended in 300µl FACS buffer per 1 x 
105 cells for flow cytometric analysis on FACSCanto II Flow Cytometer (BD Biosciences, 
UK). Anti-Mouse Ig, κ/Negative Control Compensation Plus Beads (BD Biosciences, UK) 
were used with an antibody for each fluorophore used to provide compensation 
controls for the flow cytometric analysis. Analysis of flow cytometric data was 
performed using FlowJo software (FlowJo LLC, USA). 
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3.3.3 Characterisation of Dermal T-cells  
Walkout cells were fixed as described in Section 3.3.2 then aliquoted at 1 x 105 
cells per well of a round-bottomed 96-well plate, spun down and then resuspended in 
50µl FACS buffer (1% bovine serum albumin (Sigma-Aldrich, UK) and 0.025% sodium 
azide in PBS) containing the manufacturer’s recommended concentration of the 
antibodies listed in Table 3.2. 
Table 3.2: Antibodies used to identify T-cells amongst skin walkout cells via flow cytometry 
 Antibody Conjugated Fluorophore Manufacturer 
Dermal 
T-cell 
Panel 
Anti-CD8 FITC BD Biosciences, UK 
Anti-CD3 PE BD Biosciences, UK 
Anti-CD4 APC BD Biosciences, UK 
Isotype 
Control 
Panel 
IgG1 κ FITC BD Biosciences, UK 
IgG1 κ PE BD Biosciences, UK 
IgG1 κ APC BD Biosciences, UK 
 
Cells were incubated in antibody solutions protected from light for 60 mins at 
4°C. After staining, cells were washed and resuspended in 300µl FACS buffer per 1 x 105 
cells for flow cytometric analysis. 
 
3.3.4 Walkout Cell Viability Staining 
To assess the viability of skin walkout cells, LIVE/DEAD® Fixable Far Red Dead Cell Stain 
Kit, for 633 or 635 nm excitation (ThermoFisher Scientific, UK) was used. Cells were 
collected from skin following 48-hour walkout, as in Section 3.3.1. An aliquot of 1 x 106 
each dermal or epidermal cells was heated to 65°C for 10 mins then cooled on ice to 
create a dead cell control for staining. All cells were washed with PBS before being 
stained for 30 mins with 1µl per 1 x 106 cells on ice. Following staining, cells were washed 
with PBS and fixed with 1% PFA for 10 mins at room temperature before being stained 
with the antibodies shown in Table 3.3. 
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Table 3.3: Antibodies used to assess viability of immune cells amongst skin walkout cells via 
flow cytometry 
 Antibody Conjugated Fluorophore Manufacturer 
Dermal 
Dendritic 
Cell Panel 
Anti-HLA-DR PE BD Biosciences, UK 
Anti-CD141 VioBlue® Miltenyi Biotec, UK 
Anti-CD11c APC-Cy7 BD Biosciences, UK 
Epidermal 
Langerhans 
Cell Panel 
Anti-CD1a FITC BD Biosciences, UK 
Anti-CD207 PE Beckman Coulter, UK 
Isotype 
Control 
Panel 
IgG1 κ FITC BD Biosciences, UK 
IgG1 κ PE BD Biosciences, UK 
IgG1 κ APC BD Biosciences, UK 
IgG1 κ PerCP BD Biosciences, UK 
IgG1 κ VioBlue® Miltenyi Biotec, UK 
IgG1 κ APC-Cy7 BD Biosciences, UK 
 
Following staining, flow cytometry and data analysis were performed as 
described in Section 3.3.2. 
 
3.3.5 Stimulation of Skin LCs and dDCs with TLR Agonists 
To assess the potential of the skin walkout cell model for measuring immune cell 
activation, walkout cells were collected from the dermis and epidermis as described in 
Section 3.3.1 before being plated at 2 x 106 cells per well of a 96 well plate. Cells were 
spun down and resuspended in Iscove's Modified Dulbecco's Medium (IMDM) plus 1 
µg/ml lipopolysaccharide (LPS), IMDM plus 10 µg/ml poly-I:C or IMDM alone. One hour 
after plating, brefeldin-A was added to a final concentration of 10 µg/ml to wells 
designated for intracellular cytokine staining.  Cells were then incubated overnight at 
37°C. 
The next morning, cells were fixed and stained for CD83 or intracellular cytokine 
expression. Intracellular staining was completed using using Perm/Wash Kit (BD 
Biosciences) according to the manufacturer’s protocol. The antibodies used are listed in 
Table 3.4. 
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 Table 3.4: Antibodies used to assess maturation and cytokine expression amongst skin walkout 
cells via flow cytometry 
  
 Following staining, flow cytometry and data analysis were performed as 
described in Section 3.3.2. Statistical tests comprised one-way analysis of variance 
(ANOVA) followed by Tukey's post hoc analysis performed using IBM SPSS Statistics 
(IBM, USA). 
 
3.3.6 Functional Testing of Skin Walkout Cells 
The functionality of the walkout cells was also tested to further assess the ex vivo 
skin cell model. Previous work in the lab indicated differences in the infectability of 
monocyte-derived dendritic and LC models with a HIV-1 lentiviral vector, following 
knockdown of the antiviral factor SAM domain and HD domain-containing protein 1 
(SAMHD1), which is common to skin-resident LCs and dDCs (Czubala et al., 2016). This 
investigation aimed to replace the monocyte-derived cells used in this series of 
experiment with ex vivo human skin cells in order to provide data that is more 
representative of in vivo cell behaviours. 
3.3.6.1 Production of Lentiviral Vectors 
[All plasmids were gifts from Prof. Didier Trono, EPFL, Switzerland] 
Human embryonic kidney 293 cells expressing the simian vacuolating virus 40 
large tumour antigen (HEK293T cells) were seeded at 10-15x 106 cells per T175 culture 
flask in 15mls Dulbecco's Modified Eagle Medium (DMEM) and incubated at 37°C 
 Antibody Conjugated Fluorophore Manufacturer 
Maturation Panel 
Anti-HLA-DR 
Phycoerythrin-cyanine 7 
(PE-Cy7) 
BD Biosciences, UK 
Anti-CD83 APC Miltenyi Biotec, UK 
ICC Panel 
Anti-HLA-DR PE-Cy7 BD Biosciences, UK 
Anti- TNF-α APC BD Biosciences, UK 
Anti-IL-12 APC BD Biosciences, UK 
Isotype Control 
Panel 
IgG2a PE-Cy7 BD Biosciences, UK 
IgG1 κ APC BD Biosciences, UK 
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overnight to allow cell adherence onto the flask. A confluence of 70-80% was optimal 
for transfection using this protocol. 
The following DNA plasmids (Figure 3.2) were combined in 2.5mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered ddH2O (Sigma-Aldrich, 
UK): 
VSV-G-HIV-GFP Virus  
1. 11.25µg pMD.G - envelope plasmid encoding G protein from VSV (Salmon 
et al., 2000b) 
2. 33.75µg pLOX-EWgfp - HIV-1-derived transfer gene encoding GFP 
(Salmon et al., 2000a) 
3. 45µg pR8.91 - lentiviral packaging plasmid which encodes HIV-1 group-
specific antigen (Gag) and viral enzyme (Pol) polyproteins as well as the 
regulatory proteins Tat and Rev (acronyms for ‘trans-activator of 
transcription’ and ‘regulator of expression of virion proteins’ 
respectively) (Pollard and Malim, 1998, Salmon et al., 2000a) 
SIV-Vpx Virus  
1. 20µg pMD.G - as above, envelope plasmid encoding G protein from VSV 
2. 40µg pSIV3+ - simian immunodeficiency virus-derived packaging plasmid 
(including Vpx) (Negre et al., 2000) 
A 
B 
C 
D 
Figure 3.2: Schematic representations of the pMD.G (A), pLOX-EWgfp (B), pR8.91 (C) and 
pSIV3+ (D) plasmids used in the production of VSV-G-HIV-GFP and SIV-Vpx viruses  
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Plasmids were added to HEPES buffer to a final volume of 750µl and mixed gently 
for 5 mins at room temperature. The plasmid solution was then combined with 750µl 
500mM CaCl2. The resulting solution was added dropwise to 1.5ml of 2x HEPES-buffered 
saline (HBS) under gentle vortex to facilitate mixing. The mixture was then allowed to 
stand at room temperature for 30 mins. It was then added dropwise to the HEK293T 
cells in T175 flasks (3ml per flask), ensuring to distribute it across the entire culture 
surface. Gently tilting the flask further distributed the plasmids. Cells were then 
incubated at 37°C overnight. After this media was removed from the flasks, cells were 
washed gently with 20ml sterile phosphate-buffered saline (PBS) and 25ml DMEM was 
added before the flasks were returned to the incubator for a further overnight 
incubation at 37°C. 
Cell supernatant was then removed, passed through a 0.45µm sterile filter and 
pelleted through a solution of 20% sucrose in PBS using an ultracentrifuge (Beckman 
Coulter, UK) at 26,000RPM at 4°C for 90 mins. After centrifugation, supernatant was 
aspirated and the lentiviral vector resuspended in DMEM and stored at -80°C until use. 
Viral titres were determined by a colleague using a Lenti-X p24 titre ELISA kit (Clontech, 
France) and titration of virus followed by western blot to assess SAMHD1 knockdown to 
establish the viral yield of VSV-G-HIV-GFP and SIV-Vpx viruses respectively.  
 
3.3.6.2 Knockdown of SAMHD1 in LCs/dDCs  
LCs and dDCs were isolated from skin using the walkout protocol (Section 3.3.1). 
A total of 3 x 105 dermal walkout cells and 1 x 106 epidermal walkout cells were plated 
at 1 x 105 cells per well with or without SIV-Vpx in a 96 round-bottomed well plate. Three 
hours after initial plating, cells were lysed by incubation for 30 mins at 4°C in lysis buffer 
(1mM MgCl2, 1mM EDTA, Roche cOmplete™ Mini Protease Inhibitor Cocktail (Sigma 
Aldrich, UK), 1% IGEPAL® CA-630 (Sigma Aldrich, UK), 20mM Tris base and 150mM NaCl 
in ddH2O in 1.5ml microcentrifuge tubes. Tubes were then vortexed before 
centrifugation at 13,000RPM for 18 mins. NuPAGE® LDS Sample Buffer and Reducing 
Agent were added to the supernatant and heated to 80°C for 10 mins to denature 
proteins ready for gel electrophoresis.  
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Gel electrophoresis was performed on NuPAGE™ Novex™ 4-12% Bis-Tris Protein 
Gels according to the manufacturer’s protocol. SeeBlue® Pre-stained and Mark12™ 
Unstained protein standards were run concomitantly as per manufacturer’s protocol to 
allow determination of protein size. Following gel electrophoresis, proteins were 
transferred to nitrocellulose membrane via electroblotting. Transfer success was 
determined via staining with 0.1% Ponceau S in 5% acetic acid in ddH2O. The membrane 
was washed to remove Ponceau S staining then blocked using 5% milk protein in PBS. 
Antibody staining was performed overnight at 4°C on a rocking platform using the 
manufacturer-recommended concentrations of mouse anti-actin (Millipore, UK) and 
mouse anti-SAMHD1 (Abcam, UK) antibodies in 1% BSA, 0.025% sodium azide and 0.1% 
Tween 20 in PBS. After overnight incubation, membranes were washed then stained 
with anti-mouse HRP-conjugated secondary antibody (Bio-Rad, UK) as per 
manufacturer’s protocol. SuperSignal West Pico Chemiluminescent Substrate 
(ThermoFisher, UK) was then added and the membrane imaged using x-ray film to 
detect light produced. SAMHD1 knockdown by SIV-Vpx was assessed by absence of a 
band on the developed film compared to the untreated control cells. 
 
3.3.7 Infection of LCs/dDCs with VSV-G-HIV-GFP  
LCs and dDCs were isolated from skin using the walkout protocol. Cells were 
plated at 1 x 105 cells per well with or without SIV-Vpx in a 96 round-bottomed well 
plate. Three hours after initial plating, VSV-G-HIV-GFP (17-63ng p24 per well) was added 
to the appropriate wells. Cells were fixed 96 hours after initial plating in 2% 
paraformaldehyde at room temperature for 10 mins prior to staining for flow cytometric 
analysis. Antibodies listed in Table 3.1 were used to characterise the cell populations 
based on CD141, CD45, CD11c, CD14, HLA-DR, CD1a and CD207 expression. Cells were 
incubated with antibodies for 60 mins at 4°C followed by two washes before analysis 
using a FACSCanto II flow cytometer (BD Biosciences, UK). GFP-expressing cells were 
analysed in the FITC channel. Statistical tests comprised one-way analysis of variance 
(ANOVA) followed by Tukey's post hoc analysis performed using IBM SPSS Statistics 
(IBM, USA).  
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3.3.8 Sorting of LCs and dDCs from Skin 
Analysis of infection by VSV-G-HIV-GFP in dDC subsets following 96-hour 
incubation proved to be difficult due to CD141 and CD11c downregulation during culture 
(probably due to reduced viability of cells towards the end of culture). To assess whether 
differences in infectability post-SAMHD1 knockdown existed between dDC subsets, cell 
sorting was used to isolate the various subpopulations of dDCs. The walkout protocol 
was followed as described in Section 3.3.1 up until cell counting. After counting, cells 
were stained in sterile FACS buffer without sodium azide with the antibodies listed in 
Table 3.5. 
 
Table 3.5: Antibodies used to sort dDC subsets and LCs from skin walkout cells 
 Antibody Conjugated Fluorophore Manufacturer 
dDC 
Panel 
Anti-CD45 Phycoerythrin (PE) Miltenyi Biotec, UK 
Anti-HLA-DR Allophycocyanin (APC) BD Biosciences, UK 
Anti-CD141 VioBlue® Miltenyi Biotec, UK 
Anti-CD11c 
Allophycocyanin-cyanine 7 
(APC-Cy7) 
BD Biosciences, UK 
LC Panel 
Anti-CD207 PE Beckman Coulter, UK 
Anti-HLA-DR APC BD Biosciences, UK 
 
 Cell sorting was performed on a FACSAria III cell sorter (BD Biosciences, UK). 
Following sorting, cells were counted using a haemocytometer and viability assessed 
using Fixable Viability Dye eFluor® 450 (Affymetrix eBioscience, UK) following the 
manufacturer’s protocol. Sorted cells were plated and SIV-Vpx and/or VSV-G-HIV-GFP 
added as described in Section 3.3.7. Following incubation, cells were fixed and stained 
as described in Section 3.3.7 to assess the infectability of LCs and dDC subsets in the 
presence and absence of SAMHD1 based on GFP expression.   
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3.4 Results and Discussion 
3.4.1 Isolation of epidermal LCs and dDCs from skin  
Preliminary work using enzymatic separation of the dermis and epidermis of full 
thickness human ex vivo skin was unsuccessful, with the dermis forming a gelatinous 
mass that could not be easily separated from the epidermis. Manual removal of excess 
dermis using surgical scissors was performed and allowed more efficient enzymatic 
separation but was extremely time-consuming, especially with larger skin samples. The 
inclusion of a dermatome in the protocol allowed rapid processing of large areas of skin 
to a consistent thickness. Lower skin thickness reduced the enzyme incubation time 
required and allowed easier separation of the dermis and epidermis. The 48-hour 
incubation time derived from the literature was adequate for the collection of migratory 
cells from the media in numbers suitable for downstream use.  
Flow cytometric analysis of dermal walkout cells revealed that dDCs existed in a 
separate FSC-A/SSC-A region from T-cells and cell debris (Figure 3.3 A). Analysing the 
HLA-DR+/CD45+ cells from this region revealed the existence of three distinct subsets 
based on CD141 and CD11c expression (Figure 3.3 D). The mean proportions of each 
subset within the dDCs analysed (n=10) were: 17.3% CD11c+/CD141+ (SD: 8.4), 60.3% 
CD11c+/CD141- (SD: 7.8) and 21.6% CD11c-/CD141- (SD: 9.1). CD11c+/CD141+ dDCs also 
showed CD14 expression in line with the literature (Chu et al., 2012) (Figure 3.3 E).  
 
 
 
A C B E D 
Figure 3.3: Gating strategy for migratory dermal cells. Gates: (A) exclude cell debris and T-cells (B) 
eliminate cell doublets (C) select total dDCs [CD45+/HLA-DR+] (D) distinguish between the three major 
dDC subsets [CD11c+/CD141+, CD11c+/CD141- and CD11c-/CD141-] and (E) confirm the CD14 
expression within CD11c+/CD141+ dDCs only. 
92 
 
A C B D 
Figure 3.5: Gating strategy for migratory epidermal cells. Gates (A) eliminate cell debris (B) 
eliminate cell doublets (C) select HLA-DR+ cells present and (D) confirm the cells are LCs based on 
their CD1a/Langerin (CD207) double positivity. 
It had been previously reported that B-cells, T-cells and macrophages are also 
present in human skin (Haniffa et al., 2012, Geherin et al., 2012, McCully et al., 2012). 
For this reason, the lineage markers CD3, CD19, CD20 and CD56 were analysed in 
walkout cells. It was found that isolating dDCs based on FSC-A/SSC-A region and HLA-DR 
positivity was adequate to exclude these other cells and allow analysis of dDCs alone 
(Figure 3.4).  
 
Phenotypically, LCs expressed HLA-DR, CD1a and CD207 (Langerin) (Figure 3.5) - 
the latter of which is a distinguishing marker of the cells from dDCs in human skin 
(Klechevsky et al., 2008a).  
 
 
 
 
 
 
Figure 3.4: Lineage staining of cells in the dDC FSC-A/SSC-A region, showing that HLA-DR+ dDCs do 
not stain for lineage markers (A) and the shift in Lineage-FITC MFI compared to isotype due to 
increased concentration of antibodies leading to increased non-specific staining (B) 
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Given that LCs migrate into the dermis to enter the dermal lymphatic vessels 
(Pearton et al., 2010b), it was likely that LCs would be found in dermal walkout cells. As 
Figure 3.6 shows, CD1a+/CD207+ cells made up a small fraction of the HLA-DR+ dermal 
walkout cells (less than 2% in the skin samples tested) and so do not represent a 
meaningful contamination of the dDCs in dermal walkout cells. Yields of epidermal LCs 
and dDCs varied with the size of the sample. The mean yield of LCs was over 5.25 x 105 
cells per sample with values ranging from 4.5 x 104 to 3.06 x 106 across the samples 
tested (n=16). The mean yield of dDCs was greater than 1.23 x 106 per sample with 
values ranging from 1.81 x 105 to 4.98 x 106 (n=16). The purity of LCs amongst epidermal 
cells was typically lower than that of dDCs amongst dermal cells; 7.31% versus 34.11% 
respectively. This is most likely the result of a combination of connective dermal tissue 
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CD1a 
Figure 3.6: CD1a+/CD207+ LCs amongst dermal walkout cells (A) and the difference in 
HLA-DR and CD1a expression between dDCs and LCs amongst walkout cells from skin (B). 
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being more resistant to dispersion following enzyme treatment (thus not contaminating 
walkout cells), the motility of immature dDCs and the proliferative nature of epidermal 
stem cells leading to an increase in the proportion of non-immunological cells collected 
from the epidermis.  
Cell viability was determined by fixable viability dye staining of walkout cells, 
with dead control cells and unstained cells allowing for validation (Figure 3.7). The 
viability of dermal walkout cells was consistently over 90%, while overall epidermal cell 
viability was much lower (below 50% in the samples tested).  
Concurrent staining of walkout cells with antibodies alongside the fixable 
viability dye allowed the viability of the immune cells to be observed independently. The 
viability of the immune cells at over 95% in the samples tested was much higher than 
the mean values of the walkout cells (Figure 3.8). It is likely that amongst epidermal 
walkout cells a large amount of keratinocytes, which lose viability as they move towards 
the stratum corneum in natural turnover (Fore, 2006), formed the majority of the dead 
cells seen. Their non-migratory nature means they likely dissociated from the epidermis 
following enzymatic treatment. Dermal cells contained less contaminating cells, perhaps 
due to the gel-like state of the dermal tissue after enzyme exposure acting to better 
retain non-migratory cells. Thus it was concluded that although cell viability was 
generally poor amongst walkout cells, the immune cells appeared to be viable and 
therefore suitable for use in downstream experimentation. 
Figure 3.7: Cell viability staining of epidermal walkout cells (A) and dermal walkout cells (B) 
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3.4.2 Characterisation of dermal T-cells  
Flow cytometric analyses revealed that T-cells occupied a distinct FSC-A/SSC-A 
region proximal to the dDC FSC-A/SSC-A region (Figure 3.9 A) (Chu et al., 2012). 
Epidermal walkout cells did not show significant numbers of T-cells (Figure 3.9 C). The 
majority of cells (91%) in the T-cell region were CD3+ compared to only 2.2% in the dDC 
region confirming the location of the total T-cell population (Figure 3.10). Within the 
CD3+ T-cell population, CD4+ helper T-cells made up the majority of the cells. The ratio 
of CD4+:CD8+ T-cells obtained from the dermis varied between patients but was on 
average approximately 2:1. This is roughly equivalent to the ratio of T-cell populations 
that exists within the blood (McCully et al., 2012).  
Figure 3.8: Viability of walkout immune cells. Plots show gating for LCs on CD207 [PE] and 
CD1a [FITC] (A) and dDCs on HLA-DR [PE] (C) and their viability by viability dye exclusion- 
97.7% for LCs (B) and 98.7% for dDCs (D).  
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Figure 3.9: FSC-A/SSC-A regions occupied by T-cells and dDCs, the two major constituents of 
total dermal walkout cells (A).  Proportion of cells found in the T-cell FSC-A/SSC-A region of 
dermal (B) and epidermal (C) walkout cells 
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Figure 3.10: Staining of dermal walkout cells to characterise T-cells using PE anti-CD3, APC anti-
CD4 and FITC anti-CD8 antibodies 
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3.4.3 Stimulation of Skin LCs and dDCs with TLR Agonists 
 Attempts to stimulate walkout dDCs and LCs with the TLR agonists LPS and 
poly(I:C) failed to elicit a meaningful upregulation of maturation marker CD83 with 
untreated cells already showing expression, suggesting walkout cells were already partly 
matured (Figure 3.11 A). There was also no distinguishable cytokine expression in TLR 
agonist-treated cells versus untreated controls (Figure 3.11 B). Thus, it was concluded 
that walkout cells exist in a partially-matured state and therefore are not responsive 
enough to stimuli to make the model a useful readout for immune stimuli.  
3.4.4 Knockdown of SAMHD1 in LCs/dDCs  
Knockdown of SAMHD1 by exposing walkout cells to SIV-Vpx virus proved 
successful, with a reduction in the protein visible on western blot (Figure 3.12). Unlike 
SAMHD1 knockdown in mdDCs (as completed by a colleague), it was not possible to fully 
eliminate the antiviral factor. This may be due to viral uptake and SAMHD1 degradation 
being active processes, meaning dead or dying walkout cells will not show SAMHD1 
knockdown. Thus, the Western blot shows a reduction rather than elimination in the 
levels of the protein in the cell population. This should not affect downstream 
investigations adversely as only the viable cells will be able to be integrate and express 
the GFP gene in the VSV-G-HIV-GFP lentiviral vector.  
              Dermal cells       Epidermal cells 
SAMHD1 
Actin 
Figure 3.12: SAMHD1 knockdown in dermal and epidermal walkout cells from 
human ex vivo skin following incubation with SIV-Vpx virus 
CD83 TNF-α 
A B 
Figure 3.11: CD83 (A) and TNF-α/IL-12 (B) expression in dDCs treated with TLR agonists. LCs 
showed a similar lack of response to stimulation. 
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3.4.5 Infection of LCs/dDCs with VSV-G-HIV-GFP  
Infection of primary skin LCs and dDCs with VSV-G-HIV-GFP alone showed low 
levels of GFP expression, mean values of 1.54% and 1.64% respectively (n = 4), which 
was not significantly different between the cell types. Following pre-treatment for 3 
hours with Vpx-encoding SIV3, mean GFP expression rose to 3.99% in LCs and 14.04% in 
dDCs (Figure 3.13). The inherent variability in baseline and post-SAMHD1 knockdown 
infectability of dDCs from the skin samples used compromised the ability to detect 
statistically significant differences between the infection conditions Figure 3.14 A). LC 
baseline infectivity was more consistent between donors, with significant differences 
existing between control and infected cells with or without SIV3 (p ≤ 0.05 in both cases). 
Eliminating the variability in baseline infectivity between donors by normalising the data 
to baseline infectivity (VSV-G-HIV-GFP infection without SIV3 pre-treatment) revealed 
the effect of SAMHD1 inhibition and revealed statistically significant differences in fold-
change of infection between untreated cells, cells infected with VSV-G-HIV-GFP alone 
and those infected following SAMHD1 knockdown (Figure 3.14 B). Normalised data also 
confirmed the significant increase in infectability of dDCs over LCs (mean increases of 
11.1- and 2.5-fold respectively; p ≤ 0.05). This agreed with results in monocyte-derived 
dDC and LC equivalents and appears to suggest that LCs possess some extra post-entry 
Figure 3.13: Flow cytometric plots from a single skin sample showing GFP expression in dDCs 
and LCs after infection with VSV-G-HIV-GFP ± SIV-Vpx . 
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viral restriction factor over dDCs that allow them to remain resistant to infection even 
after SAMHD1 degradation.  
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Figure 3.14: Infection of skin walkout immune cells by VSV-G-HIV-GFP with and without prior exposure 
to SIV-Vpx to knock down SAMHD1. Graphs present data as mean % GFP+ cells (A) and normalised 
within each skin sample to show fold-change in infection following SIV-Vpx pre-treatment (B). Error 
bars ± SD. 
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3.4.6 Sorting of LCs and dDCs from Skin 
Sorting was attempted on walkout cells from two separate skin samples. The first 
skin sample was particularly large and yielded a high number of cells - 16.5 x 106 total 
dermal cells and 46 x 106 total epidermal cells. Antibody concentrations were reduced 
from the standard protocol by 50% to reduce the reagent usage of staining such large 
cell populations. As a result, the HLA-DR+/CD207+ population was less distinct than 
usual (Figure 3.15 A) - though the double positive population should still represent LCs. 
The staining of dDC subsets produced data in line with previous results despite the 
reduction antibody concentration (Figure 3.15 B). The quantitative data from the 
FACSAria cell sorter gave the figures for cells sorted listed in Table 3.6. 
 
 
 
Table 3.6: Skin walkout cell numbers sorted into dDC subset and LC populations 
Cell Type Sorted Cell Number (FACSAria Software Readout) 
++ dDCs 9.5 x 105 
+- dDCs 4.1 x 105 
-- dDCs 1.8 x 106 
LCs 3.0 x 105 
Figure 3.15: Phenotypic analysis of sorted epidermal migratory cells (A) and of dermal 
migratory cells (B) 
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The analysis of cells for GFP expression following the 5-day incubation post-sort 
is shown in Figure 3.16. The low levels of GFP expression with any treatment condition 
suggests the cells did not possess functionality after sorting. There were also fewer cells 
during analysis than expected based on readouts from the cell sorter. This led to 
unreliable data, with high levels of signal noise in untreated samples. As a result, there 
was no distinguishable difference in GFP expression between treated and untreated 
cells.  
Given that the first attempt at sorting suffered practical setbacks, with a 
breakdown of the first choice cell sorter necessitating storage of cells on ice for an 
extended period of time (both of which might have adversely affected cell viability and 
functionality), a second skin sample was processed for cell sorting. The second skin 
sample was markedly smaller than the first and as a result the yield of total dermal (2.7 
x 106) and epidermal (2.2 x 106) cells was lower. Staining was clearer, perhaps due to the 
lower cell number. LCs formed a distinct population that was 9.85% of the total 
epidermal cell events whilst dDCs accounted for 43.2% of the dermal cell events (Figure 
3.17). Cell numbers from the second sample were assessed using a haemocytometer 
after sorting (Table 3.7). The cell numbers were too low for lentiviral vector infection of 
the cells was not feasible. Therefore, cell viability was utilised as an endpoint. Viability 
was measured 24 hours after sorting to allow any cells which had become apoptotic 
during sorting to progress to cell death and give a more accurate readout of cell viability. 
Figure 3.16: GFP-expressing cells amongst sorted dDC subsets and LCs from skin sample 324. 
Key: +/+ = CD11c+/CD141+ dDCs, +/- = CD11c+/CD141- dDCs and -/- = CD11c-/CD141- dDCs. 
102 
 
Of all the cells, -- dDCs were the only sorted cell population with a viability over 10%. 
Thus, it was concluded that the large number of cells required and the poor viability 
after sorting meant that cell sorting was unsuitable for use in this investigation.  
 
Table 3.7: Walkout cell numbers from ex vivo human skin at the various stages of cell sorting 
Cell 
Type 
Predicted Number 
(Subset Frequency x Pre-
Sort Haemocytometer 
Count) 
Sorted Cell 
Number 
(Software 
Readout) 
Sorted Cell Number 
(Post-Sort 
Haemocytometer 
Count) 
++ dDCs 1.8 x 105 8.3 x 104 3 x 104 
+- dDCs 5.7 x 105 2.9 x 104 8 x 104 
-- dDCs 2.2 x 104 8.4 x 103 
No cells in countable 
area 
LCs 1.1 x 105 7.6 x 104 2 x 104 
  
Figure 3.17: Phenotypic analysis of sorted epidermal migratory cells (A) and of 
dermal migratory cells (B) from second sorted skin sample 
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3.5 General Discussion 
The human ex vivo skin immune cell model was developed to address some of 
the limitations of the full thickness skin model. The initial challenge was processing skin 
to separate dermis from epidermis, so that walkout cells from each could be used 
separately. The thickness of dermis on the skin samples when they are received impedes 
enzyme cocktail access to the basement membrane and so increases the incubation time 
required. The connective tissue of the dermis, which contains collagen fibrils, is also 
partly broken down by the enzyme cocktail (which contains collagenase) and forms a 
gelatinous substance, making separation from the epidermis more difficult after 
extended incubation periods in enzyme cocktail. The use of surgical scissors to remove 
excess lower dermis reduced the required incubation time, though increased processing 
time as skin needed to be divided into punch biopsies initially before trimming away the 
lower dermis. Given the limited time window of viability of ex vivo skin tissue and the 
fact that manual handling occurs at room temperature, any steps to reduce the 
processing time will benefit tissue (and downstream cell) viability.  
The use of a dermatome to remove excess lower dermis allowed large areas of 
the skin to be processed more quickly than could be achieved using the previous biopsy 
punch method. This reduced the time that skin was out of media and thereby helped to 
maintain its viability. The reduced thickness of the skin after the dermatome was used 
also helped to minimise enzyme incubation time, protecting the structural integrity of 
the dermis and epidermis and reducing the contamination from non-migratory cells in 
the walkout media. The differences in purity observed between cells from the dermis 
and epidermis is most likely the result of a combination of connective dermal tissue 
being more resistant to dispersion following enzyme treatment (limiting non-dDC 
presence in the walkout media) and the proliferative nature of epidermal stem cells 
which fall out of the epidermal tissue leading to an increase in the proportion of non-
immunological cells collected from the epidermis. 
It was possible to collect walkout cells from both the epidermis and dermis. 
Phenotypically, LCs were straightforward to characterise given their HLA-
DR/CD1a/CD207 triple positivity, which is unique amongst skin cells (Klechevsky et al., 
2008a). Though dDCs have been reported to probe the epidermis (Rattanapak et al., 
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2014), they do not migrate into it and so LCs are the lone HLA-DR+ cell type present in 
the upper layer of skin, confirmed by CD207 expression. Identifying dDCs was more 
challenging, given their diverse subsets.  
The ability to separate dDCs from dermal T-cells by their size/granularity 
(quantified as FSC-A and SSC-A respectively) proved advantageous in analysing dDCs. 
They could then be gated specifically based on their HLA-DR/CD45 double positivity 
(dermal T-cells are CD45+/HLA-DR- (Koretzky et al., 1990)). This then allowed the total 
dDC population to be analysed for the various subset markers. Subset classification 
varies by group along with the method used to isolate the dDCs, some groups lyse the 
dermis completely (Haniffa et al., 2012) whilst others perform a walkout similar to the 
one described (Chu et al., 2012). The lysis protocol means that all cells from the dermis 
are present, whether migratory or not. This leads to a lower purity of dDCs. Also, it 
allows for the analysis of other skin-resident cells, such as macrophages, which do not 
spontaneously migrate from dermal tissue (Haniffa et al., 2009). It has also been 
reported that macrophages are adherent cells (Haniffa et al., 2009), so will not be 
collected during the harvesting of walkout media, where the plate is only gently washed 
to collect non-adherent dDCs. The walkout protocol produced two major cell 
populations, dDCs and dermal T-cells, as confirmed by lineage marker staining. The 
gating strategy used to classify dDC subsets was adapated from the work of the Nestle 
lab, due to the similar protocols used in obtaining cells from the dermis. Their work 
identified CD141+ dDCs as a cell type of particular interest (Chu et al., 2012) and so it 
was important that this subset could be reliably identified.  
The frequency of T-cells amongst migratory dermal cells were in line with those 
observed by Bernhard Moser’s group, who utilise a comparable isolation protocol 
(frequencies around 30% are routine) (McCully et al., 2012). Their work also normally 
obtains CD4:CD8 ratios like those in blood (a ratio of 2:1 CD4:CD8 exists in average blood 
samples). The usefulness of these cells, given their broad antigen-specificity as a 
population, is limited in intradermal injection studies (as a very small proportion will be 
responsive to any given antigen, making assays less robust) (Murphy et al., 2012). It is 
however useful data in the characterisation of the overall ex vivo skin cell model 
obtained using this protocol. A number of studies reported using skin T-cells (Clark et 
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al., 2006, Watanabe et al., 2015), so it could also represent an interesting avenue for 
future work. 
Overall cell viability in walkout cells was found to be much lower in the epidermis 
than the dermis, less than 50% versus more than 90% respectively. Further analysis of 
the cells, however, revealed that both LC and dDC viabilities were consistently over 95% 
and that the contaminating cells (e.g. keratinocytes from the epidermis and fibroblasts 
from the dermis) were responsible for the vast majority of dead cells. As well as being 
viable, it was also necessary to characterise the functionality of LCs and dDCs obtained 
from skin. Attempted stimulation proved fruitless, with both sets of immune cells 
exhibiting partial maturation at the time of collection, which meant further stimulation 
with LPS or poly(I:C) was difficult. The small increases in CD83+ cell population and CD83 
median fluorescence intensity (MFI) when exposed to potent TLR agonists highlighted 
the lack of robustness in the model for this use. It is possible that the use of bacterially-
derived enzymes in the enzyme cocktail, which will likely be recognised as foreign 
antigen, may lead to this activation of the immune cells in skin. The tissue damage during 
patient surgery and dermatome processing of skin may also release damage-associated 
molecular patterns (DAMPs) which can mature DCs (Bianchi, 2007). Other separation 
methods that have been published tend to expose the skin to harsh thermal (60°C water) 
(Kligman and Christophers, 1963) or chemical (ammonium thiocyanate) (Pearton et al., 
2010c) conditions which would likely drastically affect the viability of cells so do not 
represent usable alternatives. 
The functionality of the cells was therefore assessed in a different manner. The 
recent results from a colleague within the group utilising monocyte-derived DC models 
to test lentiviral vector HIV models provided a unique opportunity for model validation. 
The work confirmed that both skin LCs and dDCs remained functional as well as viable, 
expressing the GFP gene following infection with the lentiviral vector. It was not 
expected that the cells would retain viability to the end of the 5-day infection period but 
the persistence of GFP within the cells following cell death allowed for the analysis of 
infection rates regardless. The overall infectivity levels witnessed were lower than in 
monocyte-derived models, potentially due to the improved viability of blood-derived 
cells or due to the partial maturity of ex vivo skin immunological cells reducing their 
infectability. The pattern of infectability between primary cells and the equivalent 
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models was consistent though, thus prompting the conclusion that LCs possess an extra 
antiviral factor over dDCs. Work to identify this factor is ongoing.  
Analysis of the infection rates in the various dDC subsets proved to be difficult 
due to the down-regulation of subset markers CD11c and CD141 during cell culture. 
There appeared to be a greater increase in infectability following degradation of 
SAMHD1 in CD11c+/CD141+ dDCs than in the other two subsets, though this could not 
be confirmed with any reliability. The most feasible solution to this subset identification 
problem was sorting of the dDCs into their subsets prior to infection with VSV-G-HIV-
GFP, eliminating doubt of the subsets present at time of analysis.  
Attempted infection of sorted skin cells with VSV-G-HIV-GFP revealed that cell 
functionality was greatly reduced by the sorting process and that sorted cells were not 
usable for this experiment. There were discrepancies between the sorted cell number 
recorded by the sorting software and the cell number quantified by haemocytometer 
count, highlighting the cell loss that occurs during sorting. The results also showed an 
inversely proportional relationship between dDC subset frequency and cell viability. 
Given that each subset was sorted into the same volume of media, this might suggest 
that the tubes receiving more cell-containing droplets accumulate levels of sheath fluid 
that adversely affect cell viability (as it contains sodium azide). To eliminate this 
possibility, larger vessels containing a greater volume of media will be used to collect 
cells in future. It was also apparent that cell viability was poor 24 hours after sorting, the 
extra stresses placed on LCs and dDCs in staining and sorting meaning that a large 
proportion of cells are dead after 24 hours in culture post-sort. Optimisation of sorting 
conditions is clearly required and it is likely that even under optimal conditions, cells 
may only have a brief period of usability. This would make them unusable for studies 
that require extended culture and cell activity such as the lentiviral vector studies but 
could still allow them to be useful in antigen presentation experiments where less than 
24 hours of cell functionality is required. Future work will explore the model to assess 
the antigen processing capacity of the skin cells. If sorting is possible in these 
experiments, it will allow for the comparison of dDC subsets against LCs, properties of 
skin immune cells that are not currently understood.  
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3.6 Potential for Publication 
The isolation of dDCs and LCs from ex vivo human skin, knockdown of SAMHD1 
using SIV-Vpx virus and subsequent infection of these cells has been published already 
(Czubala et al., 2016). The quantitative data regarding dDC subsets found in this and 
subsequent studies may be publishable if enough repeats are obtained to allow 
comparison of subset frequencies to factors such as patient age. The identification of 
dermal T-cells amongst walkout skin cells has been published previously so would 
require further development to allow publication- perhaps with downstream 
experimentation looking at responses of skin-resident T-cells to immunostimulatory 
substrates. 
 
3.7 Conclusion 
The work in this chapter achieved its primary objective of producing a protocol 
for obtaining immune cells from ex vivo human skin samples. The LCs and dDCs could 
then be characterised by flow cytometry, revealing a phenotype in line with previously 
published work in the field (Chu et al., 2012, Haniffa et al., 2012). It was also possible to 
divide the dDCs into subsets based on CD11c and CD141 expression. The dDC subset 
proportions found were also consistent with the literature. Two potential uses for the 
model were explored- a TLR agonist stimulation assay and a HIV lentiviral vector study. 
Whilst the former generated little success, with the cells being partially matured at the 
time of collection and difficult to stimulate further, the latter proved to be an 
appropriate use for the model. It was possible to provide supporting data for results 
obtained in monocyte-derived DC models, increasing the reliability of the conclusions 
drawn from the work and leading to a publication (Czubala et al., 2016). The next step 
will be to assess the potential use of the ex vivo skin cell model to study the processing 
of vaccine by skin-resident immune cells, with the aim of informing intradermal vaccine 
design and delivery strategies at a cellular level. 
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Chapter 4 - Cross-Presentation of Influenza Vaccine Antigen 
4.1 Introduction 
The previous chapters explored the ex vivo human skin tissue and cellular 
models. One of the limitations of the skin cell model was that isolated cells show a 
partially mature phenotype and thus are not able to respond to TLR-agonist stimulation 
(Section 3.4.3). The purposes of this chapter are therefore twofold: (i) to explore the use 
of a monocyte-derived dendritic cell model as an alternative to skin-derived immune 
cells and (ii) to explore the use of skin-derived cells in antigen cross-presentation studies. 
 
4.1.1 Monocyte-Derived Dendritic Cell Models 
Whilst a useful model, the irregular availability of ex vivo human skin samples 
(which relies on surgical lists and informed patient consent) and the unpredictable size 
of samples means that this model has practical disadvantages. Ex vivo human skin is also 
not widely available, with many groups lacking the ethical approval and access to a 
clinician to obtain samples. This has led to the development of cellular models of the 
immunological cells of the skin utilising monocytes obtained from blood donations by a 
number of groups (Sallusto and Lanzavecchia, 1994, Piemonti et al., 2000, Albert et al., 
1998). Monocyte-derived dendritic cell (mdDC) models have been widely used for a 
number of years and are well understood (Leon et al., 2005), providing insight into the 
behaviour of dendritic cells (DCs).  
Monocytes can be isolated from donated blood, following removal of 
erythrocytes and plasma (Repnik et al., 2003). Monocytes form part of the peripheral 
blood mononuclear cells (PBMCs) which consist of lymphocytes (B-cells, T-cells and 
natural killer cells) along with macrophages (Murphy et al., 2012). Centrifugation over a 
density gradient (for example an aqueous cell suspension layered over a more dense 
Ficoll solution (Repnik et al., 2003)) can be used to isolate the PBMCs from the 
erythrocytes, remaining leukocytes and plasma. After this, magnetic-activated cell 
sorting (MACS) is often used to isolate the monocytes from the PBMC population 
(Caucheteux et al., 2016, Mayer et al., 2011). This involves labelling cells with antibodies 
conjugated to magnetic nanoparticles (Schmitz et al., 1994). In the case of isolating 
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monocytes, anti-CD14 antibodies are used. The entire population is then passed through 
a magnetic column, which will retain cells labelled with the magnetic nanoparticle-
conjugated antibody, whilst unlabelled cells can pass freely through. The column is then 
removed from the magnetic housing and the labelled cells eluted, providing a purified 
CD14+ monocyte population (El-Sahrigy et al., 2015). 
Monocytes require cytokine stimulation to develop a DC-like phenotype.  A 
general model for DCs is most commonly used, where interleukin 4 (IL-4) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) are utilised to develop 
mdDCs from monocytes over 7 days’ culture (Leon et al., 2005). The derivation process 
can also be tailored to produce DC subset models- for example CD141+ dermal DC-like 
cells which are derived by the addition of vitamin D3 to the culture medium (Chu et al., 
2012) and Langerhans like cells, which are produced by the addition of transforming 
growth factor-beta (TGF-β) to the culture medium (Geissmann et al., 1998). 
 
4.1.2 T-cells 
As their name suggests, one of the major functions of antigen-presenting cells 
(APCs) such as epidermal Langerhans cells (LCs) and dermal DCs (dDCs) within the 
immune system is presentation of antigenic epitopes to T-cells. Naïve T-cells lack cell 
surface receptors to extracellular antigen and so can only become activated by 
presentation of antigen on the surface of APCs (Ni and O'Neill, 1997). Antigen is 
presented via one of two types of receptor, the major histocompatibility complex (MHC) 
type I or type II molecules. MHC molecules differ from the other major antigen-binding 
molecule, antibodies, in that they can only bind peptide antigen (Turley et al., 2000). 
They also do not bind peptides in their native form (i.e. after folding), but instead bind 
linear peptide sequences. Thus, their specificity is to amino acids which are proximal to 
one another in a peptide sequence rather than those that only exist in proximity in a 
folded protein (Murphy et al., 2012).  
The MHC molecules each have a number of subtypes, for example MHC class I 
includes HLA-A, HLA-B and HLA-C (where HLA refers to human leukocyte antigen, 
synonymous with MHC). Each subtype then contains a number of different molecules 
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(e.g. HLA-A1 and HLA-A2 amongst HLA-A molecules) (Makhatadze et al., 1997). T-cells 
possess T-cell receptors (TCRs) on their surface that allow them to interact with MHC 
molecules. Each TCR is specific to a MHC molecule with a specific peptide sequence 
bound within it (Baker et al., 2012), for example a given T-cell may only respond to 
binding a HLA-A2 molecule containing an influenza peptide 9mer (Clement et al., 2011). 
The assorted MHC molecules possess different specificities to antigens that relies on a 
number of ‘anchoring’ amino acids within a peptide, as defined by their physicochemical 
properties (e.g. an aromatic side chain or polar group). This allows them to bind a range 
of antigenic peptides with common characteristics (Murphy et al., 2012). Thus, a broad 
range of peptide sequences can be bound by the limited number of MHC receptor 
subtypes each person possesses (Engelhard, 1994). MHC-I molecules normally only bind 
peptide sequences which are 8-10 bases long, whilst MHC-II can bind peptide with its 
terminal ends extending beyond the molecule, allowing it to present much longer 
peptides (Murphy et al., 2012).  
Binding of the TCR to the MHC:antigen complex requires the involvement of a 
co-receptor to stabilise the interaction and to increase the response within the T-cell. 
For MHC-I and II the co-receptors are CD8 and CD4 respectively (Campanelli et al., 2002, 
Janeway, 1991). These co-receptors have long been used to define the two major 
subsets of T-cells; cytotoxic T-cells express CD8 whilst helper T-cells express CD4 on their 
surface (Amadori et al., 1995). MHC-II is expressed on APCs and mediates the induction 
of CD4+ helper T-cell responses to antigen taken up from the extracellular environment 
(Santambrogio et al., 1999). Conversely, MHC-I is found on the surface of all nucleated 
cells within the body (Murphy et al., 2012). Its main function is to present viral antigens 
synthesised within the cell on the cell’s surface, thereby alerting CD8+ cytotoxic T-cells 
to their infection and triggering cell death signalling to prevent the further viral 
production or spread of infection to further cells (Bedoui et al., 2009).  
 
4.1.3 Cross-Presentation  
Whilst presentation of antigen on MHC-I is vital for alerting CD8+ T-cells to the 
presence of infection in a cell, infected cells are unable to activate naïve T-cells directly 
(Murphy et al., 2012). APCs are able to present exogenous antigen on MHC-I molecules 
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via endosomal processing without direct infection in a process known as cross-
presentation (Heath and Carbone, 2001). This is a vital part of the immune response to 
pathogens, both live and in their antigenic state within vaccines (Ruedl et al., 2002). The 
different cross-presentational abilities of human DC subsets are not yet fully understood 
(Joffre et al., 2012) and so it is vital in intradermal vaccination research that the antigen 
used and its delivery are tailored to best suit the most potent cross-presenting cells of 
the skin. This investigation therefore aimed to compare the cross-presentation of 
influenza vaccine antigen by the LCs and various dDC subsets of the skin. 
 
4.1.4 T-Cell Response Testing 
Given their important role in the adaptive immune system, investigating the 
response of T-cells to a novel vaccine can provide useful pre-clinical data. Animal models 
are often used in pre-clinical studies and possess the advantage of allowing the response 
of the immune system as a whole to be studied (Mestas and Hughes, 2004). There are, 
however, differences in animal and human immune systems, which mean that human 
cell models remain a useful laboratory tool. There are two main options for laboratory 
T-cell experimentation. The first is to use the total T-cell population from human blood, 
with its broad range of peptide-MHC complex specificities. The T-cells are then mixed 
with APCs and those T-cells possessing the correct antigen specificity will be ‘primed’ by 
the APCs- becoming activated and undergoing proliferative clonal expansion (Wölfl and 
Greenberg, 2014). T-cells may be stained with carboxyfluorescein succinimidyl ester 
(CFSE) to show proliferation (Quah and Parish, 2010). T-cells of a single specificity can 
also be quantified via tetramer staining, which utilises 4 MHC molecules, bound to a 
streptavidin core, each containing the peptide of interest (Dolton et al., 2015). The use 
of multiple peptide-MHC complexes on a single tetramer increases the binding affinity 
of the tetramer, thus increasing the success of staining for the cells of interest. The 
tetramer is often fluorescently-conjugated, allowing for flow cytometric analysis (Sims 
et al., 2010). This allows the proportion of a particular T-cell clone within the overall T-
cell population to be quantified and the effect of a treatment or vaccine measured. This 
method possesses advantages in that T-cells may be obtained from blood buffy coats 
alongside monocytes, using MACS (Caucheteux et al., 2016). This allows monocyte-
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derived DCs to be produced that are HLA-matched to the T-cells being used. It is also 
very similar to the in vivo situation, where T-cells exist as a heterogeneous population 
that APCs must interact with (Murphy et al., 2012). Its drawbacks include the extremely 
diverse nature of TCR specificity. Even epitopes that can be recognised by multiple TCRs 
tend not to prime more than 0.05% of the overall T-cell population (Challier et al., 2013). 
The alternative to this is to utilise a pure population of a single T-cell clone. 
 
4.1.4.1 T-Cell Clones 
T-cell clones are a population of T-cells which possess uniform TCR expression 
i.e. they will only successfully interact with a specific peptide-MHC complex (Mariotti 
and Nisini, 2009). They are obtained by the isolation and proliferation of T-cells, often 
by tetramer staining and FACS (Matthis and Reijonen, 2013). Using a pure population 
allows the stimulation of T-cells that important to a certain immune response to be 
quantified, with theoretical responses between 0 and 100% of the cells possible. 
However, since they are produced from T-cells from a single donor, any APCs that are 
used must be HLA-matched to the clones. Each MHC molecule type has differing 
prevalence within the general human population with prevalence varying between 
geographical and ethnic populations (Makhatadze et al., 1997, Arnaiz-Villena et al., 
1995). This can provide an obstacle to experimentation if the HLA-type is particularly 
rare in the geographical location that is used to source APC donors (blood or skin). T-cell 
clones also only permit the assessment of vaccines containing the specific peptide 
sequence that the clones recognise. However, the use of T-cell clones does allow for a 
straightforward quantitative readout. Following co-culture with vaccine-treated APCs 
and the addition of brefeldin-A (to prevent the release of cytokines from the cell), the 
T-cell clones can be analysed for interferon-γ (IFN-γ) expression by flow cytometry as a 
marker of activation (Caucheteux et al., 2016, Norris et al., 2001). The uniformity of the 
clone population means that the frequency of activated cells can theoretically be 
detected in up to 100% of the cell population used, providing a robust readout for 
comparative experiments. 
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4.2 Aims and Objectives 
This chapter aims to explore the use of monocyte-derived DC models as an 
alternative to skin-derived cells for immunological studies. It also aims to investigate the 
abilities of skin immune cells to cross-present an influenza vaccine. The specific practical 
objectives are: 
1. Isolate monocytes from blood using previously established protocols and derive a 
number of DC models from them, assessing success of derivation using flow 
cytometry. 
2. Use monocyte-derived DCs (mdDCs) to assess the concentration of LPS that is 
required to stimulate ex vivo human skin LCs/dDCs  
3. Assess ALF3 T-cell clone for specificity to influenza A matrix protein (M1)-derived 
peptide (residues 58-66; GILGFVFTL). 
4. Use mdDCs to develop a protocol for a T-cell clone activation experiment which 
assesses the cross-presentation of inactivated virus and virus-like particle influenza 
vaccines and transition this protocol to utilise ex vivo human skin dDCs and LCs to 
assess the cross-presentational ability of these cells. 
5. Assess the differences in cross-presentation of antigen between the subsets of dDCs 
(based on CD11c and CD141 expression) and LCs using fluorescence-activated cell 
sorting to purify the cell subsets prior to co-culture with vaccine and ALF3 cells. 
 
4.3 Materials and Methods 
[All reagents were obtained from Fisher Scientific, UK unless otherwise stated] 
4.3.1 Derivation of Monocyte-Derived Cell Models  
4.3.1.1 Isolation of CD14+ Monocytes 
Buffy coats were produced by the removal of erythrocytes and plasma from 
whole blood donations (obtained from Welsh Blood Service). After collection, they were 
diluted to a total volume of 180ml with sterile PBS. Next, 30ml of the diluted buffy coat 
was layered over 15ml Ficoll-Paque density gradient media in 50ml centrifuge tubes. 
Tubes were spun at 800 x g for 30 minutes and the rotor allowed to stop without 
application of the brake to preserve the density gradient. Peripheral blood mononuclear 
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cells (PBMCs) formed a distinct white layer within the density gradient, which was 
isolated by gentle pipetting. PBMCs were then labelled using anti-human CD14 
MicroBeads and passed through a magnetic-assisted cell sorting (MACS) column (both 
Miltenyi Biotec, UK), according to manufacturer guidelines, to isolate CD14+ monocytes. 
 
4.3.1.2 Monocyte-Derived Dendritic Cells  
Monocytes were plated at 2 x 106 cells per well on a 6-well plate in 3ml complete 
IMDM (IMDM with 50U/ml penicillin, 50µg/ml streptomycin, 10% foetal bovine serum 
(FBS), 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 1mM 
sodium pyruvate (all Sigma-Aldrich, UK)). The following were also added: 500U/ml 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Miltenyi Biotec, UK), 
500U/ml interleukin 4 (IL-4) (Miltenyi Biotec, UK) and 50µM 2-mercaptoethanol (β-2M) 
to stimulate the differentiation of monocytes towards a DC phenotype. 1ml of media 
was removed and replaced with complete IMDM containing 1500U/ml each of GM-CSF 
and IL-4 every 2 days until day 7 when the cells were visually assessed for dendritic 
morphology and phenotyped using flow cytometry to establish success of DC derivation.  
 
4.3.1.3 Monocyte-Derived CD141 Dendritic Cells (CD141 mdDCs) 
Monocytes were cultured in an identical manner to deriving mdDCs (section 
4.3.1.2) until day 4 of culture, when 100nM vitamin D3 was added to the culture media. 
Cell culture was then continued as described in Section 4.3.1.2 until day 7 when cells 
were collected for use. 
 
4.3.1.4 Monocyte-Derived Langerhans Cells (mdLCs) 
Monocytes were cultured in T25 cell culture flasks at a concentration of 1 x 106 
cells/ml in RPMI-1640 growth medium (supplemented with 2mM L-glutamine, 50U/ml 
penicillin, 50µg/ml streptomycin and 10% FBS) plus 500U/ml each of GM-CSF and IL-4 
plus 10ng/ml transforming growth factor-beta (TGF-β). Media and cytokines were 
refreshed every 2 days.  Cells were harvested for use on day 7 of culture. 
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4.3.2 Responsiveness of Monocyte Models to LPS Stimulation 
Given the lack of meaningful stimulation of ex vivo human skin walkout cells in 
the previous chapter using Toll-like receptor (TLR) agonists, the mdDC model was used 
to determine whether a sub-optimal dose of TLR agonist had been used. The immature 
state of blood monocytes cultured in a sterile environment allows them to show marked 
upregulation of maturation markers and cytokine production from baseline when 
stimulated. LPS was used due to its potent immunostimulatory properties and the 
optimal dose for DC stimulation sought.  
The mdDCs were plated at 1 x 105 cells per well of a 96-well plate in 100µl 
complete IMDM containing 10ng/ml, 100ng/ml, 1µg/ml or 2µg/ml LPS or 100µl 
complete IMDM alone. Three hours after plating, brefaldin A was added to a final 
concentration of 10µg/ml to cells that were designated for analysis of cytokine 
expression. Cells were fixed in 1% paraformaldehyde at room temperature for 10 
minutes after either 24 or 48 hours in culture. Cytokine expression was analysed in cells 
exposed to LPS for 24 hours and maturation markers analysed after 24 and 48 hours’ 
exposure. 
Cells to be analysed for cytokine expression were stained using Perm/Wash Kit 
(BD Biosciences) according to the manufacturer’s protocol to allow intracellular staining. 
The 3-colour panels listed in Table 4.1 were used to stain cells. 
Flow cytometry was performed using a BD FACSCanto II cytometer. Statistical 
tests comprised one-way analysis of variance (ANOVA) followed by Tukey's post hoc 
analysis performed using IBM SPSS Statistics (IBM, USA). 
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Table 4.1: Antibodies used to assess intracellular cytokine (ICC) and maturation marker 
expression on mdDCs via flow cytometry 
 
4.3.3 ALF3 T-Cell clones 
This investigation utilised a pair of influenza A vaccines against the H1N1 
influenza A/Puerto Rico 8/1934 virus. One vaccine was an inactivated whole virion (IV) 
vaccine, produced by formalin inactivation of virions produced in chicken eggs, in a 
manner similar to that used for producing the commercial vaccine (Furuya et al., 2010). 
The second vaccine was a virus-like particle (VLP) vaccine consisting of hemagglutinin 
and matrix M1 peptides in the absence of viral genetic material (Quan et al., 2011). Both 
vaccines were provided by Sang-Moo Kang’s laboratory in the Centre for Inflammation 
Immunity & Infection, Georgia State University. As discussed in Chapter 2, VLP vaccines 
are a developing vaccine technology which eschews the need for inactivation of virus 
and the risk of reversion to wild-type virus, whilst still delivering viral peptides in a similar 
way to virions (Kang et al., 2009). The investigation sought to study the ability of skin 
immune cells to cross-present the two vaccines, comparing the results between dDCs 
and LCs and IV and VLP vaccines. 
HLA A*0201-restricted CD8+ T-cell clones (ALF3 clones) specific for the influenza 
A matrix protein (M1)-derived epitope GILGFVFTL (residues 58-66) were kindly provided 
by David Price’s laboratory in the department of Infection and Immunity, Cardiff 
University. ALF3 cells were propagated in advance of planned experimentation by the 
 Antibody Conjugated Fluorophore Manufacturer 
Maturation 
Panel 
Anti-HLA-DR Allophycocyanin (APC) BD Biosciences, UK 
Anti-CD1a 
Fluorescein isothiocyanate 
(FITC) 
BD Biosciences, UK 
Anti-CD83 Phycoerythrin (PE) 
Beckman Coulter, 
UK 
ICC Panel 
Anti-CD1a FITC BD Biosciences, UK 
Anti-DC-SIGN PE BD Biosciences, UK 
Anti- TNF-α APC BD Biosciences, UK 
Anti-IL-12 APC BD Biosciences, UK 
Isotype 
Control 
Panel 
IgG1 κ FITC BD Biosciences, UK 
IgG1 κ PE BD Biosciences, UK 
IgG1 κ APC BD Biosciences, UK 
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Price group and were collected in a ready-to-use cell suspension on the morning of each 
experiment. 
 
4.3.3.1 Validation of ALF-3 Peptide Specificity 
ALF3 clones were tested for specific responsiveness to the 9mer peptide of 
interest to validate their use in this investigation.  ALF3 clones were plated at 6 x104 cells 
per well in complete RPMI in a round-bottomed 96 well plate with: 
1. 1µg of HLA A*0201-restricted influenza A matrix protein (M1)-derived 
peptide (residues 58-66; GILGFVFTL) 
2. 1µg of irrelevant HLA-A*0201-restricted HIV-1 p17 Gag-derived peptide 
(residues 77-85; SLYNTVATL)  
3. 1µg formaldehyde-inactivated H1N1 influenza A/Puerto Rico 8/1934 
virus  
4. 1µg H1N1 influenza A/Puerto Rico 8/1934 virus-like particles 
5. Media alone (untreated control) 
ALF-3 cells were incubated for 1 hour prior to the addition of brefaldin-A to a 
final concentration of 10µg/ml then incubated overnight. Cells were fixed after 
overnight culture and stained intracellularly utilising FITC anti-CD3 and PE anti-IFN-γ 
antibodies (both BD Biosciences, UK) before analysis on a BD FACSCanto II flow 
cytometer (BD Biosciences, UK) to quantify IFN-γ expression amongst ALF3 cells. 
Analysis of flow cytometric data was performed using FlowJo software (FlowJo LLC, 
USA). Statistical tests comprised one-way analysis of variance (ANOVA) followed by 
Tukey's post hoc analysis performed using IBM SPSS Statistics (IBM, USA). 
 
4.3.4 Cross-Presentation by Monocyte-Derived DCs/LCs  
Initial studies utilised mdDCs in the place of primary skin cells to generate 
preliminary data and optimise the protocol without the constraints of infrequent skin 
samples. HLA-A*0201 expressing monocytes were selected by flow cytometric analysis 
of FITC anti-HLA-A2 (BD Biosciences, UK) antibody-stained monocytes following 
isolation from buffy coats. The mdDC models (mdDCs, CD141 mdDCs and mdLCs) were 
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then produced as described in Section 4.3.1. To assess the cross-presentation ability of 
the DC models, they were plated at 2 x 104 cells per well of a 96-well plate and treated 
with one of the vaccines (either VLP or IV) at 1µg per well. Then they were incubated for 
4-6 hours to allow uptake and processing of the vaccines. 6 x 104 ALF3 cells were then 
added, mixed thoroughly and incubated for 1 hour. Brefaldin-A was then added (to 
10µg/ml) and the cells incubated overnight. Cells were fixed the next morning and 
stained/analysed to quantify IFN-γ expression as described in Section 4.3.3.1.  
 
4.3.5 Cross-Presentation by Skin-Derived DCs/LCs  
Given ex vivo skin cells’ closer representation of in vivo cell behaviour, compared 
to monocyte-derived models, the investigation utilising ALF3 T-cell clones was extended 
to utilise primary skin LCs and dDCs as the APCs. 
Human skin was collected, processed and dermal and epidermal walkout cells 
collected separately as described in Section 3.3.1. An identical protocol to that used for 
monocyte-derived cells was used, with the exception that dermal walkout cells were 
plated out at 7.5 x 104 cells per well and epidermal walkout cells at 2 x 105 to account 
for the differing purities of the immunological cells obtained from each skin region. Cells 
were processed, co-cultured with ALF3 cells and analysed as described in Section 4.3.4. 
 
4.3.6 Sorted Skin Cell Subset Cross-Presentation Investigation  
The two human skin samples used in this study were obtained from patients 
undergoing abdominoplasty surgery at Spire Hospital, Cardiff under informed written 
patient consent and local ethical committee approval (South East Wales Research Ethics 
Committees Panel C, Reference: 08/WSE03/55). Sample transport and processing for 
cell walkout were performed in an identical manner to that described in Section 3.3.1. 
Following 48 hours’ walkout, the walkout cells were collected, counted and then plated 
with either 10µg/ml IV vaccine or 10µg/ml VLP vaccine in 6-well cell culture plates. Cells 
were incubated overnight at 37°C to allow vaccine uptake and processing. The next day 
they were washed and re-suspended in sodium azide-free sterile FACS buffer (1% BSA 
in PBS) at 2 million cells/ml. The antibodies listed in Table 4.2 were then added. 
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Table 4.2: Antibodies used to identify dDC subsets and LCs from dermal and epidermal walkout 
cells respectively by FACS 
 Antibody Conjugated Fluorophore Manufacturer 
Dermal 
Dendritic 
Cell Panel 
Anti-HLA-
DR 
Allophycocyanin (APC) BD Biosciences, UK 
Anti-CD141 VioBlue® 
Miltenyi Biotec, 
UK 
Anti-CD11c 
Allophycocyanin-cyanine 7 (APC-
Cy7) 
BD Biosciences, UK 
Epidermal 
LC Panel 
Anti-HLA-
DR 
APC BD Biosciences, UK 
 
Cells were stained at 4°C for 1 hour then washed and re-suspended at 50 million 
cells/ml in sterile FACS buffer for sorting. Cell sorting was performed on a custom 
FACSAria cell sorter (BD Biosciences, UK). Dermal cells were gated for size/granularity 
(FSC-A/SSC-A), singlets and HLA-DR positivity (i.e. total dDCs) before being sorted into 
CD141+/CD11c+ (++ dDCs), CD141-/CD11c+ (+- dDCs) and CD141-/CD11c- (--dDCs) 
subsets. Epidermal cells were gated for size/granularity, singlets and HLA-DR positivity 
to sort LCs from epidermal walkout cells. After sorting, cells were counted and plated at 
2 x 104 cells per well of a 96-well plate. Immediately after plating, 6 x 104 ALF3 cells were 
added to each well and the plate incubated for 60 minutes at 37°C before the addition 
of brefeldin-A (to 10µg/ml), then returned to incubation overnight. The next morning 
cells were fixed, stained and analysed for IFN-γ expression amongst ALF3 cells as 
described in Section 4.3.3.1. A portion of epidermal and dermal cells were also stained 
for HLA-A2 expression. 
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4.4 Results and Discussion 
4.4.1 Derivation of Monocyte-Derived Cell Models  
Flow cytometric analyses of the three mdDC models are shown in Figure 4.1. 
Analysis revealed mdDCs continued to express HLA-DR (as was the case on monocytes). 
The cells also showed expression of CD1a and DC-SIGN which are not expressed on 
monocytes, indicating successful transformation from monocytes into the classic mdDC 
phenotype (Leon et al., 2005). There was notably no CD141 expression on mdDCs. 
CD141 mdDCs displayed similar HLA-DR, CD1a and DC-SIGN marker expression to mdDCs 
with the addition of CD141 expression which was induced by the addition of vitamin D3 
to the media during culture (Chu et al., 2012). The mdLCs produced higher CD1a 
expression than mdDCs or CD141 mdDCs, much like LCs in skin which express high levels 
of CD1a (Pena-Cruz et al., 2001). There was also CD207 expression in mdLCs, which is 
indicative of an mdLC phenotype (Guironnet et al., 2002) though expression was not 
ubiquitous. The partial CD207 expression shows that although some monocytes were 
displaying a LC-like phenotype, many failed to transition into full LC-like cells, a fact that 
will be taken into account when interpreting results.  
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Figure 4.1: Flow cytometry data plots 
showing phenotypic analysis of mdDCs (A), 
CD141 mdDCs (B) and mdLCs (C), each 
derived from CD14+ monocytes  
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4.4.2 Responsiveness of Monocyte Models to LPS Stimulation 
The cytokine expression and maturation of mdDCs in response to LPS is shown 
in Figure 4.2. The data were normalised to the maximal response from each donor, 
negating the biological variance and allowing comparison between blood donors. The 
mean maxima for maturation and cytokine responses are shown in Figure 4.2 (B, D & F). 
The greatest cytokine expression occurred with 1µg/ml LPS, though the normalised 
response was not significantly different from 100ng/ml or 2µg/ml LPS (p = 0.098 and 
0.195 respectively). 
Maturation of mdDCs at 24 hours displayed a positive correlation between LPS 
concentration and CD83 expression, with the highest expression occurring with 2µg/ml 
LPS. Again, however, the difference in expression in the cells exposed to 100ng/ml and 
1µg/ml LPS was not significantly different. After a 48-hour exposure to LPS the 
maturation profile was different, with maximal CD83 expression occurring in the cells 
treated with 100ng/ml LPS. Maturation tailed off above 100ng/ml, with cells exposed to 
2µg/ml LPS showing a similar proportion of mature cells as those with 10ng/ml LPS. This 
may be due to higher LPS concentrations possessing some cytotoxic activity over the 48-
hour culture period. 
The results in both maturation and cytokine expression suggest that 1µg/ml LPS 
is either optimal, or not significantly different from the optimal, concentration for DC 
stimulation. This supports the conclusion that skin LCs and dDCs are partially matured 
following their walkout from skin and so are unresponsive to Toll-like receptor agonist 
stimulation. 
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Figure 4.2: Intracellular cytokine expression [A,B], 24 hours [C,D] and maturation at 48 hours [E,F] in mdDCs 
treated with varying concentrations of LPS; all expressed as raw data [A,C,E] and normalised to maximal staining 
within each sample [B,D,F]. Legends on graphs A, C and E indicate buffy coat donor number. 
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4.4.3 Validation of ALF-3 T-Cell Clones  
Prior to their use in combination with monocyte- or skin-derived antigen-
presenting cells, the ALF3 T-cell clones were assessed for their response to the influenza 
matrix peptide 9mer GILGFVFTL. As MHC-I molecules are expressed on all nucleated cells 
(Murphy et al., 2012), it was possible to add the peptide to the cells and allow them to 
‘self-present’ the peptide to one another and become activated. The results of the 
experiment are shown in Figure 4.3. There was a statistically significant (p < 0.0001) 
activation of ALF3 cells, as determined by intracellular staining for IFN-γ expression, 
following treatment with the influenza matrix peptide of interest. There was no 
significant stimulation following treatment with an irrelevant peptide 9mer or with 
either vaccine type. This shows that the ALF3 cells are functional and only activated in a 
sequence-specific manner and that the vaccines must be processed to allow the 
influenza matrix 9mer to be liberated and presented on MHC-I molecules. Thus, any 
ALF3 activation by the influenza vaccines will depend on the cross-presentation of 
vaccine antigen by either LCs or dDCs.  
 
Figure 4.3: IFN-γ expression in ALF3 cells treated in the absence of 
APCs with influenza matrix peptide or nonspecific peptide control 
(both n=3) as well as the two vaccines used in the study (both n=5). 
Untreated ALF3 cells were also analysed as a control (n=7) [A; error 
bars: ± SD]. Representative flow cytometric plots of ALF3 cells in the 
absence [B] and presence [C] of influenza matrix peptide 
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4.4.4 Cross-Presentation by Monocyte-Derived DCs/LCs  
The three different mdDC models were assessed for their ability to cross-present 
inactivated H1N1 influenza A/Puerto Rico 8 (II) vaccine and the equivalent virus-like 
particle (VLP) vaccine, the results of which are shown in Figure 4.4. The results showed 
that both the VLP and IV vaccines were able to stimulate marked IFN-γ production in 
ALF3 via APCs. Untreated APCs did not stimulate the ALF3 cells, showing that the 
response was antigen-specific. Both mdDCs and CD141 mdDCs elicited a much greater 
response with the VLP vaccine than the IV vaccine (a 2-fold increase in mean with 
mdDCs). The mdLCs showed almost identical levels of ALF3 stimulation with both 
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Figure 4.4: IFN-γ expression 
in ALF3 cells co-cultured with 
vaccine-treated monocyte-
derived dendritic cell models. 
Mean data (A) is shown from 
experiments using mdDCs 
(n=6), CD141 mdDCs (n=4) 
and mdLCs (n=3); error bars: 
±SD. Representative flow 
cytometry plots for each cell 
type are also shown (B). 
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vaccines, both of which were lower than the levels seen with mdDCs or CD141 mdDCs. 
As with the stimulation with TLR agonists, there was high inter-donor variability seen 
within the results meaning mdDCs treated with VLP vaccines were the only treatment 
condition that had a significantly significant difference in IFN-γ+ ALF3 cells compared to 
the untreated control (p < 0.01). The overall pattern appeared to be that both mdDCs 
and CD141 mdDCs were able to cross-present the vaccine antigen more readily than the 
mdLCs. It is possible that the incomplete conversion of monocytes to mdLCs (based on 
low CD207 expression) meant that the mdLCs used still possessed some mdDC-like 
characteristics and so differences were perhaps diminished. Skin-derived LCs will 
possess the full LC phenotype and provide a truer representation of the in vivo situation. 
This protocol was transitioned into the ex vivo skin cell model to benefit from its 
comparability to the in vivo behaviour of cells. 
 
4.4.5 Cross-Presentation by Skin-Derived DCs/LCs  
Figure 4.5 and Figure 4.6 show the pattern of ALF-3 stimulation achieved using 
ex vivo skin dDCs and LCs as the APCs. The skin APCs performed differently to monocyte-
derived cell models, with IV vaccine-treated APCs eliciting significantly greater 
responses than VLPs or untreated cells with both dDCs and LCs.  The IV vaccine also 
elicited the greatest overall response in combination with dDCs. LCs showed reduced 
cross-presentation of both vaccine types, in line with the preliminary work done in 
monocyte-derived models. HLA-A2- controls also showed no stimulation with either 
VLPs or IV vaccines. The skin samples used were largely HLA-A2+ (HLA-A2+ cells: n=5; 
HLA-A2- cells: n=1), meaning statistical differences could not be determined between 
HLA-A2 positive and negative cells. However, IFN-γ levels in HLA-mismatched cells were 
almost identical to untreated cells, suggesting that the stimulation was specifically 
linked to the HLA-A2 MHC-I molecule on APCs. 
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Figure 4.5: Flow cytometry plots showing ALF3 cell IFN-γ expression following 
co-culture with vaccine treated skin walkout cells from a single donor 
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4.4.6 Sorted Skin Cell Subset Cross-Presentation Investigation  
The final portion of the investigation aimed to distinguish the differences in 
cross-presentation between the different subsets of dermal DCs rather than the 
population as a whole. The sorting of skin cells also allows for the effects of non-APC 
contamination (especially in walkout epidermal cells) on ALF3 stimulation to be 
eliminated as a pure APC population will be used. This was an important part of the 
investigation as the subsets of dDCs have only recently begun to be characterised and 
their properties are still not fully understood. As discussed in Chapter 3, cell sorting 
involves a high level of cell loss. Thus, a high number of cells must be sorted to ensure 
adequate cell numbers can be used in downstream experimentation. The acquisition of 
abdominoplasty skin samples, which were much larger than the mastectomy or breast 
reduction skin samples normally obtained, enabled this. The donors were also younger 
than normal, 32 and 31 years old versus a mean age of 66 years for breast skin samples 
used in this study. These two factors allowed a large pool of viable cells to be collected 
for sorting and meant that a cell sorting experiment was possible.  
The results of the investigation are shown in Figure 4.7. Only two 
abdominoplasty samples were available and therefore results are limited. There was, 
however, one HLA-A2+ and one HLA-A2- sample, allowing for an internal control with a 
single batch of T-cell clones. The size of skin samples also meant that each treatment 
condition could be tested in duplicate, granting some reliability to the data. The overall 
pattern was similar to the results seen in unsorted walkout cells, with only HLA-A2+ cells 
able to elicit a response from the ALF3 cells. Within the HLA-A2+ skin cells, IV vaccine 
produced a markedly stronger response than VLP vaccine. The greatest stimulation was 
observed with dDCs treated with IV vaccine, both ++ and +- dDCs producing strong ALF3 
stimulation (58% and 66% respectively). -- dDCs produced a much lower response, 
though this was still greater than the response with LCs. Previously published literature 
(Jongbloed et al., 2010, Chu et al., 2012, Haniffa et al., 2012) reported that CD141+ dDCs 
are able to cross-present antigen, but little work had been done to compare the three 
subsets of dDCs in parallel. Only limited conclusions can be drawn from the experiment 
due to low N values but initial data appears to show that both ++ and +- dDCs are able 
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to cross present antigen and that +- dDCs may even be able to do so more readily than 
++ dDCs.  
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Figure 4.7: Results of the sorted skin cell cross presentation investigation. Graphs show IFN-γ 
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4.5 General Discussion 
The mdDC model proved to hold a number of practical advantages over cells that 
are isolated from ex vivo human skin samples. Firstly, the buffy coats that are used are 
available much more frequently than ex vivo human skin samples as they do not rely on 
irregular surgery dates. This provides greater flexibility in planning experiments and 
allows the completion of experimental repeats in a much shorter timeframe than 
experiments that rely on skin samples. It is also possible to isolate a large number of 
monocytes; yields of tens of millions of CD14+ cells from a single buffy coat are routine 
(Schwanke et al., 2006). Thus, the model was ideal for the optimisation of LPS 
stimulation of DCs protocol, which had yielded poor results in skin cells. The results 
confirmed that an optimal LPS concentration was used to try and stimulate the skin 
walkout cells in Section 3.3.5.  Thus, skin walkout cells will not be used for stimulation 
assays of this type in the future. The high yield of cells from buffy coats can be used 
flexibly; monocytes can be cultured to produce a number of different DC models. This 
means equal numbers of the various models can be produced for experiments, unlike 
skin-derived cells, which exist in predefined subsets (Nestle et al., 1993) which are 
unequal in proportion to one another. This can allow better controlled comparative 
experiments, with equal numbers of cell types of each subset in comparable purities to 
one another to be used in parallel from a single donor. 
 Conversely, there are a number of drawbacks to mdDC models. They are less 
representative of the in vivo cells than skin-derived cells, as they do not receive the full 
milieu of environmental signals that an immature DC would encounter in the skin (Leon 
et al., 2005). The derivation process from monocytes into DC-like cells also introduces a 
source of variability, as monocytes from different donors may respond differently to the 
cytokines used, as exemplified by different levels of DC markers on cells from different 
donors. This may amplify differences in responsiveness to stimuli in downstream 
experimentation and explain the range of results seen in the LPS concentration titration 
study, where maximal stimulation ranged from less than 10% to over 90% of cells 
between donors. The fact that monocytes are obtained from blood, which is a sterile 
environment, may mean that they are more responsive to pathogens than skin APCs, 
which may encounter PAMPs more regularly. This may account for the partial maturity 
of skin cells witnessed in the Chapter 3. The complex ontogeny of DCs (Shortman and 
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Naik, 2007) means it is unlikely that the model will be truly representative of DCs until 
this is resolved. The protocols for producing monocyte-derived models also vary 
between groups. For example, when producing mdLCs some protocols only add IL-4 at 
the outset (day 0) (Peiser et al., 2004) whilst others do not use it at all (Guironnet et al., 
2002). The use of IL-4 in this investigation may account for the low CD207 expression on 
mdLCs and their retained ability to cross-present antigen, both of which are mdDC-like 
characteristics. It may be prudent in future work to optimise the mdLC derivation 
process to improve the reliability of the model. Cell sorting to purify CD207+ cells would 
also improve the model by eliminating cells which had not developed the full mdLC 
phenotype. 
 The ALF3 clones used proved to be an extremely useful tool in the study of cross-
presentation of vaccine antigen. The ubiquity of the M1 protein (Ito et al., 1991) meant 
that the vaccines from a relevant strain of influenza could be used without worries on 
compatibility. The conserved structure of the matrix protein between influenza strains 
has led to its use in candidate universal influenza vaccines (De Filette et al., 2005, 
Neirynck et al., 1999). ALF3 cells proved to be specific to the peptide of interest, showing 
no stimulation with irrelevant peptide or either unprocessed vaccine. This meant that 
any stimulation resulting from the co-culture of ALF3 cells with APCs and vaccines would 
be a result of vaccine being processed and presented and that false positive results from 
direct ALF3 stimulation by the vaccines used were not possible.  
 The results of T-cell clone experiments with the monocyte-derived cells showed 
all three models were able to process antigen from both vaccine types and produce 
mean ALF-3 activation levels higher than untreated cells. Unfortunately, the high level 
of variability in the responses between donors meant that significance could only be 
attached to the difference between untreated mdDCs and mdDCs treated with the VLP 
vaccine. The monocyte models were also able to produce numbers of activated ALF3 
cells that were comparable or greater than stimulating the clones with the readily-
processed M1 peptide 9mer, perhaps due to the presence of costimulatory molecules 
on the APCs, which enhance the response versus presentation of the peptide between 
ALF3 cells alone. Interestingly, the response was reduced when using mdLCs in place of 
mdDCs, which suggests less cross-presentation of vaccine with these cells. The results 
were validated when using skin cells, with LCs being unable to produce anywhere near 
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the same response from ALF3 cells as dDCs. These results suggest that LCs are less able 
to cross-present antigen derived from influenza virus matrix protein than dDCs.  
A lower level of T-cell clone activation using primary skin APCs was predicted as 
they possess a lower responsiveness to stimulation than their monocyte-derived 
counterparts. In actuality, the dermal walkout cells were able to produce a greater level 
of ALF3 activation than either of the mdDC models, perhaps due to the more mature 
phenotype of skin cells than mdDC models. There was also much less inter-donor 
variability, allowing statistically significant differences to be observed between the 
treatment conditions. Notably though, the cross presentation of VLPs was much lower 
than that of inactivated virus. This was the opposite of monocyte-derived models, where 
VLPs tended to produce a stronger response. The main difference between inactivated 
virus and VLPs is the presence of viral genetic material in the inactivated viral particles 
(Sitrin et al., 2015). Thus, it may be speculated that the RNA present is essential for skin 
dDCs to cross-present the viral antigen. As the main sensors of viral genetic material, 
TLR3 (for dsRNA) or TLR7/8 (for ssRNA) might be involved in this immune cell activation. 
These PRRs have been found to be involved in cross presentation previously (Davey et 
al., 2010, Le Goffic et al., 2007, Oh et al., 2011). However, further work is required to 
confirm this from this data. The monocyte-derived models may detect VLPs by some 
other receptor not found on skin LCs/dDCs, allowing them to eschew the requirement 
for activation by viral RNA, meaning they can uptake and cross-present antigen from 
VLPs as well as inactivated virus. Further work is required to determine whether this is 
a true property of monocyte-derived models over skin-derived cells. 
The results were in contrast to studies utilising mice (Stoitzner et al., 2006) or 
human (Klechevsky et al., 2008b) tissue that found that epidermal LCs readily cross-
present antigen. It has been speculated that LCs may perform more of an immune-
regulatory function, controlling tolerance rather than initiating immune responses 
(Stoitzner, 2010). This is logical, given their location closest to the external environment 
and ability to sample the stratum corneum (Yoshida et al., 2014). If LCs brought about 
inflammatory immune responses, they would likely cause responses to commensal 
organisms which do not present a pathogenic threat (van der Aar et al., 2013). The 
response of the dermal cells on the other hand, is in line with the literature, which found 
that dDCs (Segura et al., 2013), and more specifically the CD141+ dDC subset (Joffre et 
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al., 2012, Chu et al., 2012, Jongbloed et al., 2010), are potent cross-presenting APCs. The 
use of cell sorting allowed concurrent testing of the three dDC subsets (classified by 
CD11c and CD141 expression). It found that whilst the CD141+/CD11c+ dDCs could 
present vaccine antigen and elicit a strong response from the T-cell clones, the CD141-
/CD11c+ dDCs proved to be equally able to do so. This has been found in previous studies 
using DCs from human lymph nodes (Segura et al., 2013). It is also possible that whilst 
the relatively small CD141+ subset of dDCs is more prone to cross-presentation, the 
other subsets are also able to do so in certain circumstances, thus providing a ‘back up’ 
system for immune response generation (Bachy et al., 2013). For example, following 48 
hours’ culture to induce maturation, human skin LCs have been shown to be able to 
cross-present influenza antigen (van der Aar et al., 2011). It is likely that the cross-
presentational abilities of skin immune cells depends on the antigen type and method 
of DC exposure (Lee et al., 2009), antigen receptor expression (Burgdorf et al., 2007) or 
activation state (Schulz et al., 2005). Thus, the results should not be considered a 
universal property for all skin DCs with all antigen as only the cross-presentation of a 
single peptide from one strain of influenza virus was studied. The lack of available 
abdominoplasty skin samples meant that repeats could not be obtained, rather the data 
can be taken as a starting point for further work. One limitation of the work was the high 
cell loss associated with cell sorting and the relative scarcity of CD11c-/CD141- and 
CD11c+/CD141+ dDCs within the overall dDC population also meant that insufficient cell 
numbers were available for post-sorting purity validation. Thus, there was no way of 
determining whether the sorting gates displayed on the software correlated to the final 
cell purity. The results instead represent an interesting starting point of an investigation 
which has implications for the intradermal delivery of vaccines, especially in conditions 
such as influenza, where CD8+ T-cell responses are critical for viral clearance from the 
lungs (Helft et al., 2012). 
It was also noted that HLA-A2 frequency in the general population is roughly 50% 
(Ellis et al., 2000) but five of the six donors used in the unsorted cell experiment were 
positive for HLA-A2. The results with the single HLA-A2- sample obtained appear to 
validate the HLA-A2 specificity of the T-cell clone response though further repeats may 
be necessary to provide full confirmation. The sorted cell experiment, which had one 
HLA-A2+ and one HLA-A2- sample provided further confirmation of initial results and 
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allowed an initial insight into the behaviour of each subset in isolation but again further 
repeats would confer greater reliability on the conclusions that can be drawn. The 
limited supply of abdominoplasty tissues of the size needed for these experiments 
meant that further repeats could not be obtained during the period of this study. 
The next stage of investigation will aim to combine the immunological study with 
vaccine delivery optimisation. This will involve delivery of vaccine via a number of 
candidate microneedle devices as well as via the currently used hypodermic delivery 
route. Skin can then be cultured to allow vaccine uptake and then the tissue processed 
for cell walkouts. The walkout cells can then be immediately co-cultured with T-cell 
clones to measure cross-presentation of antigen. Histological studies of the tissue will 
also be utilised to show both delivery site and tracking of the antigen in tissue following 
uptake.  
 
4.6 Potential for Publication 
The work investigating the cross-presentation of influenza virus matrix peptide 
by ex vivo human skin cells is currently being prepared for submission for publication. 
Monocyte-derived models were used mainly for protocol validation and so will not form 
part of the publication, though may be useful as supplementary data. The sorted skin 
cell data represents an interesting initial result, though the lack of post-sort purity 
validation will limit its usefulness in a publication. 
 
4.7 Conclusion 
This chapter explored monocyte-derived DC models, which proved to be a 
flexible and useful model to study DC functions, though less representative of actual DCs 
in vivo than the ex vivo skin-derived walkout cells. Monocyte-derived DCs were utilised 
to optimise protocols for both cell stimulation and antigen presentation assays. The 
protocols could then be applied to walkout ex vivo skin cells. The walkout ex vivo skin 
cell model proved to be well-suited to an antigen cross-presentation experiment using 
influenza vaccines and CD8+ T-cell clones. The results showed that concerning the 
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inactivated influenza A virus-derived matrix protein (M1)-derived peptide GILGFVFTL, ex 
vivo human skin dDCs were more potent cross-presenting cells than LCs. The results 
confirm that targeting the dermis is a good strategy for intradermal delivery 
technologies, as the epidermis is thin and tightly packed which acts as a barrier to 
delivery there and LCs in our model had a more limited capacity to mount an effective 
immune response compared to dDCs. Future work should investigate other viral 
peptides that are integral to an antiviral immune response against influenza. 
  
143 
 
4.7 Bibliography 
ALBERT, M. L., SAUTER, B. & BHARDWAJ, N. 1998. Dendritic cells acquire antigen 
from apoptotic cells and induce class I-restricted CTLs. Nature, 392, 86-9. 
AMADORI, A., ZAMARCHI, R., DE SILVESTRO, G., FORZA, G., CAVATTON, G., 
DANIELI, G. A., CLEMENTI, M. & CHIECO-BIANCHI, L. 1995. Genetic control 
of the CD4/CD8 T-cell ratio in humans. Nat Med, 1, 1279-83. 
ARNAIZ-VILLENA, A., BENMAMAR, D., ALVAREZ, M., DIAZ-CAMPOS, N., VARELA, P., 
GOMEZ-CASADO, E. & MARTINEZ-LASO, J. 1995. HLA allele and haplotype 
frequencies in Algerians. Relatedness to Spaniards and Basques. Hum 
Immunol, 43, 259-68. 
BACHY, V., HERVOUET, C., BECKER, P. D., CHORRO, L., CARLIN, L. M., HERATH, S., 
PAPAGATSIAS, T., BARBAROUX, J. B., OH, S. J., BENLAHRECH, A., 
ATHANASOPOULOS, T., DICKSON, G., PATTERSON, S., KWON, S. Y., 
GEISSMANN, F. & KLAVINSKIS, L. S. 2013. Langerin negative dendritic cells 
promote potent CD8+ T-cell priming by skin delivery of live adenovirus 
vaccine microneedle arrays. Proc Natl Acad Sci U S A, 110, 3041-6. 
BAKER, B. M., SCOTT, D. R., BLEVINS, S. J. & HAWSE, W. F. 2012. Structural and 
dynamic control of T-cell receptor specificity, cross-reactivity, and binding 
mechanism. Immunol Rev, 250, 10-31. 
BEDOUI, S., WHITNEY, P. G., WAITHMAN, J., EIDSMO, L., WAKIM, L., CAMINSCHI, 
I., ALLAN, R. S., WOJTASIAK, M., SHORTMAN, K., CARBONE, F. R., BROOKS, 
A. G. & HEATH, W. R. 2009. Cross-presentation of viral and self antigens by 
skin-derived CD103+ dendritic cells. Nat Immunol, 10, 488-95. 
BURGDORF, S., KAUTZ, A., BOHNERT, V., KNOLLE, P. A. & KURTS, C. 2007. Distinct 
pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell 
activation. Science, 316, 612-6. 
CAMPANELLI, R., PALERMO, B., GARBELLI, S., MANTOVANI, S., LUCCHI, P., NECKER, 
A., LANTELME, E. & GIACHINO, C. 2002. Human CD8 co-receptor is strictly 
involved in MHC-peptide tetramer-TCR binding and T cell activation. Int 
Immunol, 14, 39-44. 
CAUCHETEUX, S. M., MITCHELL, J. P., IVORY, M. O., HIROSUE, S., HAKOBYAN, S., 
DOLTON, G., LADELL, K., MINERS, K., PRICE, D. A., KAN-MITCHELL, J., 
SEWELL, A. K., NESTLE, F., MORIS, A., KAROO, R. O., BIRCHALL, J. C., 
SWARTZ, M. A., HUBBEL, J. A., BLANCHET, F. P. & PIGUET, V. 2016. 
Polypropylene Sulfide Nanoparticle p24 Vaccine Promotes Dendritic Cell-
Mediated Specific Immune Responses against HIV-1. J Invest Dermatol, 136, 
1172-81. 
144 
 
CHALLIER, J., BRUNIQUEL, D., SEWELL, A. K. & LAUGEL, B. 2013. Adenosine and 
cAMP signalling skew human dendritic cell differentiation towards a 
tolerogenic phenotype with defective CD8(+) T-cell priming capacity. 
Immunology, 138, 402-10. 
CHU, C. C., ALI, N., KARAGIANNIS, P., DI MEGLIO, P., SKOWERA, A., NAPOLITANO, 
L., BARINAGA, G., GRYS, K., SHARIF-PAGHALEH, E., KARAGIANNIS, S. N., 
PEAKMAN, M., LOMBARDI, G. & NESTLE, F. O. 2012. Resident CD141 
(BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory 
T cells that suppress skin inflammation. J Exp Med, 209, 935-45. 
CLEMENT, M., LADELL, K., EKERUCHE-MAKINDE, J., MILES, J. J., EDWARDS, E. S., 
DOLTON, G., WILLIAMS, T., SCHAUENBURG, A. J., COLE, D. K., LAUDER, S. 
N., GALLIMORE, A. M., GODKIN, A. J., BURROWS, S. R., PRICE, D. A., SEWELL, 
A. K. & WOOLDRIDGE, L. 2011. Anti-CD8 antibodies can trigger CD8+ T cell 
effector function in the absence of TCR engagement and improve peptide-
MHCI tetramer staining. J Immunol, 187, 654-63. 
DAVEY, G. M., WOJTASIAK, M., PROIETTO, A. I., CARBONE, F. R., HEATH, W. R. & 
BEDOUI, S. 2010. Cutting edge: priming of CD8 T cell immunity to herpes 
simplex virus type 1 requires cognate TLR3 expression in vivo. J Immunol, 
184, 2243-6. 
DE FILETTE, M., MIN JOU, W., BIRKETT, A., LYONS, K., SCHULTZ, B., TONKYRO, A., 
RESCH, S. & FIERS, W. 2005. Universal influenza A vaccine: Optimization of 
M2-based constructs. Virology, 337, 149-161. 
DOLTON, G., TUNGATT, K., LLOYD, A., BIANCHI, V., THEAKER, S. M., TRIMBY, A., 
HOLLAND, C. J., DONIA, M., GODKIN, A. J., COLE, D. K., THOR STRATEN, P., 
PEAKMAN, M., SVANE, I. M. & SEWELL, A. K. 2015. More tricks with 
tetramers: a practical guide to staining T cells with peptide–MHC 
multimers. Immunology, 146, 11-22. 
EL-SAHRIGY, S. A., MOHAMED, N. A., TALKHAN, H. A. & RAHMAN, A. M. 2015. 
Comparison between magnetic activated cell sorted monocytes and 
monocyte adherence techniques for in vitro generation of immature 
dendritic cells: an Egyptian trial. Cent Eur J Immunol, 40, 18-24. 
ELLIS, J. M., HENSON, V., SLACK, R., NG, J., HARTZMAN, R. J. & KATOVICH HURLEY, 
C. 2000. Frequencies of HLA-A2 alleles in five U.S. population groups: 
Predominance of A∗02011 and identification of HLA-A∗0231. Human 
Immunology, 61, 334-340. 
ENGELHARD, V. H. 1994. Structure of peptides associated with class I and class II 
MHC molecules. Annu Rev Immunol, 12, 181-207. 
145 
 
FURUYA, Y., REGNER, M., LOBIGS, M., KOSKINEN, A., MULLBACHER, A. & 
ALSHARIFI, M. 2010. Effect of inactivation method on the cross-protective 
immunity induced by whole 'killed' influenza A viruses and commercial 
vaccine preparations. J Gen Virol, 91, 1450-60. 
GEISSMANN, F., PROST, C., MONNET, J.-P., DY, M., BROUSSE, N. & HERMINE, O. 
1998. Transforming Growth Factor β1, in the Presence of 
Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, 
Induces Differentiation of Human Peripheral Blood Monocytes into 
Dendritic Langerhans Cells. The Journal of Experimental Medicine, 187, 961-
966. 
GUIRONNET, G., DEZUTTER-DAMBUYANT, C., VINCENT, C., BECHETOILLE, N., 
SCHMITT, D. & PEGUET-NAVARRO, J. 2002. Antagonistic effects of IL-4 and 
TGF-beta1 on Langerhans cell-related antigen expression by human 
monocytes. J Leukoc Biol, 71, 845-53. 
HANIFFA, M., SHIN, A., BIGLEY, V., MCGOVERN, N., TEO, P., SEE, P., WASAN, P. S., 
WANG, X. N., MALINARICH, F., MALLERET, B., LARBI, A., TAN, P., ZHAO, H., 
POIDINGER, M., PAGAN, S., COOKSON, S., DICKINSON, R., DIMMICK, I., 
JARRETT, R. F., RENIA, L., TAM, J., SONG, C., CONNOLLY, J., CHAN, J. K., 
GEHRING, A., BERTOLETTI, A., COLLIN, M. & GINHOUX, F. 2012. Human 
tissues contain CD141hi cross-presenting dendritic cells with functional 
homology to mouse CD103+ nonlymphoid dendritic cells. Immunity, 37, 60-
73. 
HEATH, W. R. & CARBONE, F. R. 2001. Cross-presentation, dendritic cells, tolerance 
and immunity. Annu Rev Immunol, 19, 47-64. 
HELFT, J., MANICASSAMY, B., GUERMONPREZ, P., HASHIMOTO, D., SILVIN, A., 
AGUDO, J., BROWN, B. D., SCHMOLKE, M., MILLER, J. C., LEBOEUF, M., 
MURPHY, K. M., GARCIA-SASTRE, A. & MERAD, M. 2012. Cross-presenting 
CD103+ dendritic cells are protected from influenza virus infection. J Clin 
Invest, 122, 4037-47. 
ITO, T., GORMAN, O. T., KAWAOKA, Y., BEAN, W. J. & WEBSTER, R. G. 1991. 
Evolutionary analysis of the influenza A virus M gene with comparison of 
the M1 and M2 proteins. Journal of Virology, 65, 5491-5498. 
JANEWAY, C. A., JR. 1991. The co-receptor function of CD4. Semin Immunol, 3, 153-
60. 
JOFFRE, O. P., SEGURA, E., SAVINA, A. & AMIGORENA, S. 2012. Cross-presentation 
by dendritic cells. Nat Rev Immunol, 12, 557-569. 
JONGBLOED, S. L., KASSIANOS, A. J., MCDONALD, K. J., CLARK, G. J., JU, X., ANGEL, 
C. E., CHEN, C. J., DUNBAR, P. R., WADLEY, R. B., JEET, V., VULINK, A. J., HART, 
146 
 
D. N. & RADFORD, K. J. 2010. Human CD141+ (BDCA-3)+ dendritic cells (DCs) 
represent a unique myeloid DC subset that cross-presents necrotic cell 
antigens. J Exp Med, 207, 1247-60. 
KANG, S.-M., YOO, D.-G., LIPATOV, A. S., SONG, J.-M., DAVIS, C. T., QUAN, F.-S., 
CHEN, L.-M., DONIS, R. O. & COMPANS, R. W. 2009. Induction of Long-Term 
Protective Immune Responses by Influenza H5N1 Virus-Like Particles. PLoS 
ONE, 4, e4667. 
KLECHEVSKY, E., MORITA, R., LIU, M., CAO, Y., COQUERY, S., THOMPSON-SNIPES, 
L. A., BRIERE, F., CHAUSSABEL, D., ZURAWSKI, G., PALUCKA, A. K., REITER, 
Y., BANCHEREAU, J. & UENO, H. 2008. Functional Specializations of Human 
Epidermal Langerhans Cells and CD14(+) Dermal Dendritic Cells. Immunity, 
29, 497-510. 
LE GOFFIC, R., POTHLICHET, J., VITOUR, D., FUJITA, T., MEURS, E., CHIGNARD, M. 
& SI-TAHAR, M. 2007. Cutting Edge: Influenza A virus activates TLR3-
dependent inflammatory and RIG-I-dependent antiviral responses in 
human lung epithelial cells. J Immunol, 178, 3368-72. 
LEE, H. K., ZAMORA, M., LINEHAN, M. M., IIJIMA, N., GONZALEZ, D., HABERMAN, 
A. & IWASAKI, A. 2009. Differential roles of migratory and resident DCs in T 
cell priming after mucosal or skin HSV-1 infection. J Exp Med, 206, 359-70. 
LEON, B., LOPEZ-BRAVO, M. & ARDAVIN, C. 2005. Monocyte-derived dendritic 
cells. Semin Immunol, 17, 313-8. 
MAKHATADZE, N. J., FRANCO, M. T. & LAYRISSE, Z. 1997. HLA class I and class II 
allele and haplotype distribution in the Venezuelan population. Hum 
Immunol, 55, 53-8. 
MARIOTTI, S. & NISINI, R. 2009. Generation of human T cell clones. Methods Mol 
Biol, 514, 65-93. 
MATTHIS, J. & REIJONEN, H. 2013. Production of Primary Human CD4+ T Cell Lines 
and Clones. Methods in molecular biology (Clifton, N.J.), 960, 545-555. 
MAYER, A., LEE, S., LENDLEIN, A., JUNG, F. & HIEBL, B. 2011. Efficacy of CD14(+) 
blood monocytes/macrophages isolation: positive versus negative MACS 
protocol. Clin Hemorheol Microcirc, 48, 57-63. 
MESTAS, J. & HUGHES, C. C. 2004. Of mice and not men: differences between 
mouse and human immunology. J Immunol, 172, 2731-8. 
MURPHY, K., TRAVERS, P., WALPORT, M. & JANEWAY, C. 2012. Janeway's 
Immunobiology (8th ed.), New York, Garland Science. 
147 
 
NEIRYNCK, S., DEROO, T., SAELENS, X., VANLANDSCHOOT, P., JOU, W. M. & FIERS, 
W. 1999. A universal influenza A vaccine based on the extracellular domain 
of the M2 protein. Nat Med, 5, 1157-63. 
NESTLE, F. O., ZHENG, X. G., THOMPSON, C. B., TURKA, L. A. & NICKOLOFF, B. J. 
1993. Characterization of dermal dendritic cells obtained from normal 
human skin reveals phenotypic and functionally distinctive subsets. J 
Immunol, 151, 6535-45. 
NI, K. & O'NEILL, H. C. 1997. The role of dendritic cells in T cell activation. Immunol 
Cell Biol, 75, 223-30. 
NORRIS, P. J., SUMAROKA, M., BRANDER, C., MOFFETT, H. F., BOSWELL, S. L., 
NGUYEN, T., SYKULEV, Y., WALKER, B. D. & ROSENBERG, E. S. 2001. Multiple 
Effector Functions Mediated by Human Immunodeficiency Virus-Specific 
CD4(+) T-Cell Clones. Journal of Virology, 75, 9771-9779. 
OH, J. Z., KURCHE, J. S., BURCHILL, M. A. & KEDL, R. M. 2011. TLR7 enables cross-
presentation by multiple dendritic cell subsets through a type I IFN-
dependent pathway. Blood, 118, 3028-3038. 
PEISER, M., WANNER, R. & KOLDE, G. 2004. Human epidermal Langerhans cells 
differ from monocyte-derived Langerhans cells in CD80 expression and in 
secretion of IL-12 after CD40 cross-linking. J Leukoc Biol, 76, 616-22. 
PENA-CRUZ, V., ITO, S., OUKKA, M., YONEDA, K., DASCHER, C. C., VON 
LICHTENBERG, F. & SUGITA, M. 2001. Extraction of human Langerhans cells: 
a method for isolation of epidermis-resident dendritic cells. J Immunol 
Methods, 255, 83-91. 
PIEMONTI, L., MONTI, P., SIRONI, M., FRATICELLI, P., LEONE, B. E., DAL CIN, E., 
ALLAVENA, P. & DI CARLO, V. 2000. Vitamin D3 affects differentiation, 
maturation, and function of human monocyte-derived dendritic cells. J 
Immunol, 164, 4443-51. 
QUAH, B. J. C. & PARISH, C. R. 2010. The Use of Carboxyfluorescein Diacetate 
Succinimidyl Ester (CFSE) to Monitor Lymphocyte Proliferation. J Vis Exp, 
2259. 
QUAN, F. S., KIM, Y., LEE, S., YI, H., KANG, S. M., BOZJA, J., MOORE, M. L. & 
COMPANS, R. W. 2011. Viruslike particle vaccine induces protection against 
respiratory syncytial virus infection in mice. J Infect Dis, 204, 987-95. 
REPNIK, U., KNEZEVIC, M. & JERAS, M. 2003. Simple and cost-effective isolation of 
monocytes from buffy coats. J Immunol Methods, 278, 283-92. 
148 
 
RUEDL, C., STORNI, T., LECHNER, F., BACHI, T. & BACHMANN, M. F. 2002. Cross-
presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a 
dispensable role for TAP. Eur J Immunol, 32, 818-25. 
SALLUSTO, F. & LANZAVECCHIA, A. 1994. Efficient presentation of soluble antigen 
by cultured human dendritic cells is maintained by 
granulocyte/macrophage colony-stimulating factor plus interleukin 4 and 
downregulated by tumor necrosis factor alpha. J Exp Med, 179, 1109-18. 
SANTAMBROGIO, L., SATO, A. K., CARVEN, G. J., BELYANSKAYA, S. L., STROMINGER, 
J. L. & STERN, L. J. 1999. Extracellular antigen processing and presentation 
by immature dendritic cells. Proceedings of the National Academy of 
Sciences of the United States of America, 96, 15056-15061. 
SCHMITZ, B., RADBRUCH, A., KUMMEL, T., WICKENHAUSER, C., KORB, H., 
HANSMANN, M. L., THIELE, J. & FISCHER, R. 1994. Magnetic activated cell 
sorting (MACS)--a new immunomagnetic method for megakaryocytic cell 
isolation: comparison of different separation techniques. Eur J Haematol, 
52, 267-75. 
SCHULZ, O., DIEBOLD, S. S., CHEN, M., NASLUND, T. I., NOLTE, M. A., 
ALEXOPOULOU, L., AZUMA, Y. T., FLAVELL, R. A., LILJESTROM, P. & REIS E 
SOUSA, C. 2005. Toll-like receptor 3 promotes cross-priming to virus-
infected cells. Nature, 433, 887-92. 
SCHWANKE, U., NABEREIT, A. & MOOG, R. 2006. Isolation of monocytes from 
whole blood-derived buffy coats by continuous counter-flow elutriation. J 
Clin Apher, 21, 153-7. 
SEGURA, E., DURAND, M. & AMIGORENA, S. 2013. Similar antigen cross-
presentation capacity and phagocytic functions in all freshly isolated human 
lymphoid organ-resident dendritic cells. J Exp Med, 210, 1035-47. 
SHORTMAN, K. & NAIK, S. H. 2007. Steady-state and inflammatory dendritic-cell 
development. Nat Rev Immunol, 7, 19-30. 
SIMS, S., WILLBERG, C. & KLENERMAN, P. 2010. MHC-peptide tetramers for the 
analysis of antigen-specific T cells. Expert Rev Vaccines, 9, 765-74. 
SITRIN, R., ZHAO, Q., POTTER, C., CARRAGHER, B. & WASHABAUGH, M. 2015. 
Recombinant Virus-like Particle Protein Vaccines. In: NUNNALLY, B. K., 
TURULA, V. E. & SITRIN, R. D. (eds.) Vaccine Analysis: Strategies, Principles, 
and Control. Springer Berlin Heidelberg. 
STOITZNER, P. 2010. The Langerhans cell controversy: are they 
immunostimulatory or immunoregulatory cells of the skin immune 
system[quest]. Immunol Cell Biol, 88, 348-350. 
149 
 
STOITZNER, P., TRIPP, C. H., EBERHART, A., PRICE, K. M., JUNG, J. Y., BURSCH, L., 
RONCHESE, F. & ROMANI, N. 2006. Langerhans cells cross-present antigen 
derived from skin. Proc Natl Acad Sci U S A, 103, 7783-8. 
TURLEY, S. J., INABA, K., GARRETT, W. S., EBERSOLD, M., UNTERNAEHRER, J., 
STEINMAN, R. M. & MELLMAN, I. 2000. Transport of peptide-MHC class II 
complexes in developing dendritic cells. Science, 288, 522-7. 
VAN DER AAR, A. M., DE GROOT, R., SANCHEZ-HERNANDEZ, M., TAANMAN, E. W., 
VAN LIER, R. A., TEUNISSEN, M. B., DE JONG, E. C. & KAPSENBERG, M. L. 
2011. Cutting edge: virus selectively primes human langerhans cells for 
CD70 expression promoting CD8+ T cell responses. J Immunol, 187, 3488-
92. 
VAN DER AAR, A. M., PICAVET, D. I., MULLER, F. J., DE BOER, L., VAN CAPEL, T. M., 
ZAAT, S. A., BOS, J. D., JANSSEN, H., GEORGE, T. C., KAPSENBERG, M. L., VAN 
HAM, S. M., TEUNISSEN, M. B. & DE JONG, E. C. 2013. Langerhans cells favor 
skin flora tolerance through limited presentation of bacterial antigens and 
induction of regulatory T cells. J Invest Dermatol, 133, 1240-9. 
WÖLFL, M. & GREENBERG, P. D. 2014. Antigen-specific activation and cytokine-
facilitated expansion of naive, human CD8+ T cells. Nat. Protocols, 9, 950-
966. 
YOSHIDA, K., KUBO, A., FUJITA, H., YOKOUCHI, M., ISHII, K., KAWASAKI, H., 
NOMURA, T., SHIMIZU, H., KOUYAMA, K., EBIHARA, T., NAGAO, K. & 
AMAGAI, M. 2014. Distinct behavior of human Langerhans cells and 
inflammatory dendritic epidermal cells at tight junctions in patients with 
atopic dermatitis. Journal of Allergy and Clinical Immunology, 134, 856-864. 
150 
 
Chapter 5 - Delivery of Peptide Antigen into Skin Utilising 
Cubosomes 
5.1 Introduction 
5.1.1 Colloidal Formulations for Intradermal Vaccine Delivery 
The hydrophobic stratum corneum (SC) is a significant barrier to the delivery of 
vaccines into the skin (Desai et al., 2010). Chapter 2 explored mechanical SC disruption 
using microneedle arrays to allow vaccine delivery into the skin. An alternative strategy 
is chemical negation of the barrier properties of the SC to allow antigen penetration into 
the skin (Benson and Namjoshi, 2008, Williams and Barry, 2012). One such technology 
that has been explored is formulation of the vaccine into an emulsion- colloidal systems 
where antigen is entrapped within lipid droplets that are dispersed in an aqueous 
continuous phase (Watson et al., 2012). The mechanism by which colloidal systems 
improve transdermal delivery are not fully understood. There are four methods that 
have been described - intact vesicles penetrating the skin, vesicles acting as penetration 
enhancers by fluidising skin lipids, exchange between the vesicles and skin lipids termed 
‘collision complex transfer’ and enhanced delivery via appendages such as sweat glands 
(Hua, 2015). The mechanism(s) by which a given formulation will enhance delivery into 
the skin are a function of the lipid components and the lipid droplet size contained in 
the formulation (Verma et al., 2003, Pierre and dos Santos Miranda Costa, 2011). 
Historically, vesicular systems have most commonly been used for the 
intradermal delivery of small molecule drugs (Cevc, 1996, Hua, 2014, Honeywell-Nguyen 
and Bouwstra, 2003) into the skin rather than biological macromolecules. There have 
however been a number of studies that utilised lipid colloid formulations to aid the 
delivery of DNA (Alexander and Akhurst, 1995), protein (Weiner et al., 1989) or peptide 
(Fleisher et al., 1995) into the skin. Colloidal formulations not only improve the 
movement of molecules across the stratum corneum but can also improve the 
presentation of antigen (Schwendener, 2014) and favour retention within the skin (Cevc, 
1996)- both of which can help to improve the immune response brought about by the 
subsets of skin-resident immune cells. The delivery characteristics of colloidal systems 
can be tailored by altering the type and proportions of lipid components used to form 
their dispersed phase (Schwendener, 2014). This provides a level of design flexibility to 
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the delivery technology so that delivery kinetics, depth of delivery in the skin and 
retention at the site of delivery can all be optimised.  
The lipid components and manufacturing processes used determine the 
structure of the dispersed phase. The earliest systems described were liposomes, where 
an amphiphilic dispersed phase spontaneously arranges into spherical particles 
contained by a bilayer. This allows the entrapment of hydrophilic substances within the 
particle’s aqueous interior or entrapment within the bilayer of hydrophobic drugs. Other 
technologies that have developed from conventional liposomes are shown in Figure 5.1. 
Transfersomes® and ethosomes are ‘ultradeformable’ particles, being able to alter 
shape to fit through the tight junctions in the skin without losing structural integrity 
(Hua, 2015). Niosomes are composed of a single chain surfactant molecule and 
cholesterol; their surfactant properties make the stratum corneum more permeable to 
the delivery of the drug within it (Kazi et al., 2010). All three of these liposomal 
formulations have improved stability compared to conventional liposomes (Hua, 2015).  
 
Figure 5.1: Structure of liposomal delivery technologies (taken from (Hua, 2015)) 
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5.1.1.1 Cubosomes 
A further colloidal formulation which shows potential for use in intradermal 
delivery of biological macromolecules such as vaccines is cubosomes. The lipid 
components of cubosomes arrange into an ordered liquid crystalline structure Figure 
5.2 termed the ‘cubic phase’ (Karami and Hamidi, 2015). This cubic structure led to the 
coining of the term cubosomes to describe the cubic liposomes. It is possible to disperse 
the lipid phase in an aqueous medium, producing lipid nanoparticles which retain the 
cubic phase characteristics at the nanostructural level (Demurtas et al., 2015). Within 
the particles, the cubosome lipid phase forms a continuous bilayer that separates two 
non-intersecting channels containing the aqueous phase (Karami and Hamidi, 2015). 
This property allows them to entrap a range of hydrophilic, hydrophobic and amphiphilic 
molecules or macromolecules (Pan et al., 2013). The tortuous water channels contained 
within the dispersed phase give cubosomes potential use in controlled release 
applications also (Clogston and Caffrey, 2005). 
Cubosomes have been studied by a number of groups, using various lipid 
components including glycerol monooleate (Lopes et al., 2006) and phytantriol  (Bender 
et al., 2008). This chapter builds upon the work of Professor Sarah Hook’s lab in the 
University of Otago who produced cubosomes using phytantriol as the lipid phase, 
propyleneglycol as a hydrotrope and poloxamer 407 to stabilise the particulate system 
(Kojarunchitt et al., 2011, Rattanapak et al., 2014). Two methods of producing 
cubosomes have been described- top-down and bottom-up techniques (Garg and Saraf, 
2007). The top-down method involves the assembly of the cubic lipid phase first before 
dispersion in the aqueous medium by some high-energy process such as vortexing. The 
bottom-up technique involves dispersing the components of cubosomes into water at 
Figure 5.2: The structure of cubosomes- a liposomal formulation that spontaneously 
arranges into a cubic liquid crystal structure (adapted from (Bei et al., 2010)) 
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80°C before cooling the water to allow the components to crystallise into cubosomes. 
Most work to date uses the top-down technique though this requires high energy input 
and the viscosity of the bulk cubic phase makes scaling-up the process difficult (Prashar 
and Sharma, 2011). Care must also be taken to ensure the compatibility of entrapped 
drugs or vaccines in the formulation to ensure they do not disrupt the cubic phase 
structure. 
Previous work by the Hook lab (Rattanapak et al., 2013) and others (Bender et 
al., 2005, Lopes et al., 2007) has shown that when applied to intact stratum corneum, 
cubosomes can improve the permeation of protein, peptide or drug into the skin. They 
speculated that the nanostructural similarities between lipids in cubosomes and the 
stratum corneum can allow the cubosomes to ‘fluidise’ the stratum corneum and 
improve the movement of substances across it (Esposito et al., 2005). A synergistic 
improvement was seen when cubosomes were applied to skin following microneedle 
pre-treatment (Rattanapak et al., 2014). It was also shown that cubosomes tended to 
aggregate at the site of delivery, creating a depot of formulation which can improve 
retention within the skin (Rattanapak et al., 2013, Clogston and Caffrey, 2005). This may 
increase the time immune cells are exposed to antigen and therefore increase the 
number of cells that can transport antigen to the lymph nodes and increase the 
likelihood of immunity being established. 
 
5.1.2 Formulation Characterisation 
Though cubosome studies had been performed previously in collaboration with 
Cardiff University, the earlier formulation work had been completed in the labs in New 
Zealand. With no guarantee of consistency of formulation manufacture between the 
two labs, it was essential to establish that formulations of an acceptable standard could 
be produced in Cardiff. It was also vital that stability testing was performed to verify the 
timescales over which formulations could be used in experimentation. Two methods are 
commonly used to characterise the cubosome formulations - transmission electron 
microscopy, to provide visual characterisation, and particle analysis, to provide 
quantitative data on the diameter, polydispersity and surface charge of lipid particles.  
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5.1.2.1 Transmission Electron Microscopy 
Transmission electron microscopy (TEM) is a powerful tool for imaging samples 
at high resolution. For liquid formulations, such as the cubosomes used in this chapter, 
sample preparation requires snap freezing of the sample at a thickness of less than 
500nm and maintenance at low temperature throughout imaging (Almgren et al., 2000). 
The sample is then exposed to a beam of electrons and a detector underneath the 
sample monitors electrons which are ‘transmitted’ through the sample- the absorption 
of electrons is a function of the sample density in a given area (Reimer, 2013). The 
electrons which are transmitted through the sample are detected and an image can be 
produced with density differences apparent. TEM’s high magnification is possible due to 
the wavelength of electrons being smaller than the wavelength of visible light, thus 
making the resolution much greater (Williams and Carter, 1996). TEM can provide an 
insight into the structural appearance of lipid particles, the arrangement of particles 
within the aqueous phase and by comparing images of cubosomes with and without 
incorporated antigen, providing qualitative data on the effects of vaccine incorporation 
into cubosomes. 
 
5.1.2.2 Malvern Zetasizer Nano 
The Malvern Zetasizer Nano utilises two analyses- dynamic light scattering (DLS) 
and zeta potential analysis- to provide quantitative data on particle size and surface 
charge of particles in colloidal liquids. DLS passes a beam of laser light through a sample, 
which will undergo refraction as it passes from aqueous phase through the dispersed 
phase. The angle of refraction varies proportionally with the size of the dispersed phase 
particles and so can be used to calculate mean particle size (Berne and Pecora, 1976). 
The software uses a simple 2 parameter fit to the cumulants analysis of particle size data 
to calculate the polydispersity index (PDI)- a measure of size distribution of particles 
within the sample (Malvern Instruments, 2011). PDI values calculated by the software 
normally fall between 0.05 (monodispersity) and 0.7 (an extremely polydisperse system) 
(Malvern Instruments, 2011). With respect to cubosome synthesis, a low PDI is desirable 
as it shows consistency in the synthesis process. It is also important to monitor size and 
PDI following storage, to provide a measure of the tendency of the colloidal system to 
flocculate or coalesce.  
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Zeta potential is a measurement of the electrical potential at the effective outer 
surface of particle within a colloidal system. As shown in Figure 5.3, the effective outer 
surface of a charged particle is not simply the edge of the dispersed phase particle but 
instead includes a layer of adsorbed ions of opposite charge (the Stern layer) and a layer 
of ions with mixed charges which are less strongly attracted to the particle (the diffuse 
layer) (Hunter, 2013). Together the Stern layer and diffuse layer form the electrical 
double layer. The zeta potential is a measurement of the potential difference between 
the outer edge of the electrical double layer (the ‘slipping plane’) and the bulk phase at 
a distal point (Figure 5.3). Zeta potential can be used as a predictor of colloid stability- a 
large zeta potential confers charge at the outer surface of the colloid particles (Hunter, 
2013). Particles with similar charge at their surface will be repelled from one another, 
thus reducing the likelihood of aggregation and improving the stability of the system 
(Riddick, 1968). A zeta potential greater than 30mV (either +30mV or -30mV) is 
considered adequate to ensure particles do not aggregate (Mandzy et al., 2005, Li et al., 
2008). Whether the dispersed phase possesses a positive or negative zeta potential 
depends on the characteristics of both dispersed and continuous phases.  
Figure 5.3: Zeta potential of a particle with a negative surface charge and therefore a positive 
zeta potential when suspended in a continuous phase (from 
http://www.horiba.com/scientific/products/particle-characterization/applications/colloids/) 
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5.1.3 Intravital Two-Photon Microscopy 
As discussed in previous chapters, immunofluorescence is a powerful tool for the 
visualisation of cells and formulation following delivery into ex vivo human skin. There 
are a number of limitations in using immunofluorescence to study the excised human 
skin model. Whilst the ex vivo human skin model is useful for generating data on the 
delivery of substances into skin and the behaviour of skin immune cells, it exists in 
isolation of the patient (and their complex body processes which may influence the skin) 
and only has a limited time frame of use (Ng et al., 2009). Imaging of ex vivo skin requires 
fixed samples- thus can only provide a snapshot of skin processes at the time of fixing. 
The penetration depth of imaging is limited in both fluorescence and confocal 
microscopy (Helmchen and Denk, 2005), meaning tissue sectioning is often required- 
thus only a small area of tissue can be imaged at one time. 
One technique which overcomes some of the limitations of visualising tissue with 
immunofluorescence microscopy is two-photon microscopy (2PM). This is similar in 
principle to classic fluorescence microscopy, where laser light is used to excite 
fluorophores in a sample which will then emit light at a longer wavelength, allowing 
visualisation. 2PM differs from fluorescence microscopy in its excitation wavelength 
which is longer and thus the excitation photons possess lower energy- half of the energy 
of a standard fluorescence microscopy laser’s excitation photons (Denk et al., 1990). 
Concurrent excitation by two photons is therefore required to elicit fluorescence from 
a fluorophore (So et al., 2000). This difference leads to greatly reduced background 
fluorescence (Denk et al., 1995), improved depth of imaging (Helmchen and Denk, 2005) 
and less chance of photobleaching or damage to the sample from the laser (Patterson 
and Piston, 2000). 
The use of excitation and emission filters in 2PM imaging allows for the 
visualisation of multiple fluorophores concurrently. Imaging via 2PM also offers an 
advantage over fluorescence microscopy due to second-harmonic generation (SHG)- a 
phenomenon whereby laser light passing through a molecule with a non-
centrosymmetric structure will have its wavelength halved (Mohler et al., 2003). This is 
particularly useful in the imaging of skin where SHG can be used to visualise the non-
centrosymmetric structure of collagen fibrils (Williams et al., 2005). As it does not 
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involve the excitation of a fluorophore, SHG requires no pre-imaging staining and is less 
susceptible to photobleaching (Campagnola et al., 1999).  
Transgenic in vivo models are particularly useful in combination with 2PM 
imaging. This investigation utilises a transgenic mouse model that expresses enhanced 
yellow fluorescent protein (eYFP) under the transcriptional control of the CD11c 
promoter (Lindquist et al., 2004). CD11c, also known as integrin α-x (ITGAX), is a protein 
which forms part of the integrin complement receptor 4 (CR4) along with CD18 (Sadhu 
et al., 2007). Within murine skin, CD11c is found exclusively on DCs- both epidermal LCs 
and dDCs (Lindquist et al., 2004). Thus, both types of skin immune cells can be observed 
concurrently without the need for staining with a fluorophore. The structural detail of 
the collagen fibrils within the dermis can be concurrently distinguished via SHG. The 
epidermis does not contain collagen fibrils and so will not produce SHG signal, allowing 
distinction between the two skin layers to be made. Finally, the 2PM equipment 
possesses a further two fluorescence channels which will be utilised to visualise 
fluorescently-conjugated peptide and cubosome lipid phase. Thus, the delivery of 
peptide, distribution of the lipid phase and immune cell behaviours can be studied 
concurrently. 
 
5.1.4 Mouse Skin Model 
Mice are the most widely used model species in immunological research due to 
their ready availability, low cost and similarities with human immune systems (Mestas 
and Hughes, 2004). However, mouse skin is structurally very different to human skin- 
mouse fur is more coarse and densely packed than the vellus hair found on human skin 
(Pasparakis et al., 2014) (especially on female breast skin, the major source of the ex 
vivo human skin used in previous chapters). Mouse skin is also much thinner than human 
skin. Murine epidermis is between 10-20µm thick (cf. 80µm in humans) (Hansen et al., 
1984). Immunologically, mice share a number of characteristics with humans (Haley, 
2003). Both possess LCs which whilst immature occupy the epidermis (Kel et al., 2010, 
de Jong et al., 2010). In both, the dermis also contains a heterogeneous population of 
dDCs (Klechevsky et al., 2008b, Malissen et al., 2014). It is believed that subsets can be 
aligned between the two species based on function rather than surface markers, where 
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a number of differences exist (Shortman and Liu, 2002). The discrepancies between 
authors on how to classify dDC subsets based on marker expression mean that work is 
still required before consensus is reached on the subsets of dDCs (Malissen et al., 2014). 
This investigation will utilise the mouse model to take advantage of being able to 
visualise the immune response in the skin of a live organism. We will also be able to 
examine the DCs of the skin and lymph nodes of the mouse after imaging to further 
examine the movements of mouse skin DCs and their uptake of fluorescent peptide after 
encountering peptide antigen, something not possible in the human ex vivo skin model. 
The results will be interpreted in the context of vaccine processing by the human DC 
subsets found in Chapter 4. The 2PM studies using CD11c-eYFP mice will be completed 
in the laboratories of Professor Masaru Ishii at Osaka University, Japan. His group has 
completed a large amount of work using the 2PM technique to image osteoclasts 
(Kowada et al., 2011), tumour cells (Kagawa et al., 2012) and skin DCs (Rattanapak et al., 
2014) in vivo with murine models.  
 
5.2 Aim and Objectives 
The overall aim of this chapter is to produce a cubosome formulation for 
intradermal vaccine delivery, establish whether it is stable following a period of storage 
and to test how it affects delivery of ovalbumin peptide antigen into the skin of an in 
vivo mouse model. Whilst the mouse work utilises the fluorescently-conjugated peptide, 
a lack of availability meant that preliminary work in human ex vivo skin was completed 
using fluorescently-conjugated ovalbumin protein. The specific practical objectives are: 
1. Produce cubosome formulations using a protocol previously optimised by Sarah 
Hook’s group in the University of Otago (Rizwan et al., 2011) and characterise the 
formulations by TEM and using particle size, PDI and zeta potential analysis to 
indicate consistency with formulations from the literature. 
2. Establish stability of the cubosomes following storage by assessing changes in size, 
PDI and zeta potential after storage times of up to 28 days. 
3. Measure ovalbumin protein entrapment within cubosome formulations. 
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4. Use ex vivo human skin for preliminary testing of ovalbumin protein delivery into the 
skin using cubosomes in combination with solid coated microneedles and hollow 
microneedle devices. 
5. Deliver fluorescently-labelled ovalbumin peptide (residues 257–264; SIINFEKL) into 
mice and characterise microneedle channel healing and skin immune cell behaviour 
following treatment. 
6. Analyse murine immune cells isolated from skin and skin-draining lymph nodes to 
quantify peptide uptake and transport to lymph nodes by different skin-resident 
immune cells. 
 
5.3 Materials and Methods 
[All equipment and reagents obtained from Fisher Scientific, UK unless otherwise stated] 
The work in this chapter focusses on the delivery of antigen into skin using 
cubosome formulations. It aimed to build on work previously done by a collaborator 
utilising cubosome formulations containing 5(6)-tetramethylcarboxy rhodamine 
labelled OVA257–264 (SIINFEKL-TAMRA) as a vaccine antigen model delivered using a 
microneedle device (Rattanapak et al., 2013, Rattanapak et al., 2014). Before skin 
delivery studies in vivo could be completed, it was necessary to establish whether 
cubosome formulations could be consistently synthesised and whether they were stable 
following storage. It was also important to establish whether formulation could be 
delivered into the skin using the range of delivery methods that would be used in the in 
vivo study. Given that the in vivo work was to be carried out in Japan and the 
fluorescently-conjugated peptide that we would be utilising was unavailable for the 
months leading up to the work, fluorescently-conjugated ovalbumin protein was used 
in its place in the early characterisation studies. 
 
5.3.1 Synthesis of Cubosomes  
Cubosome formulations were synthesised using a previously published method 
(Rizwan et al., 2011). The lipid phase components- 100mg phytantriol (Tokyo Chemical 
Industry UK Ltd, UK), 268.3mg propyleneglycol (Sigma Aldrich, UK) and 15mg poloxamer 
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407 (Sigma Aldrich, UK)- were weighed into a 25ml round-bottomed flask and 10ml 
chloroform added to dissolve them. The flask was then attached to a rotary evaporator 
(BÜCHI Labortechnik AG, Switzerland) and mixed at 45°C for approximately 30 minutes 
until the chloroform had fully evaporated, leaving a visually homogeneous lipid phase. 
Next, 100µl of a 10mg/ml solution of ovalbumin protein with Alexa Fluor™ 555 
Conjugate (Fl-OVA; Invitrogen, UK) in ddH2O was added dropwise to the lipid phase 
whilst vortexing. Finally, the volume was made up to 5ml by the addition of ddH2O in 
two stages under vortex. This produced final concentrations of 200µg/ml Fl-OVA, 
20mg/ml phytantriol, 53.66mg/ml propyleneglycol and 3mg/ml poloxamer 407 in 
ddH2O. The formulation was then homogenised by vortexing for 10 minutes. Cubosomes 
without Fl-OVA were synthesised as above but with 100µl ddH2O being added to the 
lipid phase before being made up to the 5ml final volume. Cubosomes were stored 
under nitrogen at room temperature and protected from light prior to their use.  
    
5.3.2 Physical Characterisation of Cubosomes 
5.3.2.1 Zeta Potential and Particle Size Analysis 
Prior to analysis, cubosome formulations either containing Fl-OVA (CuFl) or 
without fluorescent protein (Cu0) were diluted 1 in 50 by making 20µl of the cubosome 
formulation up to 1ml using ddH2O. Particle size (z-average diameter) and size 
distribution of particles (polydispersity index; PDI) of colloidal particles within the 
cubosome formulation were measured using dynamic light scattering on a Zetasizer 
Nano ZS (Malvern Instruments, UK) in disposable polystyrene cuvettes with a 10mm 
light path. Three samples were taken from each formulation batch 24hrs after initial 
synthesis and size/PDI measured in triplicate at 25°C.  
The zeta potential of the colloidal particles was also measured using the Zetasizer 
Nano ZS, this time with Folded Capillary Zeta Cells (Malvern Instruments, UK). Again 
three samples were taken from each batch and diluted 1 in 50 before the zeta potential 
was measured in triplicate. 
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5.3.2.2 Transmission Electron Microscopy (TEM) 
Aliquots of 20µl each of the CuFl and Cu0 formulations were submitted to a 
collaborator in the School of Optometry & Vision Sciences, Cardiff University for analysis 
by cryogenic TEM using a JEM-2100 LaB6 Transmission Electron Microscope (JEOL, USA) 
with a high-resolution digital camera (Gatan, UK) utilised for image capture. 
 
5.3.3 Protein Entrapment in Cubosomes  
Fluorescence absorption/emission spectra for Fl-OVA were obtained using a Cary 
Eclipse fluorescence spectrophotometer (Agilent Technologies Inc., USA)- the 
absorption and emission maxima were determined to be 553nm and 572nm 
respectively (Figure 5.4). 
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Figure 5.4: Absorbance (blue line) and emission (orange line) spectra for Fl-OVA in ddH2O 
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A concentration calibration curve was produced for the concentration range 0-
150µg/ml (Figure 5.5).  
To determine the protein entrapment within cubosomes, 200µl of CuFl was 
centrifuged at 20,800 x g for 30 minutes, leading to the separation of the lipid and 
aqueous phases. The aqueous phase was then removed and diluted 1:1 with ddH2O 
before fluorescence analysis with absorption and emission set to 553nm and 572nm 
respectively. The intensity reading could then be converted into the protein 
concentration using the following formula: 
 
Concentration of Fl-OVA in aqueous phase (concaq)= (intensity + 0.4402)  
                                                                                                        2.3898 
  
This provided the concentration of FL-OVA in the aqueous phase (which had 
been diluted 1:1). The mass of protein in the aqueous phase was then calculated: 
 
Mass of Fl-OVA in aqueous phase (maq)= 2 x concaq x volume of aqueous phase 
  
y = 2.3898x - 0.4402
R² = 0.9998
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Figure 5.5: Concentration-calibration curve for Fl-OVA in ddH2O with absorbance: 
553nm and emission: 572nm 
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 Finally, the percentage of protein entrapment could then be calculated from the 
mass of protein present in the 200µl cubosome formulation (mfor): 
 
                                    % protein entrapment =     mfor – maq 
                    
 
5.3.4 Stability Testing of Formulations 
To assess the stability of cubosomes in storage, four 500µl aliquots of CuFl and 
Cu0 formulations were taken and stored under nitrogen in 1.5ml microcentrifuge tubes 
protected from light at room temperature. At 7, 14, 21 and 28 days after initial storage, 
an aliquot of each formulation was analysed for size, PDI, and zeta potential using the 
analysis protocols described in Section 5.3.2.1. 
 
5.3.5 Effects of Hollow Microneedle Delivery on Cubosome Formulations  
The effects of two methods of cubosome delivery into the skin using 
microneedles were assessed to inform the in vivo study design- delivery as a liquid 
dispersion through hollow microneedle arrays or dry-coated onto solid microneedles. 
The MicronJet™ device (NanoPass Technologies Ltd, Israel) was selected for hollow 
microneedle delivery due to its prior regulatory approval supporting its use for 
intradermal delivery. Should promising results be found in this work with pre-clinical 
models using the devices, they would be available for use in clinical trials. The device is 
available in two needle lengths: 450µm and 600µm (MicronJet450™ and MicronJet600™ 
respectively). The devices possess either three 600µm or four 450µm hollow 
microneedles attached to a solid base (Figure 5.6) which attached to a syringe via a Luer 
fit connection. The microneedles can then be used in a similar fashion to hypodermic 
needle, with the needles inserted into the skin and pressure being applied to the plunger 
of the syringe to force liquid formulation into the skin.  
  
mfor 
 
x 100 
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To ensure that the cubosome formulations were not adversely affected by 
delivery through the microneedle devices, CuFl and Cu0 formulations were passed 
through the microneedle array three times and analysed for changes in size, PDI and 
zeta potential as described in Section 5.3.2.1. Both MicronJet450™ and MicronJet600™ 
array types were assessed. 
 
5.3.6 Coating of Cubosome Formulation onto Stainless Steel Microneedles  
The potential for coating cubosome formulations onto solid stainless steel 
microneedles was also assessed. It was hoped that cubosome formulation could be 
coated onto the needles’ surface and the aqueous phase allowed to evaporate. After 
delivery, the rehydration of the formulation would allow its release from the needles 
surface and the reconstitution of the cubosome formulation in the skin where it could 
mediate its slow release of protein or peptide. The needle design and coating method 
used were both as described in Section 2.3.1. Briefly, 0.6µl of CuFl formulation was 
drawn up into a gel-loading pipette tip before being forced out gradually to form a small 
droplet of liquid which could be applied to the tips of needles. The formulation was 
allowed to dry before subsequent layers were added until the entire volume had been 
used to coat 3 microneedle arrays. Coating success was assessed using a Leica DM IRB 
epifluorescence microscope (Leica Microsystems Ltd, UK) with Retiga Exi Fast digital 
camera (QImaging, Canada). 
 
Figure 5.6: NanoPass's MicronJet device (image taken from 
http://www.nanopass.com/content-e.asp?cid=19&itemid=335#;) 
165 
 
5.3.7 Protein Delivery into the Skin by Injection of Cubosome Formulation  
Cubosome delivery into the skin by hollow microneedles or coated solid stainless 
steel microneedle arrays was assessed using ex vivo human skin. Hollow microneedle 
delivery was performed using MicronJet450™ and MicronJet600™ arrays attached to 
1ml syringes to deliver 50µl of undiluted CuFl formulation in the skin according to the 
microneedle manufacturer’s injection technique instructions. Treated skin areas, as 
determined by the ‘bleb’ that formed due to hydrostatic pressure of the injection 
volume within the upper layers of the skin, were excised using an 8mm biopsy punch 
and snap frozen in Optimal Cutting Temperature (OCT) embedding media and stored at 
-80°C prior to use. 
The protocol for testing microneedle coating release in human skin described in 
Section 2.3.2 was used for cubosome-coated needles. The needles were inserted into 
previously frozen ex vivo human skin samples using a downward force perpendicular to 
the skin’s surface and held in place for 60 seconds to allow rehydration of the 
formulation on the needles’ surface. The needles were then removed and reimaged as 
described above to assess formulation removal from their surface. The treated areas of 
skin were excised, embedded and snap frozen as described above and stored at -80°C 
prior to use. 
Sections of 10µm were produced, mounted and fixed on SuperFrost Ultra Plus 
slides before being imaged as described in Section 2.3.3 to visualise fluorescent protein 
deposition in the skin. 
 
5.3.8 Antigen Uptake by Skin APCs 
The early kinetics of antigen delivery into skin and interaction with skin-resident 
immune cells was assessed using two-photon microscopy (2PM) in a fluorescent in vivo 
immune cell model.  
Given the lack of success of coating stainless steel microneedle arrays with 
cubosome formulation for delivery into human skin, this study used a liquid cubosome 
formulation applied to the skin after microneedle channels had been made by uncoated 
needle arrays to allow entry into the skin- this had been used in previous studies with 
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different microneedle arrays and cubosome formulation (Rattanapak et al., 2013, 
Rattanapak et al., 2014). Microneedles coated with an aqueous formulation of peptide 
and adjuvant or an intradermal injection of liquid cubosome formulation were also 
assessed as potential delivery methods.  
 
5.3.8.1 Cubosome Formulations 
Three formulations were produced for use in 2PM studies:  
I. Cubosomes produced as described in Section 5.3.1- with 20mg/ml 
phytantriol (Tokyo Chemical Industry UK Ltd, UK), 53.66mg/ml 
propyleneglycol (Sigma Aldrich, UK) and 3mg/ml poloxamer 407 (Sigma 
Aldrich, UK)- plus 0.2mg/ml SIINFEKL-TAMRA (Peptides and Elephants, 
Germany), 0.4mg/ml Quil-A and 0.1mg/ml monophosphoryl lipid A (MPL-
A) (CuPQM) (both Sigma Aldrich, UK). 
II. Cubosomes produced as described in Section 5.3.1 with 38.325µg/ml Nile 
red (to create a 1:2000 ratio with the lipid phase in cubosomes) (CuNQM). 
III. An aqueous solution of the SIINFEKL-TAMRA, Quil-A and MPL-A as above 
without lipid cubosome components present (AqPQM).  
Nile red is a lipophilic dye which fluoresces when it is in a nonpolar environment 
(Greenspan et al., 1985)- in this case, within the lipid phase of the cubosome 
formulation. Nile red was selected to allow the visualisation of the lipid phase’s 
behaviour after delivery into the skin; its distinct fluorescence spectra in combination 
with eYFP, TAMRA and SHG allowing visualisation of lipid phase, immune cells, peptide 
and collagen concurrently. 
 
5.3.8.2 Transgenic Mice 
The mice utilised in this study were B6.Cg-Tg (ITGAX-eYFP) 1 Mnz/J mice (Jackson 
Laboratory, USA) which were purchased and maintained by collaborators under specific 
pathogen-free conditions in the animal facility of Osaka University, Japan. Experimental 
work was performed under an approved protocol from the Animal Experimental 
Committee of Osaka University. 
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Mice were anaesthetised with isoflurane prior to treatment- 3% isoflurane for 
induction and 1-2% for maintenance (both vaporised in 100% oxygen). First, one or both 
flanks of the mouse were trimmed using electric hair clippers to remove the bulk of the 
fur. Depilatory cream (Church & Dwight Co. Inc., USA) was then applied to the trimmed 
area and left for 5 minutes to degrade the remaining hair, which could then be wiped 
away using a cotton swab. The hairless area was wiped clean using a tissue soaked with 
PBS and subsequently patted dry with a dry tissue prior to treatment.  
 
5.3.8.3 Treatment with SIINFEKL-TAMRA Formulation 
The microneedles used in these studies were stainless steel needle arrays of a 
design similar to those described in Section 2.3.1.1 (10 needles in a single row) with a 
length of 500µm after elctropolishing. Each hairless flank was treated with one of the 
following treatments: 
a) Microneedle poke-through (MNPT): mouse flank was first treated with 
uncoated microneedles - one array applied three times in succession in 
parallel with 1mm spacing to create 30 channels in the skin. Immediately 
after MN application. 50µl of formulation was applied to the surface of 
the skin over the area with the microneedle channels. After 2 minutes, 
excess formulation was removed using tissue.  
b) Coated microneedle (coated MN): 1.3µl of an aqueous solution 
containing 3.84mg/ml SIINFEKL-TAMRA, 7.68mg/ml Quil-A and 
1.92mg/ml MPL-A was coated onto microneedle arrays as described in 
Section 2.3.1.2. Two arrays were applied at a time in parallel using a 
custom microneedle array holder, using downward pressure and held in 
place in the skin for 60 seconds to allow dissolution of the coating and 
then removed.  
c) Intradermal injection (IDInj): 50µl of CuSQP or AqSQP formulation was 
delivered intradermally using the Mantoux technique with a 26-guage 
needle. Nanopass needles were initially used but difficulties were found 
in reproducibly injecting the live mice so the hypodermic needle injection 
method was utilised instead. 
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d) Untreated control (UT): flank was left untreated to allow imaging of LCs 
and dDCs in the absence of antigen or cubosomes. 
To prepare the mouse for imaging, a glass microscope cover slip was attached to 
the flank of the mouse using tissue glue (3M, USA). The mouse was then inverted so that 
the cover slip could be fixed onto a heated microscope stage using adhesive tape. Total 
time to prepare the mouse and set up the microscope for imaging was approximately 
15-45 minutes. Mice were divided into two groups- the first of which was treated and 
then imaged immediately to allow the analysis of early events following treatment. The 
second group were treated as described above and then returned to the animal facility 
for 48hrs before imaging- to allow analysis of changes in LCs after this extended time 
period.  
 
5.3.8.4 Two-Photon Microscopy 
The heated stage was fitted onto a motorised stage holder within a custom-built 
housing. The housing served to protect the stage from external light and also contained 
an air heating unit. Both the heated stage apparatus and the air heater within the 
housing were set to 37°C to maintain the body temperature of the anaesthetised mouse. 
Isoflurane was used to maintain anaesthesia at 1-2% in 100% oxygen, adjusted to keep 
the mice’s breathing rate and depth steady so as not to introduce movement whilst 
imaging. 
Two-photon microscope imaging of treated areas of mouse flank was performed 
using an A1RMP multiphoton microscope (Nikon, Japan) driven by a Chameleon Vision 
II Ti:Sapphire laser (Coherent, USA) tuned to 920 nm with an inverted microscope 
equipped with a 206 oil immersion objective (CFIPlan-Fluor, N.A. 0.75, Nikon). Collagen 
was detected through SHG at 446nm, eYFP was detected at 525nm and SIINFEKL-TAMRA 
detected at 575nm. Images were acquired with 3µm spacing between z-planes starting 
from the surface of the skin downwards to the depth where signal became diminished 
(ranging from 30-50 z-planes). Images were acquired either as a snapshot (with one 
complete set of z-plane images) or over a time course (with sets of z-plane images being 
taken at 5-minute intervals to allow the visualisation of movement of immune cells) 
depending on whether the mouse was being imaged 48hrs after treatment or 
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immediately following treatment respectively. Mice being studied immediately 
following treatment were imaged for up to 4 hours. Raw imaging data were processed 
with a combination of NIS-Elements AR (Nikon, Japan) and Imaris (Bitplane AG, 
Switzerland) software.  
 
5.3.8.5 Antigen Uptake Analysis by Flow Cytometry 
Following imaging, mice were sacrificed by cervical dislocation. The glass cover 
slip was gently removed and the mouse’s flank washed with PBS to remove any residual 
formulation. The treated skin areas and the local inguinal lymph nodes were then 
harvested. The skin was incubated in a 1mg/ml collagenase (Wako Chemicals, Japan) 
solution in Hanks buffered salt solution (Nacalai Tesque, Japan) at 37°C in a shaking 
water bath for 1 hour to allow for dispersion of the tissue. The resulting cell suspension 
was passed through a 100µm cell strainer to eliminate cell clumps. A single cell 
suspension was also prepared from inguinal lymph nodes by mechanical disruption and 
washing through a 100µm cell strainer using PBS. After collection, skin and lymph node 
cell suspensions were fixed in 1% paraformaldehyde for 10 minutes at room 
temperature. Fixed cells were stored in FACS buffer at 4°C prior to use. 
 Skin and lymph cells were initially incubated in Fc Block (Nippon Becton 
Dickinson, Japan) according to manufacturer’s protocol. They were then washed in FACS 
buffer before being stained with the following panel: 
 Brilliant Violet 421™ anti-mouse/human CD11b antibody (Biolegend, USA) 
 APC anti-mouse/human CD207 (Langerin) Antibody (Biolegend, USA) 
 
Analysis was performed on a FACSCantoII (Nippon Becton Dickinson, Japan) with 
the Brilliant Violent 421 fluorophore being visualised in the Pacific Blue channel, eYFP in 
the FITC channel and SIINFEKL-TAMRA in the PE channel. Compensation was performed 
using BD CompBead compensation beads (Nippon Becton Dickinson, Japan) with FITC- 
and PE-conjugated antibodies used in the place of eYFP and TAMRA in the absence of 
antibodies conjugated with these fluorophores (Figure 5.7). The raw data were analysed 
using FlowJo software (FlowJo LLC, USA). Statistical tests comprised one-way analysis of 
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variance (ANOVA) followed by Tukey's post hoc analysis performed using IBM SPSS 
Statistics (IBM, USA). 
 
5.4 Results and Discussion 
5.4.1 Characterisation of Cubosomes  
5.4.1.1 Zeta Potential and Particle Size Analysis 
Analysis of cubosome batches 24hrs after synthesis revealed an average particle 
size of 169.5nm (SD ±12.5, n = 4). The insertion of Fl-OVA or Nile red into the 
formulations did not alter the particle size significantly- mean particle size was 167.7nm 
and 152.9nm with insertion of Fl-OVA and Nile red respectively. The particle distribution 
index was low for all the samples measured, with a mean PDI of 0.164 (SD ±0.022, n = 
4), indicating that relatively homogeneous particles had been produced. Both the 
particle size and PDI values seen were consistent with the values published by 
Rattanapak et al. (2013) who reported particle sizes ranging from 158-182nm and PDI < 
Figure 5.7: Fluorescence excitation and emission spectra for R-phycoerythrin, TAMRA, YFP 
and FITC used to inform analysis by flow cytometry 
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0.3. The zeta potential of cubosomes differed from those previously reported. Whereas 
Rattanapak et al. (2013) reported a zeta potential range of -21 to -25mV, the mean zeta 
potential observed in this study was -16.3mV (SD ± 3.4, n = 4)- the significance of this 
difference will be determined in the stability investigation.  
 
5.4.1.2 Transmission Electron Microscopy (TEM) 
TEM imaging of Cu0 formulation produced the images in Figure 5.8.  Based on 
previously published TEM images of cubosome formulations (Bu et al., 2015, Fraser et 
al., 2011), it was determined that the lighter areas represented the continuous aqueous 
phase, with the dark spots representing the lipid particles. The presence of other lipid 
structures was also noted, with unilamellar and multilamellar liposomes both visible.  
The addition of ovalbumin protein to the cubosome formulation led to a 
reduction in the quality of TEM images that were obtained. In a small proportion of the 
images obtained, areas of light aqueous background with darker, rounded areas the size 
of Cu0 lipid particles could be distinguished (Figure 5.9). Unlike images of the Cu0 
formulation, the continuous phase contained lighter coloured particulate material- most 
likely the Fl-OVA protein precipitated from solution following freezing of the 
formulation. This material made distinguishing cubosome particles very difficult and so 
Figure 5.8: TEM images of Cu0 formulation with unilamellar 
(white arrows) and multilamellar liposomes (red arrow) 
indicated. Two cubosome nanoparticles are indicated by 
hashed yellow circles 
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particle size and zeta potential analysis will be used to reliably characterise particles in 
the place of TEM. 
 
5.4.2 Protein Insertion into Cubosomes  
The mean entrapment of protein within the lipid phase was 28.54% (SD ± 1.63, 
n = 3). This was higher than the 23% entrapment reported for fluorescent peptide in the 
literature (Rattanapak et al., 2013) but lower than the entrapment reported for the full 
length ovalbumin protein of 73% (Rizwan et al., 2011). The results showed that 
ovalbumin protein could be entrapped in cubosomes despite its size, approximately 
7.0nm × 3.6nm × 3.0nm (Erickson, 2009), exceeding that of the peptide. Whilst the low 
entrapment efficiency is a limitation, the formulation may provide for a bolus dose of 
protein from the continuous phase followed by sustained release of protein entrapped 
the lipid phase providing a greater overall exposure time. 
Figure 5.9: TEM image of CuFl formulation 
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5.4.3 Stability Testing of Formulations 
The stability tests of cubosome batches showed a similar trend across all of the 
batches analysed- particle size and PDI both reversibly increased upon storage. This was 
presumably due to lipid particle aggregation, perhaps due to the relatively low zeta 
potential values observed. There was no significant difference in the size or PDI of 
batches analysed after vortexing at 7, 14, 21 or 28 days after initial analysis (Figure 5.10). 
This suggests that there is a stable equilibrium size that lipid particles in the formulation 
tend towards between 180 and 220nm. Vortexing formulations reversed the changes in 
size in all samples, returning them to the reported ranges of particle size (158-182nm). 
Interestingly, the PDI values on extended storage did not exceed the reported value 
(>0.3) during storage before or after vortexing.   
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Figure 5.10: Mean size and PDI of lipid particles in cubosome formulations following extended 
storage at room temperature, protected from light and under nitrogen 
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 The zeta potential of the formulations remained consistent with storage time, 
with samples tested at all time points not varying significantly from the -16.3mV value 
produced by the initial analysis (Figure 5.11). There was also no significant difference 
between Cu0 formulations and those with Nile red or Fl-OVA, suggesting that while they 
were inserted into the lipid particles, their low mass in the formulation relative to the 
mass of lipid meant they did not disturb the colloidal system.  
5.4.4 Effects of Hollow Microneedle Delivery on Cubosome Formulations  
Figure 5.12 shows the effect on cubosome characteristics of 5 consecutive passes 
through NanoPass hollow microneedle arrays. The particle size and PDI of the 
cubosomes showed only marginal increases after passing through either MicronJet450™ 
or MicronJet600™ array type- a mean increase of 7.6nm in particle size and 0.0145 in 
PDI. This represented mean changes of 3.9% and 6.6% for size and PDI respectively. The 
change in zeta potential were more marked, with decreases by both array types to 
approximately -25mV in all cases. This change may be due to the shear forces of the 
formulation being passed through the needle leading to a change in the alignment of 
components of cubosomes, altering the charge at the surface of the particles. It is also 
possible that passing the formulation through a plastic syringe and microneedle device 
will lead to adsorption of surfactant (Clint, 1998) from cubosomes, thus changing their 
composition which may have led to the difference in zeta potential seen. Further work 
is required to determine the source of this change in cubosome properties. The more 
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Figure 5.11: Mean zeta potential of lipid particles in cubosome formulations following extended 
storage at room temperature, protected from light and under nitrogen. All samples were vortexed for 
10 minutes prior to analysis 
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negative zeta potential might improve the long-term stability of formulations as 
particles are more repelled from one another, preventing aggregation. However, the 
delivery through microneedles will be the terminal use for the formulation so effects on 
stability will be inconsequential. Overall, the results support the use of hollow 
microneedle technology for delivery of cubosomes. 
  
Figure 5.12: Effect of being passed through NanoPass hollow microneedle arrays on mean particle 
size (A,B), PDI (C,D) and zeta potential (E,F). Two formulations were tested: Cu0 (blue) and CuFl 
(orange). Three separate aliquots of each formulation were tested; error bars are ±SD. 
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5.4.5 Coating of Cubosome Formulation onto Stainless Steel Microneedles 
Results of coating stainless steel microneedles with cubosome formulation are 
shown in Figure 5.13 (A & B). It was possible to achieve coverage of the needle tips 
comparable to that seen in Chapter 2 using an aqueous solution of Fl-OVA alone. The 
fluorescence was not evenly distributed across the area that was coated however. This 
was most likely due to the aqueous phase of the cubosome formulation evaporating 
preferentially from the needle edges, leading to aggregation of the dispersed phase at 
the centre of the needles due to the lyophobic nature of the dispersed phase. Reimaging 
the needles following insertion into the skin revealed that the coating on the needles 
was not physically resilient enough to insert into skin- some of the formulation appeared 
to be ‘smeared’ on the base of the arrays following skin insertion. This phenomenon was 
later confirmed by imaging ex vivo skin sections following microneedle treatment to 
determine where, if at all, the formulation had been deposited within the skin. 
  
A 
D 
B 
C 
Figure 5.13: Microneedle arrays (black) coated with CuFL formulation (red) following coating 
showing uneven distribution on the needle surface (A,B) and following insertion into ex vivo human 
skin showing formulation spread onto the base of the needle array (C,D). Scale bar: 200µm 
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5.4.6 Protein Delivery into the Skin by Injection of Cubosome Formulation  
As Figure 5.14 shows, both of the NanoPass hollow microneedle array devices 
were able to deliver cubosome formulation into skin. As is the case with intradermal 
injections using a hypodermic needle, the bulk of formulation was delivered into the 
fibrous dermis. Little formulation was seen in the epidermis, likely due to the densely 
cellular nature of the epidermis meaning that the hydrostatic pressure of injection is 
inadequate to distribute formulation into the epidermis, though delivery of formulation 
occurs adjacent to the needle channel in the epidermis (Figure 5.14 A, C & D). This 
preferential delivery to the lower dermis is likely exacerbated in ex vivo skin due to the 
lack of hypodermic tissue or muscle present, creating a path of least resistance out of 
the bottom of the skin samples which injected formulation will follow. 
 
A 
D C 
B
Figure 5.14: Delivery of CuFL formulation into ex vivo skin samples using NanoPass NP450 (A,B) and 
NP600 (C,D) hollow microneedle array devices. Scale bar: 100µm 
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Figure 5.15 shows the delivery of cubosome formulation into the skin using 
either cubosome-coated solid steel microneedles or by applying a liquid cubosome 
formulation to the skin after treatment with uncoated needles to create needle channels 
through which the formulation could enter the skin. There was a smaller area of 
fluorescent protein delivery into skin delivered into the using these methods than 
intradermal injection using microneedles. As expected from the images of microneedles 
coated with cubosome formulation following skin insertion, some of the coating was 
wiped off of the needles during insertion into skin and could be found on the skin’s 
surface adjacent to the needle channel (Figure 5.15 B). Deposition below the stratum 
corneum was limited to the edges of the needle channel and so covered a very small 
area only. Delivery of liquid formulation onto needle pre-treated skin showed only a 
small improvement in delivery, with some formulation able to permeate down into the 
dermis (Figure 5.15 D), though not in all cases (Figure 5.15 C). 
  
A 
C 
B 
D 
Figure 5.15: Delivery of CuFL formulation into ex vivo skin samples coated onto solid steel microneedles 
(A,B) and applied to the surface of skin which had previously been treated with uncoated microneedle 
arrays to create channels in the skin (C,D). Scale bar: 100µm 
179 
 
5.4.7 Two-Photon Microscopy 
5.4.7.1 Structure of Skin 
Figure 5.16 shows the skin of a B6.Cg-Tg (ITGAX-eYFP) 1 Mnz/J mouse visualised 
by 2PM after microneedle pre-treatment followed by application of a cubosome 
formulation containing fluorescent peptide, Quil-A and MPL (CuPQM MNPT). The 
stratum corneum is red due to the liquid formulation being applied to the skin’s surface, 
with the undulations of the skin’s surface causing areas of uneven fluorescence 
intensity. The dark region in the middle of the images is a microneedle channel in the 
skin. Just below the surface, the network of green LCs in the epidermis are clearly visible. 
Folds in the skin and the upper end of hair shafts containing formulation also appear red 
in the epidermis. At 21µm below the skin’s surface, the collagen fibres of the dermis are 
visible in blue, along with the lower parts of hair shafts which are green due to 
autofluorescence on the 480/40 filter. At this depth, dDCs could also be seen. They are 
distinguishable by their bright green fluorescence, rounded morphology compared to 
Legend 
SIINFEKL-TAMRA 
CD11c-eYFP/ 
autofluorescent hair 
shafts 
Collagen 
0 µm 
45 µm 
21 µm 12 µm 
Figure 5.16: Visualisation of the skin of a CD11c-eYFP mouse using two-photon microscopy (2PM). The 
legend applies to all subsequent 2PM images in this chapter. Text on each image indicates depth of imaging 
relative to the skin’s surface. Arrows indicate LCs (white arrows) at 12µm imaging depth and dDCs (yellow 
arrows)/autofluorescent hairs (grey arrows) at both 21µm & 45µm imaging depths. Scale bar: 100µm 
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LCs and motility within the dermis. The bottom of the microneedle channel could be 
seen at a depth of 45µm and was distinguishable by the presence of red formulation in 
the dermis. At depths of 70µm below the skin’s surface, the laser power was attenuated 
by the skin and so signal was reduced- this varied between mice though, with some 
producing signal to depths of as much as 200µm. The depth at which the signal was fully 
attenuated varied between mice and with the presence of microneedle channels, which 
allowed penetration of the laser to greater depths in the skin. 
 Figure 5.17 shows further characteristics of the CD11c+ cells in mouse skin that 
could be observed using 2PM. Figure 5.17 (A) shows the non-motility of LCs over 2 hours 
of imaging- this was in support of the results seen in human skin in Chapter 2 where LCs 
require longer times to respond to stimuli and migrate out of the epidermis. This was 
not the case for the motile green dDCs within the dermis (Figure 5.17 B), which could be 
seen moving both laterally and vertically within the skin in the time lapse en face images. 
It was also noted that dDCs occasionally migrated to the basement membrane and 
extended dendrites into the epidermis (Figure 5.17 C). This is most likely to allow dDCs 
to ‘sample’ antigen that may be present in the epidermis. An accumulation of dDCs at 
the dermal-epidermal junction has been previously reported in response to herpes 
simplex virus infection of the epidermis (Eidsmo et al., 2009). This may be important in 
allowing antigen transport to lymph nodes more rapidly after pathogenic infiltration of 
the epidermis than can be achieved by LCs. 
 
5.4.7.2 Microneedle Channel Healing 
One of the advantages of 2PM is the ability to image the skin in real time- useful 
both for observing cellular behaviour and that of the skin as a whole. In particular in this 
study, the healing of microneedle channels could be observed. During the investigation, 
healing of microneedle channels occurred almost completely within an hour of the 
needles’ removal as was apparent in 2PM images. This presented a challenge as the 
process of preparing the mouse for imaging after treatment and setting up the 
microscope to image the region of interest and initiating the imaging sequence took up 
to 45 minutes. This issue was particularly pronounced for CuPQM and AqPQM MNPT-
treated mice, where formulation was applied, allowed to permeate skin and excess then 
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A 
C 
B 
Figure 5.17: 2PM images that demonstrate the lack of motility of LCs over 2 hours (A) with 
white circles indicating a pair of stationary LCs, the motile nature of dDCs within the dermis 
(B) with yellow circles following a single dDC through the dermis and demonstrate a dDC’s 
movement into the epidermis (C; z-depth 72µm) with yellow arrows. Scale bar: 50µm 
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removed before attaching the glass cover slip to the mouse. The coated MN studies 
provided the best opportunity to image microneedle channels due to the fact that mice 
could be prepared for imaging immediately following microneedle removal. The fact 
that the fluorescent formulation was only deposited where microneedle arrays came 
into direct contact with skin also made aligning the microscope to the region of interest 
much more straightforward. Figure 5.16 is an example of a MN channel that was imaged 
roughly 45 minutes after the MN array was removed from the skin and as a result, the 
needle channel is more shallow (at roughly 50µm) than would be expected from 500µm 
needles being inserted into the skin. Figure 5.18 shows a microneedle channel formed 
by a coated microneedle. Of the three repeats of mice treated with coated 
microneedles, this had the shortest elapsed time from treatment of the mouse to 
imaging run being commenced (15 minutes). Thus, it provides the best insight into the 
microneedle channel healing process. The black channel area on the images can be seen 
to decrease in width from 320µm (approximately the width of the microneedles) at 15 
minutes’ post-treatment to 63µm 60 minutes later.  The depth of the channel also 
decreased from extending beyond the field of view at 15 minutes’ post-treatment to 
70µm at 60 minutes as the channel healed.  It was interesting to note that the skin 
appears to close both inwards and move upwards to effectively ‘close’ the channel. At 
75 minutes post-MN removal, the MN ‘channel’ appears as a shallow indentation in the 
skin, with the red coating formulation visible on its inner surface. 
 
5.4.7.3 Antigen Retention at the Site of Injection 
Another facet of vaccine delivery that was visualised using 2PM was retention of 
antigen at the injection site 48 hours’ post-treatment and changes in the distribution of 
immune cells as a result of the vaccination. Figure 5.19 shows the increase in dDC 
numbers at one injection site following immunisation. Though the difference is striking 
between treated and untreated areas in Figure 5.19 (A & B), high variability existed in 
the numbers of dDCs seen in different areas both between mice and across areas on the 
same mouse. The constant movement of dDCs also made quantification unreliable. 
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Figure 5.18: Time lapse imagery of a microneedle channel formed in mouse skin following 
treatment with coated microneedles. Images are shown both as a 3D projection (A) and as a 
‘slice view’ showing a single z-plane with corresponding lateral views to allow channel 
visualisation (B; depth of z-plane 180um). Time elapsed expressed as hh:mm relative to 
removal of MN array. Scale bar: 100µm 
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Figure 5.19: 2PM images showing dDCs in untreated mouse skin (A) and surrounding the site of a 
channel created by a coated microneedle (B). Antigen retention at the site of treatment was seen 
in mouse skin 48 hours after treatment with both aqueous antigen solution (C,D) and cubosome 
formulation (E) using the MNPT method described in Section 5.3.8.3. Finally, a ‘slice view’ of dDCs 
interacting with retained antigen in the skin 48 hours after treatment with aqueous peptide 
solution delivered by MNPT method (F). Scale bar (A-D): 100µm, (E): 50µm 
185 
 
 For this reason, dDC density was not used as a quantitative output. Antigen 
retention was not consistently different between the three delivery methods used 
(CuPQM/AqPQM MNPT or coated MN). In cases where antigen remained on the skin 48 
hours after treatment, it was limited to the border of healed channels in the skin Figure 
5.19 (C - E). A characteristic autofluorescent region of tissue could be seen in the area 
where needle channels had healed, which may correspond to granulation tissue as the 
channel heals. Finally, evidence of dDCs (green) interacting with antigen (red) could be 
seen 48 hours after delivery Figure 5.19 (F). 
 
5.4.7.4 Changes in LC Density Following Antigen Delivery 
There were reductions in LC density in the skin of mice following treatment with 
CuPQM MNPT, PepAdj MNPT and coated MN of 43.18%, 29.48% and 13.19% 
respectively (Figure 5.20). Unfortunately, analysable images from a low number of 
treated (n=2) or control mice (n=1) were obtained, limiting the analyses that could be 
performed to ascertain statistical significance. The trend for the data obtained shows 
that the reduction was greatest with CuPQM MNPT treated mice and lowest in coated 
MN treated- it could be speculated that this was due to the delivery over a large area of 
the stratum corneum enhanced by cubosomes in the former. Following coated MN 
delivery antigen was delivered to a more limited area, likely meaning that fewer LCs 
were directly exposed to antigen. It is also possible that a greater proportion of antigen 
was delivered from coated needles into the dermis than with the two methods that 
involved application of liquid formulation, thus limiting the effect on LCs. 
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5.4.8 Antigen Uptake Analysis by Flow Cytometry 
Cells from the treated area of skin and the inguinal lymph node proximal to the 
treated area were isolated from the mice following imaging and analysed by flow 
cytometry to determine SIINFEKL-TAMRA uptake. Based on the literature, the PE median 
fluorescence intensity (MFI) of CD11c+ cells were used as the readout. Staining cells with 
anti-CD207 and anti-CD11b antibodies also allowed for analysis of peptide uptake within 
LCs and dDC subsets individually.  
The yield of cells from mouse skin was poor and inconsistent, suggesting that the 
protocol required further optimisation. As a result, there was insufficient data to draw 
any meaningful conclusions and so this portion of the investigation was disregarded. 
0.5665
0.3218
0.3995
0.4918
Untreated CuQP MNPT PepAdj MNPT Coated MN
LC count per 1000µm²
Figure 5.20: LCs in untreated mouse epidermis (A) and 48 hours after treatment with 
CuPQM MNPT (B). Density of LCs in the epidermis of mice 48 hours after treatment (C; n=1 
for untreated, n=2  for all other treatments). Scale bar: 50µm 
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Lymph nodes isolated from mice, however, provided improved cell yields. There 
was no change in fluorescence in the cells isolated from mice treated and imaged on the 
same day, most likely due to longer than 5 hours being required for the dDCs to be able 
to uptake antigen and migrate to the lymph nodes. Data from lymph nodes isolated 48 
hours’ post-treatment are shown in (Figure 5.21). In total CD11c+ cells, CuPQM and 
coated MN-treated mice both showed significant increases in PE MFI, whilst variability 
in mice treated with AqPQM MNPT meant that no significant difference was present 
(Figure 5.21 A). Breaking this down into the cell subsets revealed that the subset of 
CD207+ dDCs (CD11c+/CD207+/CD11b-) possessed the largest increase in PE MFI (Figure 
5.21 B). This was in agreement with previous results (Rattanapak et al., 2014) and 
highlights the importance of these cells in antigen transport to lymph nodes in mice. 
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Figure 5.21: TAMRA uptake in cells measured by median fluorescent intensity (MFI) in the PE channel. 
Values shown are in the overall YFP+ (CD11c+) population (A) and in the subsets of CD11c+ cells based 
on CD207 and CD11b expression. Error bars = ± SD. Significance indicated relative to untreated (UT) 
cells; * p<0.05, *** p<0.001 
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5.4.9 Visualising Cubosome Lipid Phase Distribution 
Nile red was used to track the movement of lipid from the formulation on a 
separate channel to the SIINFEKL-TAMRA with an emission wavelength of 629nm. As 
Figure 5.22 (A) shows, this emission wavelength is near to the emission maxima for the 
CuNQM formulation in isolation. In practice, however, fluorescence was seen across at 
525nm and 575nm emission wavelengths also (Figure 5.22 B), making it impossible to 
properly visualise the CD11c+ cells and SIINFEKL-TAMRA peptide when Nile red was 
present. A possible explanation may arise from the fact that Nile red, which is not 
fluorescent alone or in polar environments, becomes fluorescent in a lipid environment 
(Greenspan et al., 1985). The fluorescence characteristics of Nile red are solvent-
dependent- thus the spectra seen in Figure 5.22 are specific to Nile red within the lipid 
phase of cubosomes. It is likely that delivery into the skin, particularly the lipid-rich 
stratum corneum led to some sequestering of Nile red into a different lipid environment 
and leading to a change in its fluorescence emission. The diversity of lipids present in 
the skin could help to explain the broad fluorescence seen via 2PM. 
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Figure 5.22: Fluorescence excitation and emission spectra for CuNQM formulation (A) and 2PM 
image (B) showing bleed-through of fluorescence from Nile red across the channels used to 
visualise EYFP (i), TAMRA (ii) and Nile red itself (iii). Scale bar: 100µm 
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5.5 General Discussion 
This chapter aimed to build on previously published work using cubosomes and 
microneedles to facilitate the delivery of an ovalbumin peptide into the skin (Rattanapak 
et al., 2013, Rattanapak et al., 2014)- a collaborative project between Cardiff University, 
Osaka University and the University of Otago. Initial work focussed on the synthesis of 
the cubosome formulation to previously reported specifications. Wherever possible, 
reagents from the supplier indicated in the literature were used. One material that 
proved difficult to acquire was phytantriol as the manufacturer named in previous work 
was no longer producing it. As phytantriol comprises a mix of isomers, having to 
purchase from a new supplier meant that a potential source of variability was 
introduced. This was in addition to different synthesis equipment being used and the 
lack of availability of a stream of nitrogen, which was used in the previous publication 
to remove residual chloroform during the production of the homogeneous lipid phase. 
Characterisation of cubosomes revealed that the particle diameter and size 
distribution (polydispersity index; PDI) of formulations were within the reported ranges 
(Rizwan et al., 2011). The zeta potential values obtained were slightly outside the range 
previously reported, though this did not affect the stability of cubosomes over the 
month-long storage test. There was coalescence within the dispersed phase, with both 
particle size and PDI increasing upon storage, though this was fully reversible with 10 
minutes’ vortexing. This stability is important to cubosome formulations that may be 
used clinically as a cracked emulsion will not possess the cubic structure desired and will 
show altered delivery properties compared to a monodisperse system. TEM imaging of 
cubosomes produced limited amounts of qualitative data, though the prohibitive cost 
of further TEM work and the characterisation data that could be rapidly obtained from 
the Malvern Nanosizer meant this avenue was not pursued further. 
It was not possible to use the SIINFEKL-TAMRA peptide (to be used in later in vivo 
studies) for the early formulation work, so ovalbumin protein was used in its place. The 
incorporation of fluorescently-conjugated ovalbumin or Nile red into the cubosome 
formulation did not significantly alter its properties. The insertion of FITC-conjugated 
ovalbumin into cubosomes had been previously reported with 73% entrapment 
achieved (Rizwan et al., 2011). The entrapment efficiency obtained in our study (28.5%) 
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may be due to the use of AlexaFluor 555-conjugated ovalbumin in the place of FITC-
conjugated protein. This was selected due to the autofluorescence of human skin 
sections in the FITC (488nm excitation) channel. AlexaFluor 555 is a much more polar 
fluorophore than FITC (LogP -1.06 and 4.90 respectively) (ChemAxon, 2016)- this could 
have reduced the protein’s ability to partition into the lipid dispersed phase. The 
entrapment value was closer to the reported value for SIINFEKL-TAMRA (23%) 
(Rattanapak et al., 2013). The unavailability of the peptide before work in Japan meant 
that entrapment data could not be obtained for SIINFEKL-TAMRA, though the 
similarities of cubosomes produced in this investigation to those previously reported 
mean it is likely that comparable entrapment efficiencies were achieved. 
Passing the cubosome formulations through NanoPass hollow microneedle 
arrays did not significantly alter the particle size of the lipid particles. This was to be 
expected, given that the bore of the microneedles was approximately 60µm, providing 
sufficient clearance for the 160nm lipid particles to pass through. This is important as 
the liposomal nanostructure of cubosomes is important both for its drug entrapment 
and for it to be able to form the cubic phase which aids skin retention. This method of 
delivery avoids altering water content of the formulation which could affect its stability. 
It is also efficient, delivering formulation into the skin without loss of formulation 
associated with topical application (Kim and Prausnitz, 2011, Norman et al., 2014, Wang 
et al., 2006). For a formulation that is difficult to scale up by the commonly used 
methods of manufacture (Garg and Saraf, 2007) (and therefore potentially expensive to 
produce in large quantities), this could reduce the formulation volume required to 
deliver a given dose and reduce costs for pharmaceutical manufacturers.  
Coating the cubosomes onto microneedles proved to be more challenging than 
coating with an aqueous formulation (Chapter 2), with the lipid phase distributing itself 
unevenly on the needles’ surface. The coating also proved ineffective for delivery into 
ex vivo human skin, with the soft lipid formulation failing to remain coated onto the 
needles’ surface during insertion into skin. Given that the ex vivo skin was used at room 
temperature, it is possible that clinical application of these coated microneedles might 
be even less successful as warmer in vivo skin would further soften the formulation. This 
provides further evidence that although coated microneedles are a potentially useful 
delivery tool (Gill and Prausnitz, 2007a), the physical properties of the coating 
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formulation are important to ensure delivery into the skin. For this investigation, an 
aqueous formulation of peptide and adjuvant was coated onto microneedle arrays 
instead of cubosomes. The topical application of liquid cubosome formulation after 
microneedle pre-treatment was also tested to allow comparison with previous work 
(Rattanapak et al., 2014). Injection through hollow microneedles, solid microneedle pre-
treatment followed by topical cubosome delivery and coated microneedles all showed 
successful delivery of Fl-OVA into human ex vivo skin in preliminary work before 
commencing in vivo mouse work in Osaka.  
2PM allowed the real-time visualisation of immune cell behaviours in live skin, 
something that was not possible in the work to date in ex vivo human skin. One 
limitation of 2PM is that it cannot be performed in human skin as genetic manipulation 
is required to produce innately fluorescent DCs. It would most likely be extremely 
difficult to achieve fluorescent labelling of immune cells by another means, with 
technical challenges of specifically delivering a fluorophore by conjugated antibody or 
some other means. The equipment used would also be unsuited to the imaging of larger 
animals which could not be contained within the light-protective microscope housing. 
The murine model was useful however due to the similarities between mouse skin and 
human skin at a cellular level. Dermal DCs and epidermal LCs, which were 
morphologically similar to human LCs, were clearly visible in the images produced. There 
was a surprising disparity between the motility of the two immune cell populations in 
the mouse skin, with dDCs appearing more mobile than sessile LCs. This was in 
agreement with LCs in human ex vivo skin, where no change in LC density was seen in 
the epidermis 4 hours after vaccine delivery and dDCs migrated out of ex vivo skin in 
greater numbers than LCs.  
Imaging the skin’s structure was straightforward, with formulation on the 
stratum corneum allowing easy identification of the skin’s surface. The stratum corneum 
was also faintly autofluorescent in the 480/80 filter, allowing its identification in 
untreated mice. The use of SHG made identification of the dermis (rich in collagen fibres) 
simple without the need for further staining or preparation. The depth of imaging 
proved to be a limiting factor in some of the treatments- in particular intradermal 
injection. The thinness of mouse skin increases the possibility that ‘intradermal’ 
injections were mistakenly subcutaneous rather than true intradermal injections. This 
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might explain why formulation could not be visualised despite depth of detection up to 
200µm which is approximately the thickness of mouse skin (Calabro et al., 2011).  
Another limitation of using 2PM in combination with live mice was the lengthy 
process of preparing the mice for imaging. This was especially important in microneedle-
treated mice, where the channel began healing the moment that microneedles were 
removed from the skin and was mostly healed at approximately 90 minutes after 
treatment. The preparation process got more efficient with repeated attempts but a 
limit of speed was reached due to the delicate process of attaching the microscope cover 
glass to the mouse- attempting to remove it after initial application damaged the skin 
due to the adhesiveness of the glue used. Excess dried glue proximal to the treatment 
area also made it difficult to remount the cover glass accurately. 
In cases where treatment and mounting of the mouse onto glass cover slip went 
as planned, there were still a number of issues which acted to the detriment of imaging. 
Firstly, the level of anaesthesia used played an important role in the quality of images 
acquired. The laboratory used a protocol with 3% isoflurane used to induce anaesthesia 
and 2% used for maintenance. Though this level was adequate for mouse work on the 
benchtop, it quickly became apparent that within the confines of the light-protective 
microscope housing that this was excessive. Excess anaesthesia presented in mice as 
respiratory depression- breathing became ‘gasping’, similar to agonal breathing. This 
was not only bad for the mouse’s welfare but led to displacement of the mouse from 
the cover glass, affecting stability of the images. Thus, in subsequent experiments, the 
inner door was allowed to remain slightly open to improve air circulation. To avoid the 
mouse being affected by the cooler air in the room, a heated microscope stage was also 
included at this point. 
The high number of treatments that were explored in this study, along with the 
fact that a mouse could only be used for one imaging session- either immediately after 
treatment or 48 hours later, after which it was sacrificed - meant that a low number of 
repeats could be obtained for the study. LCs were analysed at a later time point than 
the 4 hours used previously where no change was seen (Rattanapak et al., 2014). The 
results showed a trend of reduced LC numbers in treated skin, with the reduction 
greatest in mice treated with peptide-loaded cubosome formulation. This was in line 
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with the results found previously in human LCs at 48 hours following antigen delivery 
into the skin (Pearton et al., 2010b, Pearton et al., 2010c). Unfortunately, there were a 
low number of usable images due to poor images being acquired from some mice (due 
to movement from the slide or poor initial mounting) meaning that LCs could not be 
reliably quantified. This led to an n-number of 1 for untreated mice and 2 for each of the 
treatment conditions. This low number meant that statistical significance could not be 
assigned to the data and instead it can be stated that the data represents a potentially 
interesting trend, with further work required to determine the reliability of conclusions.  
The low number of repeats due to inconsistent imaging also limited the 
quantitative data that could be drawn from other areas of the 2PM images. Post-imaging 
analysis software is able to track the movements of dDCs over time. Unfortunately, the 
majority of the time-lapse videos showed ‘drift’ over time whereby the movements 
brought about by the mouse’s breathing (especially in cases where respiratory 
depression occurred) affected the microscope stage position and meant the plane of 
focus moved over time, making the movement of cells markedly more difficult to 
measure. It would also have been useful to obtain a greater number of videos of 
microneedle channels healing to try and quantify the process, but this proved impossible 
in the time available for the investigation. 
The low number of repeats and variability of antigen retention within treatment 
groups meant that no conclusive statement could be made about whether cubosomes 
improved the retention of antigen. The depth of imaging meant that only the upper 
layers of skin could be visualised- thus any formulation which had been delivered to the 
deep reticular dermis could not be seen. Mice are prone to self-grooming and so the 
area of treatment would likely have been cleaned between treatment and imaging 48 
hours later, potentially removing any antigen close to the skin’s surface also. Thus, no 
conclusions could be drawn regarding cubosomes’ ability to aid vaccine retention within 
the skin. This was unfortunate as cubosomes have shown promise in the retention of 
drugs (Peng et al., 2015) or vaccines (Gordon et al., 2012) within the skin and it may be 
one of their advantages over other liposomal formulations which only enhance overall 
delivery rather than alter kinetics (Clogston and Caffrey, 2005). 
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The analysis of antigen uptake by flow cytometry on inguinal lymph node cells 
confirmed that dDCs, the most motile DCs in the skin, were responsible for the greatest 
uptake of ovalbumin peptide antigen. The autofluorescence seen in untreated CD207+ 
dDCs from the mice was most likely the result of imperfect compensation as FITC and 
PE conjugated antibodies were used to compensate for eYFP and TAMRA respectively. 
In future work, compensation using untreated eYFP-expressing cells and cells stained 
with a TAMRA-conjugated antibody would likely reduce this fluorescence spill-over.  
The data agreed with previous results which found the CD207+ dDC subset were 
responsible for the greatest internalisation of peptide (Rattanapak et al., 2014). This 
subset has been compared to the CD141+ subset of human dDCs (Chu et al., 2012, 
Bennett, 2015)- reinforcing the importance of this dDC subset in intradermal 
immunisation as seen in Chapter 4. The lack of complementary skin cell data from mice 
due to poor tissue lysis meant that no robust conclusions could be drawn as to whether 
the CD207+ dDCs were internalising the peptide in the skin or whether formulation had 
been carried in solution in the lymph vessels to the lymph nodes where resident DCs 
may internalise it. If the latter is true, retention in the skin may not be desirable for the 
formulation. It is of note that this investigation did not include immunological challenge, 
so it cannot be concluded that higher peptide uptake would translate to greater 
stimulation of T-cells by CD207+ dDCs in the mice. Also, this investigation does not 
distinguish between the protein processing capabilities of skin immune cells as the 
peptide was delivered to cells without the need for them to cleave it from a larger 
polypeptide as was the case with the influenza matrix peptide in Chapter 4. 
Coated microneedle delivery led to the greatest amount of peptide internalised 
by CD207+ dDCs isolated from lymph nodes. Cubosome-based delivery, however, led to 
the greatest reduction in LCs in the epidermis- a sign of maturation which in this case 
will have been induced by the adjuvants present in the formulation as the peptide itself 
is non-immunogenic. Thus, it can be speculated that the coated microneedles represent 
the most efficient manner to deliver antigen to dDCs, which may well be responsible for 
priming early immune responses due to their more motile characteristics over LCs. 
However, if LCs prove to be more able to create an adaptive immune response against 
a certain pathogen and are to be targeted, a cubosome-based system may well prove 
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more beneficial. The retention properties of cubosomes remained untested due to the 
limitations of imaging via 2PM, though represent an interesting avenue for future work. 
 
5.6 Potential for Publication 
The work within this chapter aimed to build on previously published work 
(Rattanapak et al., 2013, Rattanapak et al., 2014) to create publishable collaborative 
data. The initial characterisation of cubosomes’ physical properties was completed to 
ensure that the manufacturing process was implemented to the standards previously 
achieved. The physical stability study represents novel data that could potentially be 
publishable, as proven stability is an important characteristic of any formulation for 
clinical use. The 2PM studies did not yield sufficient replicates to allow for publishable 
data regarding LC density in the mouse skin or the motile behaviour of dDCs following 
antigen delivery. The antigen uptake study in lymph node cells is not publishable without 
corresponding skin cell data that would allow a distinction to be made between cells 
that internalised antigen in the skin and then migrated to the lymph node and those 
cells that internalised antigen in situ in the lymph node. Optimisation of the lipid staining 
protocol (using a fluorescent substrate other than Nile red) would allow the behaviour 
of the lipid phase of cubosomes in murine skin to be visualised which could potentially 
be publishable. 
 
5.7 Conclusion 
This work has provided further evidence that cubosomes are a physically stable 
liposomal formulation that can be used to entrap vaccine antigen. This chapter focussed 
on the protein ovalbumin and its peptide SIINFEKL. Both possess aqueous solubility and 
so are likely to insert into the aqueous continuous phase. It is likely that hydrophilic 
proteins/peptides will be compatible with a cubosome formulation as they will not 
interact with the lipid phase and thus the stability of the cubic phase will be maintained. 
A size limit will however exist, above which the macromolecules will not be able to insert 
into the ‘nanopockets’ that exist within the cubic phase (Angelov et al., 2012) and 
cubosomes will therefore not improve delivery. Hydrophobic antigen will instead insert 
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into the lipid phase. In this case, care must be taken that the antigen does not adversely 
affect the ability of the stabiliser (in this study poloxamer 407) to maintain the colloidal 
system. Further work is required to establish a comprehensive list of protein/peptide 
antigen which are compatible with the cubosome formulation used in this chapter. 
Cubosomes were shown to improve delivery into the skin and can be used in 
combination with microneedles to provide a synergistic delivery improvement into the 
skin. The entrapment may also increase the immunogenicity of the antigen, though 
further work is needed to confirm this. Cubosomes appear to deliver preferentially to 
the upper layers of skin, where they stimulate LCs to mature and migrate out of the skin 
in a mouse model. However, LCs do not seem to be the most active immune cells of the 
skin, with dDCs (and CD207+ dDCs in mice in particular) being much more motile and 
internalising a greater amount of peptide antigen, even extending into the epidermis to 
sample antigen there. The work in the transgenic mouse model did not include 
assessment of responses in the T-cell compartment though, so no conclusions can be 
made about how the greater uptake of antigen by dDCs translates into an adaptive 
immune response. The data obtained in the human ex vivo skin cell model demonstrated 
a greater ability of dDCs to uptake and cross-present influenza virus-derived antigen, 
which in combination with the results within this chapter suggests that these cells are 
the optimal targets for intradermal immunisation as opposed to LCs.  
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Chapter 6: General Discussion 
6.1 Brief Overview 
The overarching aim of this Thesis was to improve the understanding of skin 
immune cell characteristics with a view to informing intradermal vaccination strategy. 
Three areas were studied to achieve this aim: dermal dendritic cells, epidermal 
Langerhans cells and the intradermal delivery of vaccines. 
 
6.2 Dermal Dendritic Cells 
Following their recognition as immune cells in the 1970s, Langerhans cells (LCs) 
garnered a reputation as the only dendritic cells (DCs) of the skin, being able to take up 
antigen in the epidermis before migrating to lymph nodes where they elicit an immune 
response (Romani et al., 2012, Stingl et al., 1978). The 1990s saw work that identified 
other dendritic cells resident within the skin- the dermal dendritic cells (dDCs) 
(Steinman, 1991, Banchereau and Steinman, 1998). Subsequent work identified the 
presence of multiple subsets of dDCs in normal and inflamed skin (Nestle et al., 1993, 
Haniffa et al., 2009, Jongbloed et al., 2010, Segura et al., 2012).  
Whilst histological and 2PM techniques are useful in observing morphological 
behaviours of both LCs and dDCs, they are limited in the number of factors that can be 
studied concurrently, which makes identification of the dDC subsets difficult. This led to 
the adoption of an immune cell isolation method within this Thesis to allow the study of 
dDCs (and LCs) in a cell suspension. A range of methods have been used previously to 
obtain a suspension of immune cells from the skin (summarised in Section 3.1.2). The 
method which was utilised allowed rapid enzymatic separation of epidermis and dermis 
(McCully et al., 2012) and also allowed for the enrichment of DCs based on their motile 
nature (Nestle et al., 1993, Artyomov et al., 2015). A number of studies had utilised a 
further enrichment step with density centrifugation (Pena-Cruz et al., 2001), 
fluorescence-activated cell sorting (FACS) (Chu et al., 2012) or magnetic-activated cell 
sorting (MACS) (Segura et al., 2012) either after walkout (Goddard et al., 2004) or 
following lysis of the tissue (Haniffa et al., 2012). Whilst this would have provided a purer 
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DC population, it would no doubt involve the loss of cells so would be unsuitable for the 
small areas of excised human skin tissue that are often used for research e.g. from 
mastectomy surgeries. Thus, the majority of work in this Thesis was performed with 
dermal and epidermal walkout cells in the purities found directly after walkout. As dDCs 
do not reside in the epidermis and LCs did not make up a significant proportion of dermal 
walkout cells (Section 3.4.1), this allowed the comparison of the two populations of skin 
DCs in parallel. However, the differing characteristics of dDC subsets, which is one of the 
most disputed areas of current skin immunology, could not be studied unless cells were 
subsequently sorted (Section 4.4.6). 
There is consensus that one subset of dDCs are the CD141+ dDCs, although the 
flow cytometric gating strategies used to arrive at this cell population are not consistent 
between groups (Chu et al., 2012, Artyomov et al., 2015, Haniffa et al., 2012). Some 
(Haniffa et al., 2012, Artyomov et al., 2015) exclude CD14+ dDCs before gating for 
CD141+ cells, whilst others gate overall dDCs for CD141+ cells (Chu et al., 2012). The 
work within this Thesis found that the vast majority of CD141+ cells amongst migratory 
dermal cells were also CD14+ (Section 3.4.1), in agreement with the latter gating method 
(Chu et al., 2012). The CD14-/CD141+ cells described were a much rarer cell population 
and have been best isolated via tissue digestion rather than walkout (Haniffa et al., 
2012), which might explain the absence of a meaningful population in the results of this 
Thesis. Thus, tissue digestion should be utilised in the place of a walkout if this subset of 
dDCs are to be studied in future work. 
Whilst most groups tend to agree there are two resident myeloid DC subsets in 
the dermis, the marker used to identify the second subset varies between groups. CD1a+ 
dDCs are sometimes used to indicate the second subset (Artyomov et al., 2015, 
Klechevsky et al., 2008b, Segura et al., 2012), though this is not an ideal marker as CD1a 
expression is low and variable in this subset. This issue is compounded by the presence 
of LCs, which have the highest CD1a expression in skin (Hunger et al., 2004, Klechevsky 
et al., 2008b) but are not dDCs. A separate strategy is to classify the remaining dDCs 
based on CD1c+ expression (Haniffa et al., 2012, Chu et al., 2012, Collin et al., 2013). 
CD1c+ dDCs also express CD11c (Chu et al., 2012), leading to the gating strategy used in 
this Thesis, with CD141+/CD11c+ dDCs representing CD141+ dDCs and CD141-/CD11c+ 
dDCs representing CD1c+ dDCs. A third subset which was negative for both CD141 and 
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CD11c was also found in migratory dermal cells. These cells have been identified in the 
blood as CD34+ dDC precursors (Haniffa et al., 2012), which may also be the case in skin 
where the cells have exited the vasculature but not fully developed into dDCs.  
CD141+ dDCs are developmentally related to the rare blood CD141+ population, 
indicating that the blood DCs are able to migrate into the skin and take up residence 
there (Carpentier et al., 2016, Haniffa et al., 2012). These CD141+ blood DCs are potent 
cross-presenting cells which exclusively express the chemokine receptor XCR1 (Bachem 
et al., 2010). The CD141+ dDCs are potent cross-presenters of protein antigen including 
hepatitis B surface antigen (Haniffa et al., 2012), pre-proinsulin (Chu et al., 2012) and 
necrotic cell antigen (Jongbloed et al., 2010). The work in this Thesis with ex vivo human 
skin LCs and dDCs utilised whole inactivated influenza virus rather than soluble protein 
or peptide. It was found that walkout dDCs were able to cross-present the HLA A*0201-
restricted influenza A virus-derived matrix protein (M1)-derived peptide (residues 58-
66; GILGFVFTL) to ALF3 T-cell clones to a much greater extent than LCs from the same 
skin sample (Section 4.4.5). This was in agreement with results using GILGFVFTL-
restricted T-cell clones with DCs incubated with live influenza virus (Ratzinger et al., 
2004). It conflicted, however, with results obtained using DCs incubated with the full-
length M1 protein which found that LCs were the better cross-presenting cells 
(Klechevsky et al., 2008b). A further study also infected skin walkout cells with live 
influenza virus and found that LCs were able to promote the greatest proliferative 
response in allogeneic CD8+ T-cells (van der Aar et al., 2011). The data utilising live virus 
is of less use as skin is not a major infection route for influenza and direct infection can 
lead to the presentation of de novo synthesised viral peptides on MHC-I molecules 
rather than true cross-presentation (van der Vlist et al., 2011). As the current influenza 
vaccines utilise inactivated virus, the work in this Thesis may provide a more accurate 
representation of the cells responsible for raising an adaptive immune response 
following intradermal immunisation. Thus, it can be concluded that targeting of the 
dermis, rather than epidermis, appears to be advantageous in producing an adaptive 
immune response against the M1 matrix peptide in influenza vaccine. Whether this is 
true for other influenza viral peptides will require further work to clarify. 
Sorting of dermal walkout cells allowed for comparisons to be made between 
the dDC subsets. The high cell loss associated with cell sorting and the lower frequency 
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of the CD141+/CD11c+ and CD141-/CD11c- subsets meant that skin samples large 
enough to provide adequate starting populations of dDCs were limited and so 
experimental repeats were low. However, the results showed that whilst 
CD141+/CD11c+ dDCs were able to cross-present the influenza M1 peptide antigen as 
expected, the CD141-/CD11c+ dDCs were able to cross-present to a slightly greater 
extent. The lack of repeats meant that only tentative conclusions could be drawn and 
data suggested that the phenotypic markers used do not correspond with the function 
of dDCs. This is an issue that has been highlighted in the literature (Carpentier et al., 
2016), where cell surface marker expression overlaps between multiple subsets. The 
cytokine receptor XCR1 has been identified as a marker unique to cross-presenting dDCs 
(Crozat et al., 2010) but neither reliable antibodies nor fluorescently conjugated ligand 
(XCL1 or XCL2) are commercially available and thus staining to identify these cells is 
challenging (Carpentier et al., 2016).  The C-type lectin CLEC9A is also expressed on 
cross-presenting DCs (Schreibelt et al., 2012, Caminschi et al., 2008) and may be a useful 
marker for distinguishing dDC subsets. It may be the case that staining for one of these 
markers is required to reliably identify cross-presenting dDC subsets in the future. The 
lower level of cross-presentation by CD141-/CD11c- dDCs supports the theory that these 
are dDC precursor cells (Haniffa et al., 2012) which have not fully developed dDC 
characteristics and so do not participate meaningfully in creating an adaptive immune 
response. 
The work in this Thesis investigated the cross-presentation of a single peptide 
derived from the complex influenza virus. An adaptive immune response against a virus 
involves the processing and presentation of multiple epitopes by APCs, with varying 
importance to counteracting the viral pathogen (Murphy et al., 2012). In the case of 
influenza, M1 matrix peptides alone are unlikely to elicit adequate immunity, otherwise 
their conserved nature between strains would allow cross-immunity to occur in patients 
immunised against any strain previously. Work has been done previously with a 
universal vaccine based on the M2 protein (De Filette et al., 2005, Huleatt et al., 2008), 
though this proved to have little clinical success. More recently, universal vaccines based 
on hemagglutinin envelope protein have shown more promise (Impagliazzo et al., 2015) 
in creating immune responses against the varying envelope proteins in seasonal  
influenza strains (e.g. H1N1, H5N2). Provided the necessary epitopes are identified and 
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the appropriate T-cell clones produced, the ex vivo skin cell model used in this Thesis 
could prove a useful tool for assessing the cross-presentation of antigen in novel 
intradermal vaccines prior to their assessment in animal models. It is also likely that data 
assessing classical antigen presentation on MHC-II molecules to CD4+ T-cells would be 
required to assess the humoral response to vaccination concurrently. The combined 
approach would allow assessment of both cellular and humoral arms of the adaptive 
immune response to be assessed in ex vivo human tissue prior to clinical work. 
Ultimately such a laboratory system could better predict the clinical response to 
candidate vaccines and thus promote more lean clinical trials. 
The yield of walkout cells from ex vivo skin was proportional to the size of the 
skin sample, with larger skin samples providing a greater yield of dDCs and LCs. There 
appeared to be a weak correlation between the yield of DCs and age, with older skin 
samples producing a lower yield. The decrease in skin DCs in older patients agrees with 
previous literature (Grewe, 2001, Bhushan et al., 2002). However, the data was obtained 
retrospectively and did not control for sample size so requires further work to confirm. 
The skin samples were also not representative of the general population i.e. the skin was 
mostly from mastectomy surgeries and therefore most patients were elderly (mean age: 
66 years) and all of them were Caucasian females. Obtaining skin from a single hospital 
also limited the genetic diversity, as patients were likely to be from the surrounding 
geographical area. This proved advantageous for cross-presentation experiments, as 6 
of the 8 samples (75%) were found to be HLA-A2+ compared to the previously reported 
frequency of 49.6% amongst Caucasians (Ellis et al., 2000). The narrow diversity of age, 
gender and race must be taken into account when interpreting the results and drawing 
conclusions covering a wider population. For example, darker skin contains a 
comparable number of melanocytes but a much greater level of melanin than lighter 
skin (Tadokoro et al., 2005), which will affect UV penetration into the skin. This could 
affect skin DC characteristics as UV radiation has previously been shown to reduce the 
antigen presenting capabilities of LCs (Dittmar et al., 1999). Obtaining skin from other 
hospitals with a greater ethnic diversity would control for the effect of skin 
pigmentation. A better range of age and also gender could be obtained if skin were 
sourced from other surgical procedures e.g. abdominoplasty. A diversity of ethnicity, 
age and gender would allow the production of data which was more representative of 
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the global patient population, increasing its usefulness to the pharmaceutical industry, 
who distribute products internationally.  
It had been reported than walkout dDCs from human skin possess a semi-mature 
phenotype following isolation that utilised a longer enzymatic incubation time and 
sorting via FACS (Chu et al., 2012). This is comparable to the dDCs that migrate at steady 
state from mouse skin to lymph nodes and possess tolerising rather than 
immunostimulatory capabilities (Kissenpfennig et al., 2005, Lutz and Schuler, 2002). Skin 
walkout DCs obtained using the shorter enzyme incubation time and without sorting (as 
described in Section 3.3.1) were assessed for their response to immunostimulatory 
substances such as LPS or poly(I:C) to determine if the reduced processing of cells 
allowed them to be isolated in an immature state. It found that it was possible to 
upregulate the maturation marker CD83 to some extent but that cells were already 
partially mature at the time of isolation, making the distinction between untreated cells 
and cells treated with TLR agonists difficult. Cytokine expression by the cells was also 
poor, even when the potent immunostimulator LPS was used. Thus, it was determined 
that the changes in the protocol did not lead to the isolation of immature DCs from the 
skin and the walkout cells that could be obtained would not be a useful tool for assessing 
the changes in maturation and cytokine expression as a result of vaccine antigen or 
adjuvants within this project. A tissue digestion protocol (Haniffa et al., 2009, Haniffa et 
al., 2012) may be advantageous as cells will not need to spontaneously migrate out of 
tissue and so will have less time to develop a semi-mature phenotype before use. 
As well as viral vaccine antigen processing, it was possible to obtain data on the 
uptake and responses of skin DCs to an adjuvanted ovalbumin peptide vaccine using a 
mouse model. This data indicated that CD207+ dDCs were the most active antigen-
internalising cells, in line with previously reported results using mouse skin-derived DCs 
(Rattanapak et al., 2014). It was not possible to distinguish lymph node-resident DCs 
from those which had migrated from the skin during the investigation. Thus, it could not 
be determined if antigen delivery to DCs occurred locally in the skin or via lymph vessels 
to lymph node-resident DCs which has been previously described (Li et al., 2014, Tozuka 
et al., 2016). Mouse CD207+ dDCs have been identified as the equivalent of the CD141+ 
skin dDCs in humans based on function (Chu et al., 2012, Bigley et al., 2015, Carpentier 
et al., 2016), which agrees with influenza virus data that indicates these cells are able to 
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uptake and process vaccine antigen rapidly. This provides further evidence for the 
dermal, rather than epidermal, targeting of vaccines. 
 
6.3 Epidermal Langerhans Cells 
The C-type lectin receptor Langerin (CD207) has made identification of LCs within 
the skin straightforward since its identification at the turn of the 21st century (Valladeau 
et al., 1999, Valladeau et al., 2000). LCs are also the lone DC population residing in the 
epidermis (Merad et al., 2008) and express higher levels of CD1a than dDCs (Stoitzner et 
al., 2010), making their phenotypic identification much more straightforward than that 
of dDC subsets. Our understanding of LCs role in skin immunity (both innate and 
adaptive), however, has been under constant revision (Romani et al., 2012).  
One of the earliest properties of Langerhans cells to be identified was their ability 
to present antigen to naïve T-cells to elicit an adaptive immune response (Stingl et al., 
1978). Their detection of foreign antigen in the skin leads to maturation and migration 
from the skin to lymph nodes (Cumberbatch et al., 2000, Johnston et al., 2000). In vivo, 
these LCs will be replaced to restore the normal complement within the epidermis by 
either mitotic LCs under normal turnover (Czernielewski and Demarchez, 1987, Kanitakis 
et al., 1993) or the recruitment of precursors from blood in cases of widespread 
depletion (Merad et al., 2002). Ex vivo human skin, which has been removed from the 
systemic circulation with carries LC precursors, can be used to study this depletion of 
LCs from the skin (Larsen et al., 1990). Tissue can be stained for CD207 to allow the 
specific visualisation of LCs (Valladeau et al., 1999). Using this model, the response of 
the LCs to vaccines (Li et al., 2014), infection by pathogens (Johnston et al., 2000), skin 
sensitising agents (Ratzinger et al., 2002) or UV exposure (Seite et al., 2003) can be 
examined.  
Previously published work (Pearton et al., 2010b, Pearton et al., 2010c) in ex vivo 
human skin showed that LCs underwent morphological changes and their numbers 
decreased significantly following treatment with influenza vaccine. This work examined 
the response of LCs at 24 to 48 hours’ post-exposure. In this Thesis the immediate 
response to influenza vaccine was evaluated at 2 and 4 hours but there was no 
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difference to the untreated samples. This suggests that LCs take some time to uptake 
antigen and migrate out of the epidermis. This may be influenced by the tightly packed 
nature of keratinocytes in the epidermis and the morphology of LCs at rest i.e. with 
dendrites extending in multiple directions between keratinocytes (Yu et al., 1994). Thus, 
even if a LC encounters antigen it must change its morphology and withdraw its 
dendrites to facilitate mobilisation. It has been previously reported that LCs are slower 
at migrating to the lymph nodes than dDCs (Kissenpfennig et al., 2005). Slow migration 
of LCs was also witnessed in those mouse models analysed using two-photon intravital 
microscopy (2PM), described in Section 5.4.7.1. An immune response to a pathogen can 
take up to 5 days to be raised and this does not preclude the involvement of LCs. The 
low level of LC motility will likely mean that vaccines need to be delivered over a large 
area of skin to ensure that a high number of LCs internalise the antigen, whereas dDCs 
were observed being able to migrate towards a single site of antigen delivery in the 
murine model.  
LCs possess the cellular machinery required to cross-present antigen to naïve 
CD8+ T-cells (Artyomov et al., 2015) and have been shown to cross-present protein-
derived (Klechevsky et al., 2008b) peptide antigens. These experiments have utilised LCs, 
obtained from skin, which have been conditioned with a cocktail of stimulatory 
substances (Artyomov et al., 2015, Klechevsky et al., 2008b) to mature the LCs prior to 
their use. Work with measles virus and skin LCs found that immature LCs neither cross-
presented viral antigen nor became infected (van der Vlist et al., 2011). Inducing 
maturity in the LCs led to viral infection and presentation of antigen on MHC-I molecules 
independent of cross-presentation machinery. The work in this Thesis used LCs directly 
from walkout (i.e. no further maturation was induced) and found that LCs were able to 
cross-present to some extent but much less so than dDCs. It is possible that incubation 
with TLR-agonists or other inducers of LC maturation prior to adding the virus may have 
improved the cross-presentation, though this would not be representative of 
vaccination with inactivated virus, which does not include pre-treatment to activate skin 
LCs. Thus, the results obtained in this Thesis may be more representative of the in vivo 
response of skin cells to intradermal influenza vaccination, with LCs providing a lesser 
contribution to activation of CD8+ T-cells over the shorter time points observed in this 
Thesis. 
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 The reduced peptide antigen uptake and reduced virus-derived cross-presenting 
abilities of LCs compared to dDCs may be explained by the growing opinion that LCs are 
not purely immunogenic cells, but can also act as tolerising cells (Romani et al., 2012, 
Steinman et al., 2003). LCs have been shown to lack TLR expression that senses bacterial 
PAMPs (van der Aar et al., 2007). This may prevent unnecessary immune responses to 
the presence of commensal bacteria at the epidermal surface. Recent genetic analysis 
has shown that LCs are derived from embryonic precursor cells, unlike dDCs which 
develop from bone marrow precursors (Carpentier et al., 2016), and so are in ontological 
terms closer to macrophages than dDCs (Ginhoux and Merad, 2010). Their functional 
gene expression, however, is more comparable to CD1c+ dDCs (Carpentier et al., 2016). 
This property of DCs, which are derived from distinct precursors but acquire functional 
similarities based on tissue conditioning, may explain the often conflicting results 
obtained when studying the immunogenic properties of LCs and dDCs.  
It has been reported that LCs in culture lose their LC-like characteristics (Schuler 
and Steinman, 1985) and are less capable of presenting peptide antigen than freshly 
isolated LCs (Romani et al., 1989). This may explain to some extent the conflicting results 
seen in studies regarding the cross-presentational abilities of LCs. Studies using lymph 
node-derived DCs (which includes those that have migrated from skin) found that all DC 
subsets present could cross-present antigen (Segura et al., 2013).  Thus, as Segura et al. 
(2013) concluded, cross-presentation of an antigen by a given DC subset is likely a 
function of the antigen type, the environment in which the DC encounters the antigen 
and the type of pathogen that the antigen is derived from. This must be taken into 
account with all work using skin cell models. The use of LCs that have migrated from skin 
suggests that they may already be at least partially matured. The lack of danger signals 
upon migration (as vaccine was added after the cells had migrated out of tissue), may 
mean that these cells are committed to a tolerogenic phenotype (Hawiger et al., 2001). 
Thus, future experiments may need to deliver antigen to LCs in situ in the epidermis or 
digest the epidermis using trypsin to ensure immature LCs encounter the vaccine as they 
would in vivo. 
The role of DCs requires them to internalise viral pathogens without becoming 
directly infected. To allow this, they possess antiviral factors such as apolipoprotein B 
mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G), which counteracts 
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HIV-1 (Sheehy et al., 2002, Pion et al., 2006) and hepatitis B (Turelli et al., 2004) infection, 
or SAMHD1 which counteracts HIV-1 infection (Laguette et al., 2011). The work in this 
Thesis found that there was a significant increase in the infectability of LCs and dDCs 
after SAMHD1 knockdown. It was also noted that this increase in infectability was much 
more pronounced in the dDCs, confirming the work which had been performed in 
monocyte-derived models where LCs were found to be more resistant to HIV infection 
after SAMHD1 knockdown (Czubala et al., 2016). Colleagues used monocyte-derived 
models in further work to uncover the source of the difference in infectability post-
SAMHD1 knockdown. This study concluded that a factor that operates at the point of 
viral reverse transcription and is independent of MX2 (another antiviral factor) was 
unique to LCs (Czubala et al., 2016). 
Given that the mechanisms by which HIV infects a person and evades the 
immune system are still not fully characterised, this work represents a step towards a 
better understanding of the virus that will allow for better drug therapies or vaccines to 
be designed. Should the future work on monocyte models uncover a potential lead on 
the LC-specific antiviral factor, the ex vivo skin cell model will be well placed to carry out 
confirmatory studies. Skin-derived cells are particularly useful in studying HIV because 
the only animal models are primates and humanised mouse models (Hatziioannou and 
Evans, 2012), and human genital mucosal tissue is not readily available for research use 
(Dezzutti and Hladik, 2013). The animal models commonly used for genital mucosa such 
as porcine (Lorenzen et al., 2015) or guinea pig (Da Costa et al., 1997) are not directly 
infectable with HIV-1. Thus, ex vivo skin walkout cells represent a model that it 
representative of human cells and avoids the costs associated with using primate 
models. It is also possible that skin walkout cells could be used to study the infection 
pathways of other viral (Gebhardt et al., 2009), bacterial (Wu and Xu, 2014) or fungal 
(Trzaska et al., 2015) pathogens which directly infect skin or mucosal immune cells to 
try and elucidate infection pathways that can be targeted with novel drugs or vaccines. 
It is also possible that vaccine strategies such as anti-oncotic vaccines which utilise anti-
tumour vaccines (Rolinski and Hus, 2010) might be able to utilise the cells e.g. in anti-
melanoma vaccines (Banchereau et al., 2001, Carreno et al., 2015).  
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6.4 Intradermal Vaccine Delivery 
The data presented within this Thesis provides insight into the cells that may be 
preferentially targeted within the skin to ensure successful adaptive immune response 
to influenza as an example of a disease where intradermal vaccination is used. This is of 
little use, however, without a means of delivering vaccine to the desired targets. Porcine 
skin is commonly used as a model for the physical barrier properties human skin (Kong 
and Bhargava, 2011), whilst murine models are used to study immune responses in vivo 
(Mestas and Hughes, 2004). Where available, ex vivo human skin provides an option for 
modelling both delivery of vaccines into skin and the response of localised skin-resident 
immune cells to the vaccine within a single model (Ng et al., 2009, Schmalfuß et al., 
1997, Larsen et al., 1990).  
The Mantoux technique, the most commonly used method for intradermal 
delivery of vaccines, is both complex and subject to high variability between healthcare 
professionals in both delivery depth and volume (Suh et al., 2014a). The skin is not well 
suited to receiving a large volume bolus dose of liquid due to the dimensions and 
properties of the tissue, with injections over 50µl tending to lead to leakage into the 
hypodermis (Diehl et al., 2001), which is not particularly immunogenic and can reduce 
immunisation success (Groswasser et al., 1997, Shaw et al., 1989). There is also injection 
pain associated with the needle used in the Mantoux technique, which reduces patient 
acceptability (Nir et al., 2003). This has led to the development of a number of 
alternative minimally invasive delivery strategies such as microneedle (Levin et al., 2015, 
Wang et al., 2006), jet injector (Williams et al., 2000, Soonawala et al., 2013) and tattoo 
gun (van den Berg et al., 2009, Verstrepen et al., 2008) delivery systems, all of which aim 
to improve the consistency of intradermal delivery. This Thesis focussed on 
microneedles as a delivery technology as they are a simple but flexible delivery platform 
which can be adapted to suit a range of delivery purposes and have the potential to 
eschew liquid formulations to avoid the need for cold-chain storage (Zehrung, 2009). 
The methods of microneedle delivery that were used in this Thesis were not 
novel, with protein or peptide formulation being coated onto stainless steel 
microneedles and the formulation dried before insertion into the skin (Bariya et al., 
2012, Gill and Prausnitz, 2007a). The fluorescently-conjugated ovalbumin protein and 
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fluorescent nanoparticle vaccine models were incorporated into a simple coating 
formulation which had been used in previous studies of delivery into human ex vivo skin 
(Pearton et al., 2010c). The model vaccine antigen allowed for straightforward 
visualisation of antigen on the microneedles, though storage stability studies would be 
required to determine whether the coating formulation also improved vaccine stability 
as has been shown for influenza virus vaccine-coated needles (Kim et al., 2010, Kim et 
al., 2011).  
Coated microneedles were able to deliver formulation into the skin, as had been 
shown many times previously (Caucheteux et al., 2016, Chong et al., 2013, Gill and 
Prausnitz, 2007a, Pearton et al., 2010c). As previously described, coated microneedles 
deposited the coated formulation proximal to the microchannel they create in human 
skin (Gill and Prausnitz, 2007b). The use of an array of many microneedles can overcome 
the limited volume of material that can be coated onto a single needle, without affecting 
the overall needle shape (Gill and Prausnitz, 2007a). Considerations must be given to 
the length, density and sharpness of needles in an array to avoid the ‘bed of nails’ effect 
and ensure that skin penetration is successful (Cheung et al., 2014). The coating 
methods used within this Thesis were crude and the variability in coating was not 
quantified. There have, however, been investigations within the pharmaceutical 
industry which have shown reproducible coating of microneedle arrays with proteins 
such as human growth hormone (Ameri et al., 2014), parathyroid hormone (Daddona et 
al., 2011) and erythropoietin (Peters et al., 2012). The processes used within the 
pharmaceutical industry are automated and coat entire arrays concurrently, allowing 
the speed of production to greatly exceed the methods used within this Thesis. This is 
important to ensure dose reproducibility, and thus the safety and efficacy of vaccines, 
and acceptable device costs. These are crucial factors to those developing microneedle 
systems for clinical use and the regulation of these devices. 
The vast majority of clinical research involving intradermal immunisation 
employs the commercially available intramuscular injection and compares its efficacy 
when delivered intradermally or via the conventional intramuscular route (Soonawala 
et al., 2013, Kenney et al., 2004). The use of formulations designed for intramuscular use 
in intradermal vaccination studies does not acknowledge the marked differences 
between the two tissues. It may be possible to improve existing formulations to suit 
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intradermal delivery, though the method of improvement will depend on the delivery 
method that is selected and the desired effects of the vaccine. For vaccines without 
adjuvant such as the seasonal influenza vaccine (Della Cioppa et al., 2014), it may be that 
a simple formulation coated onto microneedles would be adequate. On the other hand, 
a VLP vaccine such as Cervarix™ which contains 3-Odesacyl-4'-monophosphoryl lipid A 
as an adjuvant which activates TLR4 (Casella and Mitchell, 2008, Monie et al., 2008) may 
be more effective reformulated with a TLR3 agonist such as poly(I:C) to activate the 
antiviral immunity pathway in the skin based on the results in this Thesis. The results in 
this Thesis showed that influenza VLP vaccine without adjuvant was not cross-presented 
as much as inactivated virus, which is structurally identical but contains viral genetic 
material. This genetic material may well have acted as an adjuvant, activating skin DCs 
and increasing the cross-presentation of antigen. This highlights the importance of 
proper adjuvant usage in vaccines to ensure that immune cells recognise the antigen as 
representative of a pathogen threat and do not induce tolerance (Mutyambizi et al., 
2009, Steinman et al., 2003). 
The presentation of antigen in lymph nodes may be a result of APC transport of 
the antigen and/or transport of free peptide, that has avoided enzymatic degradation, 
in the skin via the lymph vessels (Reddy et al., 2007, Tozuka et al., 2016). Delivery to 
skin-resident cells, which can transport antigen to lymph nodes, was examined in 
separate stages within the Thesis. The delivery method that favoured LC exposure to 
vaccine appeared to be application of a cubosome formulation following microneedle 
pre-treatment. However this observation is based on the limited data obtained from the 
2PM imaging of murine skin 48 hours after treatment. This method of vaccine delivery 
showed a greater reduction in LC density than an identical method using an aqueous 
formulation or the use of coated microneedles. Coated microneedles (Pearton et al., 
2010c) and intradermal injection by the Mantoux technique (Pearton et al., 2010b) have 
been shown to deliver influenza vaccine to LCs and stimulate their migration out of the 
epidermis in ex vivo human skin. In both cases, however, there was no means of 
quantifying dDC activation concurrently so there is no means of comparing the relative 
activation of the two populations. The sessile nature of LCs means that antigen needs to 
be delivered locally to an LC to ensure its uptake. Thus, delivery methods that target the 
epidermis such as coated microneedles or application of a cubosome formulation 
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following microneedle pre-treatment may be favourable over the Mantoux injection 
technique, which deposits a liquid formulation in the dermal layer i.e. sub-epidermis. 
The more superficial microneedle based approaches are also able to target a greater 
surface area of the epidermis and thus a greater number of LCs.  
Based on the data gathered in this Thesis, delivery to dDCs in skin may be 
advantageous in terms of the immune response generated. In the case of inactivated 
influenza virus vaccine, dDCs showed a much greater cross-presentation of vaccine 
antigen. This suggests a more robust CD8+ T-cell response to be generated, which is 
particularly important in influenza given the role of CD8+ T-cells in viral clearance from 
the lung (Helft et al., 2012). In this case localising delivery to the papillary dermis will be 
optimal as this is the most dDC-rich region of skin (Gerlini et al., 2001, Cerio et al., 1989, 
Chu et al., 2012).  The increased mobility of dDCs also mean than delivery to an adequate 
number of dDCs to allow an adaptive immune response can be possible with delivery to 
a small area, as dDCs can migrate towards the vaccine delivery site to uptake antigen. If 
a vaccine should prove to be processed more effectively by a given dDC subset, affinity 
targeting by conjugation of an antibody to the antigen can be used to increase the 
specificity of delivery (Bonifaz et al., 2002) and improve the immune response of the 
immunised individual (Sancho et al., 2009, Idoyaga et al., 2011).  
 
6.5 Future Work 
The diverse nature of the work contained within this Thesis means that a broad 
range of further work is possible. The isolation of walkout dDCs and LCs from skin could 
form the basis of a study into the differing properties of skin immune cells in ageing skin. 
This could involve studying the varying frequencies of dDC subsets or the differing 
antigen presentational abilities of dDCs and LCs. The availability of abdominoplasty skin 
samples from younger patients would provide a comparator for the more elderly skin 
obtained via the average mastectomy surgery. This could prove informative as elderly 
patients tend to be poor responders to vaccination and so the elucidation of dDC/LC 
changes with age could help to inform vaccine design to improve immunisation in this 
population.  
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The work in this Thesis investigated the delivery of antigen into skin and its 
processing then presentation to T-cells separately. An interesting future study would be 
to deliver vaccine to ex vivo human skin using intradermal delivery technologies such as 
coated solid microneedle arrays, hollow microneedles and intradermal injection by 
hypodermic needle. The tissue could then be cultured to allow time for the vaccine to 
distribute within the skin. After this time, dDCs and LCs would be isolated from the skin 
and co-cultured with T-cell clones to allow quantification of antigen presentation. This 
would allow comparison of the effectiveness of the various delivery methods over and 
above the histological deposition studies in Chapters 2 and 5. This would also improve 
the representativeness of the model to vaccinating a patient compared to co-culturing 
isolated skin cells with vaccine, allowing the cells to encounter vaccine in their natural 
environment. This would also allow signalling from other skin cells such as keratinocytes 
to influence the immune response seen. 
The finding that dDCs cross-present an influenza virus matrix peptide to a greater 
extent also provides a starting point for further work. The walkout skin cell model could 
be used in combination with other T-cell clones to provide complementary data on the 
presentation of antigen via MHC-II molecules or on the cross-presentation of other viral 
antigens. The fact that studies regarding the cross-presentational ability of skin immune 
cells often conflict one another highlights the fact that a greater body of data is required 
before the true properties of these cells can be fully understood. 
Finally, work to improve the classification of dDCs into subsets based on 
functionality represents an important avenue of future work. The development of a 
reliable monoclonal antibody against XCR1 would allow for the co-localisation of this 
marker for cross presenting cells with other dDC markers such as CD11c and CD141 to 
determine which cells possessed this machinery. The conflicting results with skin-
derived cells means that the effect of culture conditions on DC phenotype must also be 
considered as there may plasticity in DCs for conversion between the various subsets. 
 
219 
 
6.6 Concluding Remarks 
The aim of this Thesis was to further the understanding of human skin immune 
cells in order to inform how best to deliver vaccines into the skin for effective 
immunisation. The objectives were met as follows: 
i. Peptide, protein and nanoparticle-containing formulations were 
produced and coated successfully onto solid stainless steel microneedles. 
Two coating methods were used, one of which involved the deposition of 
formulation on the terminal portion of needles only whilst the other 
coated the entire length of the needle. Both of which were able to coat 
the tips of needles with a visually even coating of formulation. 
ii. Following insertion of coated microneedles into ex vivo human skin, the 
formulation was deposited in the area proximal to the needle channel in 
the epidermis and upper dermis. The delivery of inactivated influenza 
virus from coated microneedles into ex vivo human skin did not elicit a 
change in LC density in the epidermis after 2 or 4 hours, suggesting 
migration of mature LCs occurs at some time point between 4 and 24 
hours post-delivery of vaccine into skin. 
iii. Walkout epidermal and dermal cells were obtained from live ex vivo 
human skin. Phenotyping of cells revealed on average epidermal walkout 
cells comprised 7.3% LCs, whilst dDCs were 34.1% of dermal walkout 
cells. LCs were found to be HLA-DR+/CD1a+/CD207+ by flow cytometric 
analysis. Total dDCs could be identified by size/granularity/HLA-
DR+/CD45+ gating. The viability of LCs and dDCs was over 95% in the 
samples tested. Classification of dDC subsets was made on CD11c and 
CD141 expression, revealing 3 subsets: CD141+/CD11c+ (mean 17.3% of 
dDCs), CD141-/CD11c+ (mean 60.3% of dDCs) and CD141-/CD11c- (mean 
21.6% of dDCs). 
iv. Both walkout LCs and dDCs possessed a semi-mature phenotype 
following their isolation from ex vivo skin explants, meaning that 
treatment with either TLR3 agonist (poly(I:C)) or TLR4 agonist (LPS) were 
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unable to elicit a significant increase in cell maturation markers (CD83) or 
cytokine production (TNF-α or IL-12). Thus, the cells were deemed to be 
unsuitable to quantify the ability of vaccine candidates to activate LCs and 
dDCs. 
v. LCs possess an antiviral factor which allows them to resist infection by 
HIV-1 to a greater extent than dDCs even after the knockdown of 
SAMHD1, confirming work performed using monocyte-derived dendritic 
cell models. Work is ongoing in monocyte-derived dendritic cell models 
to identify this factor. 
vi. dDCs cross-present inactivated influenza virus-derived peptide to a much 
greater extent than LCs. Replacing inactivated virus with equivalent VLPs 
(which do not contain viral DNA or RNA) led to a marked reduction in 
cross-presentation. Both CD141+/CD11c+ and CD141-/CD11c+ dDC 
sorted subsets were able to cross present the virus-derived antigen, 
though further repeats are required to validate this result. 
vii. Cubosomes were able to entrap protein or peptide vaccine and the 
colloidal formulations were physically stable for one month at room 
temperature. A cubosome formulation could be delivered into ex vivo 
human skin directly via hollow microneedles or applied to skin after pre-
treatment with solid microneedles. The cubosomes could not be dry-
coated reliably onto microneedles for delivery into skin. Work in a murine 
model showed that a topically-applied cubosome formulation could 
deliver vaccine to LCs (as determined by a decrease in LC density in the 
epidermis 48 hours after treatment). Coated microneedles enabled 
peptide delivery to dDCs, with CD207+ dDCs (considered the murine 
equivalent of CD141+ human dDCs) showing the greatest amount of 
internalised peptide in skin-draining lymph nodes, providing further 
evidence for the importance of these cells in intradermal vaccination. 
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